text stringlengths 46 525k | url stringlengths 24 420 | crawl_date timestamp[us, tz=UTC]date 2022-04-01 00:01:42 2022-09-25 07:27:13 | id stringlengths 24 420 | label bool 2 classes |
|---|---|---|---|---|
Advanced design offers the highest availability, reliability and density, resulting in lower total cost of ownership
HERNDON, Va. and AMSTERDAM, Sept. 6, 2022 /PRNewswire/ -- ST Engineering iDirect, a global leader in satellite communications, will be launching its new MCX8000 multi-carrier satellite gateway at IBC2022 in Amsterdam. The MCX8000 enables broadcasters to cater for every type of broadcast scenario, including high IP encapsulation rates for Over the Top (OTT) applications.
The MCX8000 is a high density, high availability and fully redundant modular system that is suitable for a variety of broadcast use cases. These include direct-to-home broadcasting, where bringing quality content to the largest possible subscriber base with high reliability is key. The MCX8000 Multi-Carrier Satellite Gateway is highly bandwidth efficient, thus maximizing the throughput. It utilizes the DVB-S, DVB-S2, or DVB-S2X standard, assuring highly reliable transport stream delivery.
In Distribution to Towers (DTT), the MCX8000 ideally fits as a satellite front-end, feeding multiple Integrated Receiver Decoders (IRDs), and one MCX8000 in a multi-carrier, multi-stream configuration can be used for hundreds of TV channels.
For OTT delivery, the MCX8000's high IP encapsulation rates and efficient multicast capabilities uniquely position it to provide a path to support the transport of today´s traditional broadcasts and tomorrow´s OTT services.
Built upon the trusted technology of the MDM6100 and MCX7000 software suite capabilities, the MCX8000 offers users higher density and reduced total cost of ownership (TCO) through its unique features:
With its modular design and functionality, users can easily swap out modem boards and power supply units (PSUs) without interrupting the system setup and with no requirement for tools, thus avoiding downtime for repairs and reducing operating expenses (OPEX). In the unlikely event of a failure in one PSU, the other can still power both modem boards and the redundancy switch. The MCX8000 also features ST Engineering iDirect's Clean Channel Technology which ensures the highest bandwidth efficiency, also resulting in lower OPEX. The MCX8000's energy efficient design means that this is also a more environmentally friendly option.
The MCX8000 offers higher availability to broadcasters and by combining two modem boards and a 1+1 redundancy switch in one unit, it becomes a three-in-one solution. This results in lower TCO due to reduced downtime for repairs and low power consumption.
Simple configuration and ease of use is critical, and the MCX8000 features a brand new, intuitive interface designed to streamline the entire process, reducing the requirement for specialist knowledge. This focuses on the logical flow of configuration, from general system settings to configuring inputs/outputs and defining monitoring requirements. The system also benefits from over-the-air updates rather than suspending services to carry them out manually.
"The broadcast sector relies on equipment that will promote maximum uptime, allowing operations to continue at all times," said Sean Yarborough, Vice President of Product Management at ST Engineering iDirect. "Broadcasters are also looking to lower CAPEX and OPEX and be more cost-effective in a competitive landscape. We designed the MCX8000 with the idea of bringing together the best of both worlds - high density and high reliability - through robust design and industry-leading redundancy solutions. The result is a future proof system that combines video and IP multiservice capabilities to support the transport of today´s and tomorrow´s services."
Visit ST Engineering iDirect at IBC2022, September 9-12, in Hall 1, stand #1.A49 where there will be a live demonstration of the MCX8000.
ST Engineering iDirect, a subsidiary of ST Engineering, is a global leader in satellite communications (satcom) providing technology and solutions that enable its customers to expand their business, differentiate their services and optimize their satcom networks. With over 35 years of innovation focused on solving satellite's most critical economic and technology challenges we are committed to shaping the future of how the world connects. The product portfolio, branded under the names iDirect and Newtec, represents the highest standards in performance, efficiency, and reliability, making it possible for its customers to deliver the best satcom connectivity experience anywhere in the world. ST Engineering iDirect is the world's largest TDMA enterprise VSAT manufacturer and is the leader in key industries including broadcast, mobility and military/government. In 2007, iDirect Government was formed to better serve the U.S. government and defense communities. For more information on our platforms please visit www.idirect.net.
View original content to download multimedia:
SOURCE ST Engineering iDirect | https://www.kwch.com/prnewswire/2022/09/06/st-engineering-idirect-introduces-mcx8000-multi-carrier-satellite-gateway-future-broadcasting/ | 2022-09-06T11:23:35Z | https://www.kwch.com/prnewswire/2022/09/06/st-engineering-idirect-introduces-mcx8000-multi-carrier-satellite-gateway-future-broadcasting/ | false |
Police: ‘Fat Leonard’ from Navy bribery scandal escapes house arrest in San Diego
SAN DIEGO (AP) — The military contractor who pleaded guilty to orchestrating the “Fat Leonard” corruption scandal and was under house arrest in San Diego is now on the run after cutting off his GPS monitoring ankle bracelet over the weekend, federal authorities said.
Supervisory Deputy U.S. Marshal Omar Castillo said Leonard Glenn Francis removed the tracker Sunday, the San Diego Union-Tribune reported.
After police officers found Francis’ home empty, the San Diego Regional Fugitive Task Force and the Naval Criminal Investigative Service began a high-profile search, the newspaper reported.
Castillo said neighbors witnessed U-Haul moving trucks coming to and from Francis’ home in the days before his escape.
Francis was arrested in San Diego in 2013 and pleaded guilty in 2015 to offering $500,000 in bribes to Navy officers. In exchange, the officers passed him classified information and even went so far as redirecting military vessels to ports that were lucrative for his Singapore-based ship servicing company.
Prosecutors say Francis and his company overcharged the U.S. military by more than $35 million for its services.
Francis has been on house arrest since at least 2018 and under the supervision of a federal agency that monitors defendants who are out of custody until sentencing. He was set to be sentenced at the end of month.
Francis’ defense attorney, Devin Burstein, declined to comment to the Union-Tribune on Monday.
Copyright 2022 The Associated Press. All rights reserved. | https://www.dakotanewsnow.com/2022/09/06/police-fat-leonard-navy-bribery-scandal-escapes-house-arrest-san-diego/ | 2022-09-06T11:24:12Z | https://www.dakotanewsnow.com/2022/09/06/police-fat-leonard-navy-bribery-scandal-escapes-house-arrest-san-diego/ | false |
Belfast: Teenagers rescued from George Best hotel building roof
- Published
Five teenage boys have been rescued from the site of the building which was meant to house the George Best hotel, police have said.
Police and other emergency services were called to Bedford Street in Belfast at about 19:20 BST on Monday.
It is believed the boys gained access to the roof of the Scottish Mutual Building after climbing the scaffolding.
The road was closed for a short period of time. | https://www.bbc.co.uk/news/uk-northern-ireland-62807807?at_medium=RSS&at_campaign=KARANGA | 2022-09-06T11:25:38Z | https://www.bbc.co.uk/news/uk-northern-ireland-62807807?at_medium=RSS&at_campaign=KARANGA | true |
- Proposal does not apply to Eurodollar futures and options that expire before June 30, 2023
- Conversion date aligns with OTC market plans
- Market participants invited to provide feedback until September 30
- SOFR options to be added to portfolio margining solution
CHICAGO, Sept. 6, 2022 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that based on initial client feedback, it is proposing to convert Eurodollar futures and options open interest into corresponding SOFR contracts on April 14, 2023, under the company's previously adopted fallbacks plan. Eurodollar futures and options contracts that expire before June 30, 2023 are excluded from this proposal and will continue to trade until their expiry.
"Our proposed conversion date will help our clients complete their operational work as early as possible in the transition process, while closely aligning with the recently published industry timelines for over-the-counter interest rate swaps," said Agha Mirza, CME Group Global Head of Rates and OTC Products. "SOFR futures and options are now the leading liquidity pool, as open interest has reached 19 million contracts and volume has significantly outpaced Eurodollars. Based on this growth, today's announcement provides a practical timeline by which clients can bring remaining Eurodollar contracts into the SOFR market."
In the month of August, CME Group reported record average daily volume of nearly 2.5 million contracts and record open interest of 19 million contracts for SOFR futures and options contracts. SOFR options had record volume and open interest in August and SOFR futures had record open interest during the same period. Additional highlights include:
Ahead of the final conversion under fallbacks, liquid standard and reduced-tick Inter-Commodity Spread (ICS) instruments are available to facilitate the voluntary conversion of Eurodollar open interest via the SED Spread for futures and the LS Spread for options.
In addition, to further support the deepening of SOFR markets, CME Group plans to add SOFR options to its portfolio margining solution for cleared products in December 2022, subject to regulatory approval. Portfolio margining enables clients to reduce margin requirements by offsetting their exposure on cleared swaps versus interest rate futures and options.
Now among the world's deepest and most consistently liquid markets, SOFR futures and options have broad participation from global banks, hedge funds, asset managers, principal trading firms and other types of traders.
SOFR futures and options are listed with and subject to the rules of CME. For more information, please visit www.cmegroup.com/sofr.
About CME Group
As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and, E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec and EBS are trademarks of BrokerTec Europe LTD and EBS Group LTD, respectively. Dow Jones, Dow Jones Industrial Average, S&P 500 and S&P are service and/or trademarks of Dow Jones Trademark Holdings LLC, Standard & Poor's Financial Services LLC and S&P/Dow Jones Indices LLC, as the case may be, and have been licensed for use by Chicago Mercantile Exchange Inc. All other trademarks are the property of their respective owners.
CME-G
View original content:
SOURCE CME Group | https://www.kxii.com/prnewswire/2022/09/06/cme-group-proposes-april-14-2023-fallbacks-conversion-eurodollar-futures-options-contracts/ | 2022-09-06T11:26:03Z | https://www.kxii.com/prnewswire/2022/09/06/cme-group-proposes-april-14-2023-fallbacks-conversion-eurodollar-futures-options-contracts/ | false |
- 3 new 200V MV MOSFETs will help the company grow its global market share in the LEV motor controller and industrial power supply sectors
SEOUL, South Korea, Sept. 6, 2022 /PRNewswire/ -- Magnachip Semiconductor Corporation ("Magnachip") (NYSE: MX) announced today that the company has introduced its third- generation 200V Medium Voltage (MV) Metal-Oxide-Semiconductor Field-Effect Transistors (MOSFETs) for Light Electric Vehicles (LEV) motor controllers and industrial power supplies.
To maximize energy efficiency in power devices, Magnachip's new 200V MOSFETs incorporate third-generation trench MOSFET technology. The capacitance was reduced by 50% compared to the previous generation 100V MV MOSFET and the enhanced design of the core cell and termination helps lower RDS(on)* and total gate charge** to achieve a high figure of merit.
In addition, these third-generation MOSFETs are available in surface mount device TO-Leadless Package (TOLL), M2PAK and TO-220 of a through-hole type respectively to reduce product size and enhance heat dissipation. Furthermore, the energy efficiency of these MOSFETs is greatly increased by fast switching and high power density. Coupled with a guaranteed operating junction temperature from -55°C up to 175°C and a high level of avalanche ruggedness, these MOSFETs are well-suited for LEV motor controllers and industrial power supplies requiring high efficiency and stable power supply.
Omdia, a global market research firm, estimates that the annual growth rates of the automotive and industrial sectors of the global silicon power MOSFET market will be 11.5% and 9.6% respectively from 2020 to 2025. In particular, LEV markets are expanding quickly alongside efforts to accelerate decarbonisation and demand for efficient and affordable vehicles.
"The development of advanced applications in the automotive and industrial sectors is driving the need for high-performance MV MOSFETs," said YJ Kim, CEO of Magnachip. "Magnachip will continue to upgrade its MV MOSFET product line, ranging from 40V to 200V, which will enable our customers to strengthen their product competitiveness."
*RDS(on): On resistance, the resistance value between the drain and the source of MOSFETs during on-state operation
**Total gate charge (Qg): the amount of charge required to be injected into the gate electrode to turn ON (drive) the MOSFET
Product features
- low RDS(on) and switching loss
- great heat dissipation performance
- guaranteed operating junction temperature from -55°C up to 175°C
- a wide range of application, such as LEVs, battery management systems and switch mode power supplies
Magnachip is a designer and manufacturer of analog and mixed-signal semiconductor platform solutions for communications, IoT, consumer, computing, industrial and automotive applications. The Company provides a broad range of standard products to customers worldwide. Magnachip, with more than 40 years of operating history, owns a portfolio of approximately 1,100 registered patents and pending applications, and has extensive engineering, design and manufacturing process expertise. For more information, please visit www.magnachip.com. Information on or accessible through Magnachip's website is not a part of, and is not incorporated into, this release.
View original content to download multimedia:
SOURCE Magnachip Semiconductor Corporation | https://www.kold.com/prnewswire/2022/09/06/magnachip-unveils-third-generation-200v-mv-mosfets/ | 2022-09-06T11:27:14Z | https://www.kold.com/prnewswire/2022/09/06/magnachip-unveils-third-generation-200v-mv-mosfets/ | true |
ST. PAUL, Minn., Sept. 6, 2022 /PRNewswire/ -- 3M (NYSE: MMM) announced today the final proration factor of 7.346065 percent in its split-off exchange offer to 3M stockholders in connection with the separation of 3M's food safety business and merger of Garden SpinCo Corporation ("SpinCo"), the 3M subsidiary holding the food safety business, with a subsidiary of Neogen Corporation.
A total of approximately 203,610,687 shares of 3M common stock were validly tendered and not properly withdrawn in the exchange offer, including approximately 1,114,015 shares tendered by odd-lot stockholders not subject to proration. All tenders by odd-lot shareholders were fully accepted in the offer. The remaining validly tendered shares of 3M common stock were accepted in the exchange on a pro rata basis using the final proration factor of 7.346065 percent. Shares of 3M common stock that were validly tendered but not accepted for exchange are expected to be returned to tendering stockholders on or around September 8, 2022.
Under the terms of the exchange offer, 108,269,946 shares of SpinCo common stock were available in exchange for shares of 3M common stock accepted in the exchange offer. The final exchange ratio for the exchange offer was set at 6.7713 shares of SpinCo common stock for each share of 3M common stock validly tendered and not properly withdrawn. In the merger, each share of SpinCo common stock automatically converted into the right to receive one share of Neogen common stock. Accordingly, 3M stockholders who tendered shares of 3M common stock in the exchange offer will receive approximately 6.7713 shares of Neogen common stock (subject to the receipt of cash in lieu of fractional shares) for each share of 3M common stock tendered and accepted for exchange. 3M accepted approximately 15,989,536 shares of 3M common stock for exchange in the exchange offer.
About 3M
3M (NYSE: MMM) believes science helps create a brighter world for everyone. By unlocking the power of people, ideas and science to reimagine what's possible, our global team uniquely addresses the opportunities and challenges of our customers, communities, and planet. Learn how we're working to improve lives and make what's next at 3M.com/news or on Twitter at @3M or @3MNews.
3M Media Contact:
Jennifer Ehrlich
(651) 592-0132 or 3Mnews@mmm.com
3M Investor Contact:
Bruce Jermeland
(651) 733-1807
Diane Farrow
(612) 202-2449
Cautionary Note on Forward-Looking Statements
This release includes "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, including statements regarding the transaction between Neogen, 3M and SpinCo. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "target," "endeavor," "seek," "predict," "intend," "strategy," "plan," "may," "could," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. All statements, other than historical facts, including, but not limited to, the expected benefits of the transaction, including future financial and operating results and strategic benefits, the tax consequences of the transaction, and the combined Neogen-SpinCo company's plans, objectives, expectations and intentions, legal, economic and regulatory conditions, and any assumptions underlying any of the foregoing, are forward-looking statements.
These forward-looking statements are based on Neogen and 3M's current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from Neogen and 3M's current expectations. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from the transaction; (2) uncertainty of the expected financial performance of the combined company following completion of the transaction; (3) failure to realize the anticipated benefits of the transaction, including as a result of delay in integrating the business of Neogen and the Food Safety Business, on the expected timeframe or at all; (4) the ability of the combined company to implement its business strategy; (5) difficulties and delays in the combined company achieving revenue and cost synergies; (6) inability of the combined company to retain and hire key personnel; (7) the risk that stockholder litigation in connection with the transaction or other litigation, settlements or investigations may result in significant costs of defense, indemnification and liability; (8) evolving legal, regulatory and tax regimes; (9) changes in general economic and/or industry specific conditions; (10) actions by third parties, including government agencies; and (11) risk factors detailed from time to time in Neogen's and 3M's reports filed with the Securities and Exchange Commission (the "SEC"), including Neogen's and 3M's annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC, including Neogen's registration statement on Form S-4 (Reg. No. 333-263667) that includes a prospectus relating to the shares of Neogen common stock issued in the transaction, as amended and supplemented (the "Neogen Registration Statement"), which was declared effective by the SEC on August 4, 2022, and SpinCo's registration statement on Form S-4 and Form S-1 (Reg. No. 333-263669) in connection with its separation from 3M that contains a prospectus relating to the shares of SpinCo common stock issued in the transaction, as amended and supplemented (the "SpinCo Registration Statement"), which was declared effective by the SEC on August 4, 2022, in each case, filed with the SEC in connection with the transaction. The foregoing list of important factors is not exclusive.
Any forward-looking statements speak only as of the date of this communication. None of Neogen, 3M or SpinCo undertakes, and each party expressly disclaims, any obligation to update any forward-looking statements, whether as a result of new information or development, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
View original content to download multimedia:
SOURCE 3M | https://www.mysuncoast.com/prnewswire/2022/09/06/3m-announces-final-proration-factor-7346065-percent-shares-tendered-split-off-exchange-offer/ | 2022-09-06T11:29:34Z | https://www.mysuncoast.com/prnewswire/2022/09/06/3m-announces-final-proration-factor-7346065-percent-shares-tendered-split-off-exchange-offer/ | true |
LUCERNE, Switzerland , Sept. 6, 2022 /PRNewswire/ -- As previously announced, in March 2022 the UK Gambling Commission selected Allwyn Entertainment Ltd, a subsidiary of Allwyn Entertainment AG ("Allwyn"), as its preferred applicant for the fourth license to operate the UK National Lottery. The award of the license has been contested in a legal challenge.
On June 29, 2022, the court ruled to lift the automatic suspension preventing the UK Gambling Commission from entering into agreements with Allwyn Entertainment Ltd to commence the transition process. That ruling was appealed by Camelot UK Lotteries Limited (the incumbent operator of the UK National Lottery) and Camelot Global Lottery Solutions Limited (together, the "Camelot Entities" and the "Camelot Appeal") and International Game Technology plc, resulting in the suspension continuing.
Today, Allwyn announced that the Camelot Entities have decided to withdraw the Camelot Appeal, and Allwyn Entertainment Ltd and Allwyn International A.S. have agreed to waive all claims for costs or damages against the Camelot Entities. Allwyn very much welcomes this decision and looks forward to cooperating with Camelot and the Gambling Commission on the transition process. Allwyn is excited at the prospect of becoming the custodian of Europe's biggest lottery.
About Allwyn
Allwyn is a leading global lottery operator. Allwyn builds lotteries that return more to good causes by focusing on innovation, technology, efficiency and safety across a growing casual gaming entertainment portfolio. The lottery-first approach of focusing on affordable recreational play has earned Allwyn leading market positions with trusted brands across Europe in Austria, Czech Republic, Greece and Cyprus and Italy.
Additional Information about the Business Combination and Where to Find It
Additional information about the Business Combination, including a copy of the Business Combination Agreement and prospectus, are provided in the Registration Statement. The Registration Statement has been mailed to each of Cohn Robbins Holdings Corp.'s (NYSE: CRHC) ("CRHC") shareholders as of August 15, 2022, and can be found for free on the SEC's website at www.sec.gov under the registrant "Allwyn Entertainment AG."
Cautionary Statement Regarding Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 with respect to the Business Combination between, among other parties, CRHC and Allwyn. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believe," "predict," "potential," "continue," "strategy," "future," "opportunity," "would," "seem," "seek," "outlook" and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. These forward-looking statements include, without limitation, Allwyn's and CRHC's expectations with respect to anticipated financial impacts of the Business Combination, the satisfaction of closing conditions to the Business Combination, and the timing of the completion of the Business Combination. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of CRHC's registration statement on Form S-1 (File No. 333-240277), its Annual Report on Form 10-K, as amended from time to time, for the fiscal year ended December 31, 2021 and its subsequent Quarterly Reports on Form 10-Q, and the Registration Statement filed by Allwyn. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Most of these factors are outside Allwyn's and CRHC's control and are difficult to predict. Many factors could cause actual future events to differ from the forward-looking statements in this document, including but not limited to: (1) the outcome of any legal proceedings that may be instituted against CRHC or Allwyn following the announcement of the Business Combination; (2) the inability to complete the Business Combination, including due to the inability to concurrently close the Business Combination and the private placement of common stock or due to failure to obtain approval of CRHC's shareholders; (3) the risk that the Business Combination may not be completed by CRHC's business combination deadline and the potential failure to obtain an extension of such deadline sought by CRHC; (4) the failure to satisfy the conditions to the consummation of the Business Combination, including the approval by CRHC's shareholders and the satisfaction of the minimum trust account amount following any redemptions by CRHC's public shareholders; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; (6) the risk that The Business Combination disrupts current plans and operations as a result of the consummation of the Business Combination; (7) the inability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain key employees; (8) costs related to the Business Combination; (9) changes in the applicable laws or regulations; (10) the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the risk of downturns and a changing regulatory landscape in the industry in which Allwyn operates; (12) Allwyn's ability to obtain or maintain rights or licenses to operate in any market in which Allwyn operates or seeks to operate in the future; (13) the potential inability of Allwyn to raise additional capital needed to pursue its business objectives or to achieve efficiencies regarding other costs; (14) the enforceability of Allwyn's intellectual property, including its patents, and the potential infringement on the intellectual property rights of others, cyber security risks or potential breaches of data security; and (15) other risks and uncertainties described in CRHC's registration statement on Form S-1 and Annual Report on Form 10-K, as amended from time to time, for the fiscal year ended December 31, 2020 and its subsequent Quarterly Reports on Form 10-Q, and the Registration Statement. Allwyn and CRHC caution that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Allwyn nor CRHC gives any assurance that Allwyn or CRHC will achieve its expectations. Neither Allwyn nor CRHC undertakes or accepts any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, or should circumstances change, except as otherwise required by securities and other applicable laws.
Contact: Dana Dvorakova, dana.dvorakova@allwynent.com
View original content:
SOURCE Allwyn Entertainment | https://www.mysuncoast.com/prnewswire/2022/09/06/allwyn-entertainment-announces-withdrawal-by-camelot-entities-legal-challenge-allwyns-selection-preferred-applicant-uk-national-lottery-license/ | 2022-09-06T11:29:40Z | https://www.mysuncoast.com/prnewswire/2022/09/06/allwyn-entertainment-announces-withdrawal-by-camelot-entities-legal-challenge-allwyns-selection-preferred-applicant-uk-national-lottery-license/ | false |
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced that management will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10 a.m. ET.
A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the fireside chat will be available on the same website for approximately 90 days.
Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers™, are designed to target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our participation in upcoming events and presentations and expectations regarding our business strategy and product candidate pipeline, including efficacy, trial design, regulatory submissions, approvals and timing thereof, and initiation of preclinical studies and advancement of multiple preclinical development programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Media contact:
Jason Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
Investor contact:
Kevin Murphy
Argot Partners
212.600.1902
ArgotOmega@argotpartners.com
View original content to download multimedia:
SOURCE Omega Therapeutics | https://www.kxii.com/prnewswire/2022/09/06/omega-therapeutics-participate-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-06T11:30:21Z | https://www.kxii.com/prnewswire/2022/09/06/omega-therapeutics-participate-hc-wainwright-24th-annual-global-investment-conference/ | false |
Comments / 0
Related
Bowie State takes down top 20 team with epic comeback
Bowie State scored 20 points in the fourth quarter to come away with a last-minute win over a tough New Haven team.
The post Bowie State takes down top 20 team with epic comeback appeared first on HBCU Gameday.
Central Catholic stuns Bellevue on last-second kick in battle of Oregon vs. Washington state champions
By Todd Milles | Photos by Vince Miller BELLEVUE, Wash. — Bo Robertson nearly missed his single-biggest moment of football greatness. The senior placekicker was supposed to meet his team at Central Catholic for a 7 a.m. interstate departure on the bus Friday. He was late. ... | https://www.newsbreak.com/news/2727013538292/girls-varsity-volleyball-beats-irvington-prep-3-0 | 2022-09-06T11:30:53Z | https://www.newsbreak.com/news/2727013538292/girls-varsity-volleyball-beats-irvington-prep-3-0 | true |
LONDON (AP) — Liz Truss, a onetime accountant who has served in Parliament for the past 12 years, will become Britain’s prime minister on Tuesday when Queen Elizabeth II formally asks her to form a government.
The ceremony, which will take place at a royal residence in Scotland, follows a bruising two-month contest to succeed Boris Johnson, who will formally offer his resignation to the queen shortly before Truss arrives to take up the mantle.
The handover of power is governed by rules and traditions built up over the centuries, as the U.K. evolved from an absolute monarchy to a modern parliamentary democracy where the sovereign plays an important but largely ceremonial role as head of state.
Here is a brief description of Tuesday’s events and how Britain arrived at this point.
HOW DID LIZ TRUSS BECOME PRIME MINISTER?
Boris Johnson announced his intention to step down as prime minister and leader of the ruling Conservative Party on July 7, after dozens of Cabinet ministers and lower-level officials resigned following months of scandal and growing concern that he could no longer deliver election victories.
Because Johnson’s government didn’t lose a vote of confidence, the Conservatives still command a majority in the House of Commons and so a general election wasn’t required to select a new prime minister. Instead, it was up to the Conservatives to pick a new leader who would automatically become prime minister as the leader of the majority party.
Truss and former Treasury chief Rishi Sunak squared off in the internal contest to become Conservative Party leader, holding campaign events around the country as they vied for support among 172,000 dues-paying party members. Truss was announced as the winner of that contest on Monday after she received 57% of the vote.
WHY IS THE QUEEN INVOLVED?
As head of state, the queen still formally appoints the prime minister, though the decision is now based on constitutional conventions. When one party holds a majority in the House of Commons, as is the current situation, the prime minister is always the leader of that party.
But the queen maintains a special relationship with her prime ministers, holding regular meetings with them throughout their time in office.
While the queen is constitutionally required to remain strictly neutral on all political matters, she is entitled to be informed and consulted about government policy. And she retains the right to “advise, encourage and warn ministers,” according to the official guide to the laws, rules and conventions of government.
WHY DIDN’T TRUSS IMMEDIATELY BECOME PRIME MINISTER?
First of all, because Johnson is technically still prime minister. While Johnson announced his intention to step down on July 7, prime ministers usually don’t formally resign until it is clear who their successor will be.
Now that Truss has been elected Conservative Party leader, Johnson is due to resign on Tuesday.
WHY IS EVERYONE IN SCOTLAND FOR THE CEREMONY?
Normally, the new prime minister travels the short distance from the Houses of Parliament to Buckingham Palace to meet with the queen. But this year, the 96-year-old sovereign is at Balmoral, her retreat in Aberdeenshire, Scotland, for her annual vacation.
Elizabeth has had difficulties moving around of late and decisions about her schedule are being made on a daily basis depending on what she feels up to. So rather than take the chance that she wouldn’t be ready to travel to London on Tuesday, planners injected a bit of certainty into the diary by asking the new leader to come to her.
WHAT WILL ACTUALLY HAPPEN ON TUESDAY?
Things kicked off at about 7:30 a.m., when Johnson appeared outside the prime minister’s official Downing Street residence to deliver a farewell speech before flying to Scotland. He is scheduled to meet the queen later in the morning to formally offer his resignation.
Truss, who is expected to make the 500-mile (800-kilometer) journey on a separate plane, is due to arrive at Balmoral just after noon for a 30-minute audience with the queen where she will formally be asked to form a new government.
Truss will then return to London, where she is expected to address the nation later in the afternoon. | https://www.cbs42.com/news/ap-top-headlines/ap-explainer-why-truss-is-off-to-scotland-to-become-uk-leader/ | 2022-09-06T11:31:08Z | https://www.cbs42.com/news/ap-top-headlines/ap-explainer-why-truss-is-off-to-scotland-to-become-uk-leader/ | true |
A community in Ukraine blew up a dam and flooded their village to stop the Russian army's advance into the capital Kyiv. Six months later, they're still pumping water out of their houses.
Copyright 2022 NPR
A community in Ukraine blew up a dam and flooded their village to stop the Russian army's advance into the capital Kyiv. Six months later, they're still pumping water out of their houses.
Copyright 2022 NPR | https://www.wvpublic.org/2022-09-06/how-blowing-up-a-dam-in-ukraine-flooded-a-village-but-stopped-russian-forces | 2022-09-06T11:33:38Z | https://www.wvpublic.org/2022-09-06/how-blowing-up-a-dam-in-ukraine-flooded-a-village-but-stopped-russian-forces | true |
TORONTO, Sept. 6, 2022 /PRNewswire/ - O3 Mining Inc. (TSX.V: OIII) (OTCQX: OIIIF) ("O3 Mining" or the "Corporation") is pleased to announce the completion of the Pre-Feasibility Study ("PFS"), prepared in accordance with the National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101"), for its 100% owned Marban Engineering gold project, in the world-class mining region of Val-d'Or in Québec, Canada. All figures are expressed in Canadian dollars unless otherwise stated.
- Robust Project Economics: Post-tax net present value ("NPV") (discount rate 5%) of C$463 million and post-tax unlevered internal rate of return ("IRR") of 23.2% using a long-term gold price of US$1,700 per ounce and an exchange rate of C$1.00 = US$0.77.
- Increased production profile: Annual average production increased from 115,000 ounces of gold ("oz Au") in the Preliminary Economic Assessment ("PEA") to 161,000 oz Au supported by a 50% increase in mill throughput, 15% increase in peak mine rate, lower cut-off grade of 0.30 g/t Au compared to 0.35 g/t Au in the PEA, lower strip ratio of 5.1 and increased mill gold recovery.
- Low capital intensity: Initial capital ("CAPEX") of C$435 million including mine preproduction, processing, and infrastructure (roads, power distribution, tailings facility, ancillary buildings, and water management). Capital intensity ratio ("NPV/CAPEX") of 1.1x per dollar invested.
- Competitive cost profile and rapid payback: All-in-Sustaining Cost ("AISC") of US$882 per ounce, a post-tax payback of 3.5 years, with C$1,971 million EBITDA and C$760 million post-tax free cash flow over the life of mine ("LOM").
- Optimization and exploration upside towards Feasibility Study in 2023: Well-funded to perform trade-off studies assessing new technologies including autonomous haulage and trolley assist mine fleet that may impact project economics and reduce environmental footprint. Additionally, O3 Mining will continue with a brownfield exploration program on Marban Engineering including the expansion of all lateral extensions of the near-surface mineralization, unlock the potential in the Hygrade Fold area (North-West of Kierens pit) as well as the downdip extension of the Marban deposit.
Jose Vizquerra, President and CEO, states: "We are pleased with the results of our PFS for the Marban Engineering Project which demonstrates the potential to be the next gold producer in the Abitibi region in Val-d'Or, Quebec, the next step in delivering on our promise to be in production by 2026. With robust economics, Marban has shown itself to be a profitable standalone project. Using a long-term gold price of US$1,700 oz gold, the project has a post-tax unlevered IRR of 23.2% well above the 15% IRR investment threshold used by many larger gold miners, and a post-tax NPV of C$463M as well as an NPV/CAPEX ratio of 1.1x, with an AISC of US$882 per ounce. This is a key achievement in an inflationary environment in which mining companies are seeing higher cost increases. The project has an improved production profile of over 160,000 oz Au annually, for an approximately 10-year life of mine compared with our 2020 PEA. We believe the opportunity to grow Marban remains high, with many mineralized zones not included in the Mineral Resource Estimate, which could add to the LOM, and further improve Marban's economics. Current drilling at the Hygrade Fold area (North-west of Kierens pit) has the potential to add to the current resource within the greater Marban Engineering Project. We have the privilege to be developing Marban in a jurisdiction that has a green-powered grid with 99.6% renewable power and that has a strong carbon policy. Compared to other jurisdictions developing gold mines, Quebec's carbon intensity is one of the lowest in the world. Work on the feasibility-level studies has begun which we expect to complete in 2023. O3 Mining continues to deliver on all milestones and stated goals as we continue our progress towards production, and creating fundamental value with the Marban project for our shareholders and other stakeholders."
O3 Mining Webinar to be held on September 6th, 2022 at 11:00 a.m. EST – REGISTER HERE
Marban Engineering PFS Presentation available here: VRIFY Presentation
The Marban project is located between the cities of Malartic and Val d'Or in the Abitibi gold district of Québec, Canada. The project area contains six past-producing mines, which collectively produced 585,000 ounces of gold between 1959 and 1992. The land package owned by O3 Mining, in the heart of these mining camps, covers 125 square kilometres and is located 12 kilometres from the Canadian Malartic Mine and along the same shear structure as Wesdome Gold Mine's Kiena deposit.
- The PFS is based on the updated Mineral Resource Estimate ("MRE") from March 1, 2022 (see press release).
- The PFS project team was led by Ausenco Engineering Canada Inc. ("Ausenco"), an industry leader in cost-effective design and construction. Ausenco was supported by G Mining Services ("G Mining") and WSP Canada ("WSP").
The economic analysis was performed assuming a 5% discount rate. On a pre-tax basis, the NPV is $775 million, the IRR is 30.2% and the payback period is 2.8 years. On a post-tax basis, the NPV is $463 million, the IRR is 23.2% and the payback period is 3.5 years. A summary of the project economics is listed in Table 1 and shown graphically in the figures below.
Table 1: Summary of project economics
A sensitivity analysis was conducted on the base case after-tax NPV and IRR of the Marban project, using the following variables: gold price, total CAPEX (initial + sustaining), total operating cost, and US$:C$ exchange rate. The tables below provide a summary.
Table 2a: Post-Tax NPV (5%) Sensitivity, C$M
Table 2b: Post-Tax IRR Sensitivity
The PFS is based on the Open Pit Indicated portion of the Marban Mineral Resource Estimate, as published in "Marban Engineering NI 43-101 Technical Report & Mineral Resource Estimate".
The Proven and Probable Ore Reserves for the Marban project are estimated at 56.4 Mt at an average grade of 0.91 g/t Au for 1,807 Koz of contained gold at 0.3 g/t Au cut-off grade as summarized in Table 3. The Mineral Reserve is included within the Mineral Resource.
Table 3: Open-Pit Mineral Reserve (effective date August 17, 2022)
The Marban Engineering project will be mined with a conventional drill, blast, and haul setup. The project is split into three mining pit groups: Marban, Norlartic, and Kierens which are further split into nine sub pits and phases.
- The peak mining rate is 52.3 million tonnes per year over a mine life of 9.6 years.
- A total of 56.4 million tonnes (Mt) of ore will be mined at an average grade of 0.91 g/t, with a total of 286.1 Mt of waste mined, resulting in a stripping ratio of 5.07 tonnes waste per tonne of ore.
- The primary production equipment includes 16 m3 electric production shovels and 150 tonne off highway mining trucks augmented by a smaller overburden focused secondary fleet of 100 tonne trucks and 5 m3 excavators.
- Stockpile rehandling is minimal with a peak inventory of low-grade material consisting of 0.5 Mt in Production Year 7.
Special considerations are made in the mine plan to mine out the smaller northern pits (Kierens and Norlartic) early to allow in-pit deposition of the processing plant tailings and reduce the project footprint.
Table 4: PFS Mine Plan Production Summary
Metallurgical testing was completed at Base Metallurgical Laboratories ("BaseMet") (independent of O3 Mining) in Q1 2022. The gravity leach test results were analyzed to provide recovery models for use with the mine production schedule.
In addition to the predicted extraction, plant losses include:
- Soluble losses of 0.01 g/t Au
- Carbon losses of 40 g/t
- Fine carbon assays of 80 g/t Au for carbon losses
- Other plant losses of 0.2% Au
Recoveries for ore mined from the Marban and Kierens pits were estimated as 94.9% after plant losses based on the recovery model derived from the gravity leach test results. The Norlartic pit gravity leach tests results provided an estimated leach extraction as a function of head grade, outlined in Table 6.
Table 6: PFS Calculated Recoveries (Gold)
The process flowsheet was designed based on historical and recent test work carried out by Base Metallurgical Laboratories in 2022. The 2022 test work program investigated comminution (Bond Ball Mill Work Index tests), gravity separation, leach optimization, leach variability test work, cyanide detoxification, solid-liquid separation, and pressure filtration. The results indicate that the samples were of medium hardness, with Bond Ball Mill Work Index results ranging from 9.6 to 14.6 kWh/t, and the 75th percentile of the samples tested was 14.1 kWh/t. Historical comminution data was utilized for the balance of crushing and grinding circuits design.
Based on a mine-to-mill analysis, the processing plant capacity has been increased to 6.0 million tonnes per year or 17,900 tonnes per day at 92% availability.
The process design for the project consists of:
- Two-stage crushing, consisting of a primary jaw crusher and a secondary cone crusher with material handling equipment.
- Grinding of crushed material to 80% passing size of 85 μm with a 9.14 m diameter by 4.88 m length SAG mill and a 6.71 m diameter by 10.2 m length ball mill in a closed circuit with hydrocyclones. The SAG mill and ball mill are equipped with 8.0 MW and 8.7 MW motors, respectively.
- A gravity concentration circuit is included in the grinding area. Gravity concentrate will feed intensive cyanidation and will be recovered by electrowinning. Gold recovery of 24.6% is expected from the gravity concentrate.
- Leaching and adsorption circuit includes four leach tanks and six carbon-in-pulp (CIP) tanks, for a total leach and adsorption circuit retention time of 24 hours.
- Cyanide destruction using an SO2/air system on the final tailings slurry.
- Final tails from the cyanide destruction circuit will be thickened and discharged to the tailings storage facility.
The tailings management design was completed by Ausenco, and it is based on conventional thickened tailings storage. There are two storage facilities for the project:
- An initial "starter" tailings storage facility for the first 3.5 years of mill production. This facility is of ring dyke construction type and is located immediately south of the process plant. The design incorporates three phases to build the embankment over the life of the facility. Ultimate storage capacity of this facility is 13.2M m3 (19.3 Mt).
- In-pit deposition in the exhausted Norlartic pit, following the first 3.5 years of mill production through the end of the mine life. Total storage capacity of this pit is 25.4M m3 (37.1 Mt).
The total initial (pre-production) capital cost for the Marban project is estimated to be C$435 million including allowances for contingency of C$44 million. Sustaining costs are estimated to be C$283 million over the life of mine.
Capital and sustaining costs were compiled by Ausenco from the following sources:
- Mining initial capital costs were developed by G Mining, based on the final mine plan. Pre-production of one year was assumed with an owner-purchased and operated fleet.
- Mining sustaining capital costs were developed by G Mining and include major equipment repairs and equipment down payments and loan repayments.
- Processing, infrastructure, project delivery and project indirects were developed by Ausenco, and are inclusive of 6 Mtpa conventional leach/CIP processing plant, power substation, tailings facility initial construction, diversion of Keriens Creek, realignment of Chemin Gervais and other required infrastructure.
- Sustaining capital costs for infrastructure consist of lease repayments for mobile equipment, additional truck shop bays, permanent stockpile cover for the ore reclaim stockpile, two lifts for the initial tailings facility and overland piping installation for in-pit tailings deposition in production Year 4.
Table 7: Initial and Sustaining Capital Costs (C$M)
Operating costs have been compiled based on the following sources and assumptions:
- Mining unit costs have been estimated by G Mining based on 2022 quotes and database costs.
- Processing units costs have been estimated by Ausenco from first principles, using 2022 prices for major reagents and media.
- G&A costs are based on benchmark salary tables for staff positions and other costs from Ausenco databases. Due to the location of the project close to the town of Val D'Or, a camp and general administration offices are not included in the project scope; skilled workers are available locally and offices will be rented in Val D'Or for administrative staff.
Table 8: Total Life of Mine Operating Costs
In addition to applicable regulations, the Marban project will require social acceptability. Early information and consultation meetings have been held with local communities, First Nations Communities, local, provincial, and federal governmental authorities to initiate collaborative work to obtain social acceptability of the project.
The project will be subject to the regulations under the Canadian Impact Assessment Act and Québec's Environmental Quality Act. The environmental baseline studies are well advanced which will permit the initiation of the environmental impact studies.
O3 Mining will continue to regularly meet stakeholders as project milestones are reached and will be presenting and discussing the PFS results with the host communities.
Following the release of this PFS, O3 Mining will move the project forward towards the necessary bridging work for the commencement of the feasibility-level studies. The Corporation is well-funded to continue the drilling program on Marban Engineering including the expansion of all lateral extensions of the near-surface mineralization. Additionally, the O3 Mining will be looking to unlock the potential in the Hygrade Fold area (North-West of Kierens pit) as well as the downdip extension of the Marban deposit. Furthermore, an initial project description will be filed with the environmental agencies to initiate the impact process.
Additional trade-off studies will be completed during the bridging phase to the Feasibility Study assessing new technologies including autonomous haulage and trolley assist mine fleet that may impact project economics and environmental footprint.
O3 Mining will conduct a webinar to discuss the positive PFS results for Marban Project.
Date and Time: Tuesday, September 6th, 2022, 11:00 a.m. EST
Registration: O3 Mining Marban PFS Update
Details: Participants will be able to submit questions. A recording of the webinar will be made available on o3mining.com following the webinar. If you have any technical difficulties, please email info@o3mining.com
The scientific and technical information contained in this news release has been reviewed and approved by Mr. Louis Gariépy, P.Geo (OIQ #107538), Vice President Exploration of O3 Mining, who is a "qualified person" within the meaning of NI 43-101.
Half-core samples are shipped to Agat laboratory in Val-d'Or, Québec and Mississauga, Ontario for assaying. The core is crushed to 75% passing -2 mm (10 mesh), a 250 g split of this material is pulverized to 85% passing 75 microns (200 mesh) and 50 g is analyzed by Fire Assay (FA) with an Atomic Absorption Spectrometry (AAS) finish. Samples assaying >10.0 g/t Au are re-analyzed with a gravimetric finish using a 50 g charge. Commercial certified standard material and blanks are systematically inserted by O3 Mining's geologists into the sample chain after every 18 core samples as part of the Quality Assurance, Quality Control ("QA/QC") program. Third-party assays are submitted to other designated laboratories for 5% of all samples.
Historic assays have been validated through extensive validation procedures and analyses. Re-assaying of historic drilling is ongoing with re-assayed values included in the resource estimate. Data prior to 1984 that has not been re-assayed has not been included in the resource estimate due to lack of QA/QC. The drill program design, QA/QC and interpretation of results are performed by qualified persons employing a QA/QC program consistent with NI 43-101 and industry best practices.
The Corporation has included certain non-IFRS financial measures in this news release, such as initial capital cost, sustaining capital cost, total capital cost, AISC, and capital intensity, which are not measures recognized under IFRS and do not have a standardized meaning prescribed by IFRS. As a result, these measures may not be comparable to similar measures reported by other corporations. Each of these measures used are intended to provide additional information to the user and should not be considered in isolation or as a substitute for measures prepared in accordance with IFRS.
Non-IFRS financial measures used in this news release and common to the gold mining industry are defined below.
Total Cash Costs and Total Cash Costs per Ounce
Total cash costs are reflective of the cost of production. Total cash costs reported in the PFS include mining costs, processing, general and administrative costs of the mine, off-site costs, refining costs, transportation costs and royalties. Total cash costs per ounce is calculated as total cash costs divided by payable gold ounces.
AISC and AISC per Ounce
AISC (all-in sustaining cost) is reflective of all of the expenditures that are required to produce an ounce of gold from operations. AISC reported in the PFS includes total cash costs, sustaining capital, closure costs and salvage, but excludes corporate general and administrative costs. AISC per ounce is calculated as AISC divided by payable gold ounces.
O3 Mining Inc., an Osisko Group company, is a gold explorer and mine developer on the road to produce from its highly prospective gold camps in Québec, Canada. O3 Mining benefits from the support, previous mine-building success, and expertise of the Osisko team as it grows towards being a gold producer with several multi-million-ounce deposits in Québec.
O3 Mining is well-capitalized and owns a 100% interest in all its properties (66,000 hectares) in Québec. O3 Mining trades on the TSX Venture Exchange (TSXV: OIII) and OTC Markets (OTCQX: OIIIF). The Corporation is focused on delivering superior returns to its shareholders and long-term benefits to its stakeholders. Further information can be found on our website at https://o3mining.com
This news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "interpreted", "management's view", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of management of the Corporation, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Corporation nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Corporation does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
View original content to download multimedia:
SOURCE O3 Mining Inc. | https://www.wagmtv.com/prnewswire/2022/09/06/o3-mining-completes-pre-feasibility-study-marban-engineering-with-post-tax-npv-c463-million-unlevered-irr-232-annual-production-over-160koz-gold/ | 2022-09-06T11:33:40Z | https://www.wagmtv.com/prnewswire/2022/09/06/o3-mining-completes-pre-feasibility-study-marban-engineering-with-post-tax-npv-c463-million-unlevered-irr-232-annual-production-over-160koz-gold/ | false |
- From 24th September to 13th November, PortAventura World will be celebrating the longest edition in its history with top new additions such as the first Halloween passage of terror for children, Trick or Treat, and MTV Hor-Rock in Texas, a spooky musical circuit.
- The 12,000 pumpkins that will decorate PortAventura World are locally sourced and will be used after Halloween as food for the animals from nearby farms as an example of circular economy.
- Last year more than 800,000 people visited PortAventura World during Halloween, and the 2022 edition it is expected to surpass this number and the turnover of previous years
TARRAGONA, Spain, Sept. 6, 2022 /PRNewswire/ -- The longest and most terrifying season in PortAventura World's history, which will last for more than 50 days, is here with big new additions. From 24th September until 13th November, thrill-seekers will be able to visit 6 passages of terror, as well as a wide range of shows involving more than 200 artists with almost 200 hours of shows per week. One of the most special new additions is the first children's horror show, Trick or Treat, and MTV Hor-Rock in Texas. The resort will also celebrate its black edition on the night of 8th October at MTV Hor-Rock Night.
For David García Blancas, General Business Manager at PortAventura World, "Halloween is one of the most anticipated times of the year for our customers and this was proven last year with our more than 800,000 visitors. This year we will be celebrating one of the longest seasons ever, with more than 50 days to have a scarily great time, with the aim of reaching record figures yet again and surpassing the revenues of previous years".
Sustainability and good environmental practices will also play their part during the season. As has become tradition, every corner of the park will be decorated with over 12,000 pumpkins, which will weigh more than 120,000 kg in total and will be grown on a farm in the Penedés region near the resort, following the circular economy and zero waste strategy implemented by the company. Halloween will also be celebrated in a special way at PortAventura's Village Dreams, the PortAventura Foundation's play area where families with children with serious illnesses are staying as part of their emotional recovery therapy.
Photo: https://mma.prnewswire.com/media/1892218/Halloween_celebration.jpg
View original content to download multimedia:
SOURCE PortAventura World | https://www.wibw.com/prnewswire/2022/09/06/portaventura-world-is-showcasing-its-longest-most-sustainable-halloween-celebration-yet-with-two-new-passages-terror/ | 2022-09-06T11:33:51Z | https://www.wibw.com/prnewswire/2022/09/06/portaventura-world-is-showcasing-its-longest-most-sustainable-halloween-celebration-yet-with-two-new-passages-terror/ | false |
MONTREAL and CHARLOTTE, N.C., Sept. 6, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 12:00 p.m. ET in New York, NY.
A live webcast of the presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.
Contact
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
View original content to download multimedia:
SOURCE Milestone Pharmaceuticals, Inc. | https://www.mysuncoast.com/prnewswire/2022/09/06/milestone-pharmaceuticals-present-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-06T11:34:51Z | https://www.mysuncoast.com/prnewswire/2022/09/06/milestone-pharmaceuticals-present-hc-wainwright-24th-annual-global-investment-conference/ | true |
Digital pathology platform will improve collaboration across multi-site network and lay the foundation for unlocking new diagnostic insights with AI
JAÉN, Spain and PHILADELPHIA, Sept. 6, 2022 /PRNewswire/ -- Proscia®, a leader in digital and computational pathology solutions, and University Hospital of Jaén have partnered to modernize the hospital's pathology practice. University Hospital of Jaén will leverage Proscia's Concentriq® Dx to optimize routine diagnosis while laying the foundation for implementing artificial intelligence (AI), better informing patient care. This news comes on the heels of Proscia's formal expansion into Spain to accelerate its international growth.
Laboratories are rapidly adopting digital pathology, which shifts the 150-year-old standard of care from microscope to whole slide image, to overcome systemic challenges in the traditional laboratory model and capitalize on the growing potential to improve treatment decisions. These digital laboratories are not only driving quality and efficiency gains in routine workflows but also streamlining collaboration among distributed teams and unlocking new diagnostic insights with AI. As University Hospital of Jaén sits at the center of a multi-site network in Andalusia, it recognized that it was in prime position to benefit from digital pathology and selected the scalable, highly-interoperable Concentriq Dx to enable its digital transformation.
CE-marked under IVDR, Concentriq Dx is a singular, secure digital pathology platform that powers routine workflows across the connected enterprise.* Pathologists at University Hospital of Jaén will draw on its intuitive experience for viewing and accessing images to optimize their primary diagnostic workflows. Concentriq Dx also offers live, asynchronous, and remote access to whole slide images, enabling the hospital to streamline collaboration among sites and provide patients with faster access to expertise. The platform's best-of-breed interoperability will further help pathologists to make more confident diagnoses by unifying siloed data across the network.
"We are excited to have found a platform that will empower us to remain at the forefront of diagnostic medicine," said Rafael J. Luque Barona, MD Ph.D., Director of the Pathological Anatomy Laboratory at the University Hospital of Jaén. "As Concentriq Dx is flexible and open, it will allow us to leverage the latest innovations in digital and computational pathology throughout the Andalusian region to best serve our patients."
In addition to integrating with leading scanners, laboratory information systems, and image analysis applications, Concentriq Dx is AI-ready and designed to support laboratories in realizing pathology's computational future. The platform will support the future integration of AI applications into clinical workflows, enabling pathologists to expand the breadth of diagnostic information available and view these insights alongside all of their other pathology data to better inform diagnosis.
"Digital pathology is delivering real benefits today and holds even more promise for tomorrow," said Arun Ananth, Proscia's Chief Commercial Officer. "As we formally expand into Spain, it is especially energizing to work with a laboratory that is eager to capitalize on the unfolding potential in seeing through its commitment to excellent patient care."
*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.
Proscia is a software company that is accelerating pathology's digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 10 of the top 20 pharmaceutical companies rely on Proscia's software each day. For more information, visit proscia.com.
The University Hospital of Jaén is the result of the merger of the hospitals of the city of Jaén that took place on June 28, 2003. It is made up of a Diagnosis and Treatment Center, the Doctor Sagaz Hospital, the Maternal-Infant Hospital, the General Hospital and Neurotramatological Hospital. Its main axes are to orient the center to citizens, improve efficiency in management and healthcare provision, expand training and promote research at the University Hospital of Jaén.
Responding to the user's health demand and effectively attending to the health needs of the people of Jaén are some of the priority lines, so that the patient is provided with comprehensive, personalized and top-quality care, betting on the technological innovation, continuous training of its professionals and research. The objective is to offer care focused on the needs of the patient, to offer an increasingly agile, accessible, humane service, where assistance is based on the development of knowledge, innovation, motivation and teamwork of our professionals. For more information, visit hospitaljaen.es.
CONTACT: Sydney Fenkell, Sydney@proscia.com
View original content to download multimedia:
SOURCE Proscia | https://www.kswo.com/prnewswire/2022/09/06/university-hospital-jan-adopts-proscias-concentriq-dx-better-inform-patient-care/ | 2022-09-06T11:37:13Z | https://www.kswo.com/prnewswire/2022/09/06/university-hospital-jan-adopts-proscias-concentriq-dx-better-inform-patient-care/ | false |
Gale Strategies Addresses Demand for Results-Driven B2B Technology Marketing
DARIEN, Conn., Sept. 6, 2022 /PRNewswire/ -- Today Gale Strategies announced the launch of its first principles marketing platform. Building on their already widely successful marketing and public relations process - connecting businesses with the audiences that drive their growth - Gale Strategies' new capabilities take marketing performance to a new level.
"We pursue a first principles approach, which is to say we don't just do things for our clients because it's considered marketing," said Gale Strategies co-founder Chris Gale. "We narrow down to a process focused on actually bringing in deals, investments or credible category leadership. We cut away the nonsense and exercise healthy skepticism in selecting, testing and proving the right package and sequence of tactics, and overall strategy for our clients."
Gale Strategies was launched to dispense with B2B technology public relations and marketing that could not show its value and relied on vague measures of success. The new platform includes:
- Publication relations
- Social marketing
- Branding
- SEO
- SalesOps
Gale Strategies' offering is rooted in bringing in specific opportunities in a highly targeted manner that aligns with clients' sales pipelines, investor relations and deal flow. The team was built from the ground up to deliver a scalable, seamless, tech-driven marketing platform. Gale Strategies delivers high touch service with intuitive processes, connecting audiences with businesses through intelligent, efficient production.
The firm's clients include leading private equity, enterprise technology and tech startup teams. Gale Strategies intentionally diversifies the industry verticals they serve to focus on intersections where technology is transforming longstanding, complex, high stakes work.
About Gale Strategies
Gale Strategies streamlines marketing and public relations on a single platform. The firm was founded in Darien, Connecticut in 2019 and operates nationwide and in Europe. For more information visit www.GaleStrategies.com.
CONTACT: Chris Gale at Chris@GaleStrategies.com
View original content:
SOURCE Gale Strategies LLC | https://www.kbtx.com/prnewswire/2022/09/06/gale-strategies-launches-first-principles-marketing-platform/ | 2022-09-06T11:39:48Z | https://www.kbtx.com/prnewswire/2022/09/06/gale-strategies-launches-first-principles-marketing-platform/ | false |
CARMIEL, Israel, Sept. 6, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference. The conference is being held on September 12-14, 2022 at the Lotte New York Palace Hotel in New York City. Virtual participation will also be available.
Dror Bashan, the Company's President and Chief Executive Officer, will provide a corporate overview at the conference. A webcast of the presentation will be available commencing on Monday, September 12, 2022 at 7:00 AM, Eastern time, and will be archived.
Webcast Details:
The conference will be webcast live from the Company's website and will be available via the following links:
Company Link: https://protalixbiotherapeutics.gcs-web.com/events0
Webcast Link: https://journey.ct.events/view/326342b0-083d-4eca-81f7-f93cc78d3394
The Company's management will participate in one-on-one meetings with investors who are registered to attend the conference. If you are an institutional investor and would like to attend the Company's presentation, registration for the conference is available at https://hcwevents.com. Once your registration is confirmed, you will be prompted to log onto the conference website to request a one-on-one meeting with the Company.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α–Galactosidase–A protein for the treatment of Fabry disease; alidornase alfa or PRX–110, for the treatment of various human respiratory diseases or conditions; PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.
Investor Contact
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:
SOURCE Protalix BioTherapeutics, Inc. | https://www.kbtx.com/prnewswire/2022/09/06/protalix-biotherapeutics-present-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-06T11:43:00Z | https://www.kbtx.com/prnewswire/2022/09/06/protalix-biotherapeutics-present-hc-wainwright-24th-annual-global-investment-conference/ | true |
'He said no!' Harry Styles is seen refusing to stand next to girlfriend Olivia Wilde on the Don't Worry Darling red carpet in viral video
They have done their best to keep their romance out of the spotlight during the promotional trail for their new movie.
And Harry Styles has now been filmed refusing to stand next to his girlfriend Olivia Wilde at Monday night's Venice Film Festival premiere of Don't Worry Darling.
In a clip shared by fans on Twitter, Harry, who plays the male lead in the movie directed by Olivia, is shown politely declining a request from a member of his girlfriend's team to switch positions on the red carpet.
The video shows Olivia, Harry and his castmates lining up for a group photo in front of the world's cameras.
Harry is seen taking his position between co-stars Gemma Chan and Sydney Chandler before a staff member gestures for him to move to stand next to Olivia.
Harry seems to refuse, staying in position between his co-stars.
'SOMEONE FROM OLIVIA'S TEAM ASKED HARRY TO TAKE PICTURES WITH HER/STAN NEXT TO HER AND HE SAID NO,' the tweeter captioned the clip.
Polite no: Harry Styles has been filmed refusing to stand next to his girlfriend Olivia Wilde at Monday night's Venice Film Festival premiere of Don't Worry Darling
Staying out: Harry is seen taking his position between co-stars Gemma Chan and Sydney Chandler before a staff member gestures for him to move to stand next to Olivia
Harry and Olivia fell for each other on the set of Don't Worry Darling last year, when Olivia replaced her original male lead Shia LaBeouf with Harry in Autumn 2020.
There have been conflicting reports as to the timeline of Olivia's split from her ex husband Jason Sudeikis, with whom she shares two children, and when she started her new relationship with Harry.
Rumours of Harry and Olivia's romance were confirmed when they were seen holding hands at his agent's wedding in Montecito, California, on January 3 2021, raising eyebrows over just how quickly she had moved on.
Since then the couple have rarely appeared in public together or spoken about their relationship.
Sweet moment: The couple, who fell for each on the set of the movie, kept their distance all night but did exchange a loving glance at one point
Feud: Harry and Olivia's romance is said to be the catalyst for a rumoured feud between Olivia and Don't Worry Darling's lead actress Florence Pugh (pictured at the premiere)
Their romance is said to be the catalyst for a rumoured feud between Olivia and Don't Worry Darling's lead actress Florence Pugh.
A report from Page Six in late July claimed that Pugh was upset that Wilde was hooking up with Styles during the production — while still married to Jason Sudeikis — before they split in November.
'I can tell you for a fact that Flo seeing Olivia and Harry all over each other on set did not go down well as Olivia was still with Jason when she first hooked up with Harry,' the source said.
Others have noticed that Pugh has sparsely posted about the film on her social media accounts, which has also fueled rumors of friction on the set.
Florence skipped Monday's photocall and press conference for the movie, with the official line being that she was tied up with filming her next movie Dune 2 in Budapest.
She did fly in for the world premiere though, wowing in a bejewelled Valentino playsuit but keeping an awkward distance from Harry and Olivia.
Drama: A report from Page Six in late July claimed that Pugh was upset that Wilde was hooking up with Styles during the production (Styles and Pugh pictured in the film) | https://www.dailymail.co.uk/tvshowbiz/article-11184773/Harry-Styles-seen-refusing-stand-Olivia-Wilde-Dont-Worry-Darling-premiere.html?ns_mchannel=rss&ns_campaign=1490&ito=1490 | 2022-09-06T11:45:34Z | https://www.dailymail.co.uk/tvshowbiz/article-11184773/Harry-Styles-seen-refusing-stand-Olivia-Wilde-Dont-Worry-Darling-premiere.html?ns_mchannel=rss&ns_campaign=1490&ito=1490 | false |
Congress begins work on next Farm Bill
WASHINGTON (Gray DC) - The initial steps for deciding the next five years of U.S. agriculture policy is underway.
Ranking member of the Senate Agriculture Committee John Boozman, R-AR, will play a significant role in the process. He is currently touring farms to ask farmers what they need.
Boozman said a better safety net for crops is a top priority.
“They spend all the money to get it planted, and maybe they have crop failure because of drought,” Boozman said. “We’ve experienced so much throughout the country.”
A new Farm Bill is passed every five years. The previous Farm Bill expires in September of 2023.
The National Farmers Union said the COVID-19 pandemic exposed the issue of farmers not having enough control over getting their products to market.
“Because of corporate monopolies in the middle of the food chain, we didn’t have a lot of marketing options for farmers when tough times hit,” National Farmers Union VP of Advocacy Mike Stranz said. “When the pandemic upended supply and demand.”
Boozman and the NFU both said high input costs for items like fertilizer and gasoline are hurting the industry.
Boozman also said the next Farm Bill should also focus on conservation and innovation to protect farmers from severe weather.
“The research dollars that we put into the Farm Bill, scientists are discovering different strains of crops that are more drought tolerant,” Boozman said.
The NFU says the next farm bill needs to address production, distribution and attract a lot of support. Stanz said that will help the agriculture industry, and ultimately customers, when prices on store shelves are lower.
“We need to protect our food supply. We need to have a competitive agriculture economy,” Stanz said. “So by having this big, broad coalition, we’ll all be better off with a stronger farm bill.”
Boozman says lawmakers will continue learning about differences in regional needs from farmers throughout the country before crafting any legislation.
Copyright 2022 Gray DC. All rights reserved. | https://www.wflx.com/2022/09/05/congress-begins-work-next-farm-bill/ | 2022-09-06T11:45:41Z | https://www.wflx.com/2022/09/05/congress-begins-work-next-farm-bill/ | false |
BERLIN (AP) — Russia sent significantly more oil and coal to India and China over the summer compared with the start of the year, while European countries that long relied on Russian energy have cut back sharply in response to the war in Ukraine, said a report published Tuesday.
The Centre for Research on Energy and Clean Air said Russia received about 158 billion euros ($158 billion) in revenue for the sale of oil, natural gas and coal from February to August, more than half of which — some 85 billion euros worth — was exported to the European Union.
Within the EU, Germany was the biggest importer, buying 19 billion euros worth of fossil fuels from Russia during the six-month period.
The single biggest importer worldwide, however, was China, which bought 35 billion euros worth of Russian energy, the Helsinki-based group said.
While Russia's revenue rose, overall export volumes dropped by 18% compared with when the country invaded Ukraine, the report said.
The EU has cut its imports from Russia by 35% since the war began, with Russian coal now banned in the 27-nation bloc and a halt to oil sales due to take effect at the end of the year.
Russia itself has sharply cut flows of natural gas to the EU, indicating this week that they would not resume unless Western sanctions are lifted.
Germany's economy minister, Robert Habeck, said Monday that his country doesn't expect gas imports from Russia to resume anymore.
Meanwhile, India and China imported significantly more coal and crude oil from Russia in July and August than in February and March, the group said. | https://www.taiwannews.com.tw/en/news/4649770 | 2022-09-06T11:47:13Z | https://www.taiwannews.com.tw/en/news/4649770 | false |
American Frances Tiafoe, 24, has reached the quarterfinals for the first time. Of the eight men left at the U.S Open, six are ranked outside of the top 10.
Copyright 2022 NPR
American Frances Tiafoe, 24, has reached the quarterfinals for the first time. Of the eight men left at the U.S Open, six are ranked outside of the top 10.
Copyright 2022 NPR | https://www.nepm.org/2022-09-06/no-22-seed-ends-rafael-nadals-22-match-grand-slam-streak-at-the-u-s-open | 2022-09-06T11:47:17Z | https://www.nepm.org/2022-09-06/no-22-seed-ends-rafael-nadals-22-match-grand-slam-streak-at-the-u-s-open | true |
Footage released after tyres damaged in Kettering street
Can you help police identify this man?
By Stephanie Weaver
Tuesday, 6th September 2022, 10:13 am
Updated Tuesday, 6th September 2022, 10:13 am
Police have released footage of a man they wish to speak to after incidents of criminal damage in Wallis Road, Kettering.
The incidents happened in the early hours of Sunday, August 21, when a number of tyres were punctured by an unknown object.
The man in the footage or anyone who recognises him should call Northamptonshire Police on 101 quoting incident number 22000485832.
Most Popular
-
1
PICTURES: Spectacular storms light up Northampton skies at 1am
-
2
Plans unveiled to DEMOLISH busy Northampton petrol station as part of 'much-needed' refurbishment
-
3
Emergency services called to Northampton town centre due to concerns for woman’s welfare
-
4
Motorcyclist dies in fatal road traffic collision with ambulance in Northamptonshire
-
5
Thieves, vandals, drink-drivers and thugs from Northampton, Daventry, Moulton and Hardingstone sentenced in court | https://www.northamptonchron.co.uk/news/crime/footage-released-after-tyres-damaged-in-kettering-street-3832640 | 2022-09-06T11:48:03Z | https://www.northamptonchron.co.uk/news/crime/footage-released-after-tyres-damaged-in-kettering-street-3832640 | false |
NEW ORLEANS, La. (AP) — Former New Orleans Mayor Moon Landrieu — whose early, lonely stand against segregationists in the Louisiana legislature launched a political career at the forefront of sweeping changes on race — died Monday, a family friend confirmed. He was 92.
Ryan Berni, a longtime friend of the family, confirmed that Landrieu passed away early Monday.
“He died peacefully this morning surrounded by family,” Berni told The Associated Press.
A progressive white Democrat whose demeanor could be combative at times, Landrieu came from a blue-collar Roman Catholic family, served in the Army and sat alongside the first Black students at the city’s Loyola law school before winning a statehouse seat in 1960.
By then, six years had passed since the U.S. Supreme Court ordered public schools to desegregate nationwide, and Landrieu couldn’t in good conscience go along when Gov. Jimmie Davis steamrolled legislation to keep students in New Orleans separated by race. They passed by lopsided margins with Landrieu, at least once, the lone “no” vote.
The white politicians who had a lock on power on Louisiana said he’d dug his political grave, but he held onto his House seat in 1963 and then won a city council seat in 1965 with strong support from Black voters, whose influence was beginning to be felt at the polls.
To win his first mayoral term, Landrieu assembled a coalition of white liberals and African Americans and campaigned to bring Black people into important positions in government.
Integrating City Hall had its costs: In a 2018 memoir, Mitch Landrieu wrote that death threats were phoned into his family home and his school. Moon Landrieu discussed the blowback over race in a 1977 speech to the National League of Cities convention.
“If you embark on a campaign to end racial discrimination in your hometown, you will need nerves of steel, a will of iron, skin like leather and testicles of brass to withstand the slings and arrows,” he said. “I have myself these past eight years been known in some quarters as ‘Moon the Coon,’ an epithet that has caused me some pain at times, but that is also a badge of honor that bears testimony to what we try to do.”
His mayoral legacy also includes his support for the state’s construction of the Louisiana Superdome, which finally opened in 1975. It’s a beloved fixture of the city landscape now, but cost overruns and a contract scandal caused headaches for its supporters, including Landrieu.
“There has been an unbelievable emphasis on the few things that have been wrong with it and total neglect of the many, many things that are right with it,” he said several years later.
As Black voters gained influence, the coalition that elected Landrieu to the maximum two terms helped make Ernest “Dutch″ Morial the city’s first Black mayor, in 1978.
Landrieu then became President Jimmy Carter’s secretary of housing and urban development, an agency whose programs came under attack when President Ronald Reagan took office on a platform to reduce the federal government’s size and power.
Landrieu criticized Reagan for “gutting” public aid programs, and briefly considered a presidential bid of his own. But he never sought national office. Instead, he became a judge — “I really wanted to get out of my kids’ way,” he said – serving on Louisiana’s 4th Circuit Court of Appeal from 1992 to 2000.
Several of Landrieu’s nine children continue his legacy in law and politics: Mitch, also a two-term New Orleans mayor, is now President Joe Biden’s infrastructure coordinator; Mary, who served three terms as a U.S. senator, is now a policy adviser with a Washington law firm. Madeleine became dean of the law school at Loyola University New Orleans, and Maurice is a federal prosecutor.
Born Maurice E. Landrieu on July 23, 1930, he was called Moon, a family nickname, throughout his life and eventually made that his legal first name. He served three years in the Army before opening a small, walk-up law office with law school classmate Pascal Calogero, later the chief justice of the Louisiana Supreme Court.
Landrieu credited his wife, Verna, with nudging him into politics, and his Black classmates, including Norman Francis, who would become Xavier University’s dean and president, for opening his eyes.
“It wasn’t just a question of racial justice, but from a practical standpoint, I recognized — as a politician, as a legislator and councilman — that we were wasting so much talent, wasting so much energy, by precluding Blacks from participation in all matters,” he recalled in a 2020 interview with the New Orleans weekly newspaper Gambit.
“And I was determined, as I became mayor, to revitalize this city and to bring about racial integration, so that the city could enjoy the full benefit of white and Black participants.”
Gov. John Bel Edwards called Landrieu a man of “bold vision.”
“Moon Landrieu was a courageous and defining voice for Louisiana and his beloved hometown of New Orleans,” Edwards said in a statement. “In addition to his many contributions to our state and nation, he leaves behind the most enduring legacy of all – a family that continues his fight for equality.” | https://www.pahomepage.com/news/politics/ap-new-orleans-political-patriarch-moon-landrieu-has-died/ | 2022-09-06T11:50:46Z | https://www.pahomepage.com/news/politics/ap-new-orleans-political-patriarch-moon-landrieu-has-died/ | true |
NEW YORK (AP) — Serena Williams has reached her break point — she caught up on her rest following her last match at the U.S. Open.
The 40-year-old Williams posted a photo on Instagram Monday of herself under a “Moana” blanket and seemingly asleep as she used a stuffed animal as a pillow. The mother of 5-year-old Olympia, Williams wrote, “How was your weekend? This was mine.”
Her career seemingly came to an end when she lost last week in her final U.S. Open. Williams won 23 Grand Slam titles and was celebrated by celebrities, fellow competitors and fans throughout her matches at Flushing Meadows. The tributes from tennis players to the NFL stretched into Monday.
Rising American standout Frances Tiafoe recalled after his upset win Tuesday over Rafael Nadal the inspiration he received from watching Serena and her older sister, Venus.
“At that time watching Serena and Venus play finals of Grand Slams at that time, when I was super young, I was like, how cool would it be to play Wimbledon, to play on Arthur Ashe and stuff like that,” Tiafoe said after his big win at Ashe.
Tampa Bay quarterback Tom Brady — like Williams, another age-defying championship athlete — praised Williams on Monday on his weekly podcast.
“What a joy it was to watch her play,” Brady said. “She didn’t play for a little while, and I think she realized it’s a lot of fun to play. And I think sometimes when you’re in the middle of it, you take it for granted to a degree, like, ‘Oh, it will be there.’ And then it’s not there for a year and you go, ‘God, I really love it. I really want to play.’ And then you get out there and play and you enjoy it.”
Williams turns 41 on Sept. 26 and says she wants to grow her family and pursue business interests.
___
More AP coverage of U.S. Open tennis: https://apnews.com/hub/us-open-tennis-championships and https://twitter.com/AP_Sports | https://www.pahomepage.com/sports/ap-serena-williams-gets-well-earned-rest-following-us-open-exit/ | 2022-09-06T11:53:09Z | https://www.pahomepage.com/sports/ap-serena-williams-gets-well-earned-rest-following-us-open-exit/ | true |
TEMPE, Ariz., Sept. 6, 2022 /PRNewswire/ -- Bierman Autism Centers recently announced that it has appointed Dr. Bryan Davey, BCBA-D, LBA as its new Chief Operating Officer. In this role he will lead the operations team and will closely partner with the clinical leadership of the company.
Dr. Davey has clinical expertise in training personnel in applying behavioral principles and procedures, functional behavior assessments, assessment and treatment of severe and complex behaviors, organizational behavior management and effective teaching practice.
He has held various executive leadership positions at both for profit and non-profit organizations. He has served as an SVP of Operations for a national behavioral health organization that operated a continuum of treatment programs for children, adolescents, adults, and families. Prior to that he served as CEO of a multi-site integrated physical and behavioral health organization, which primarily focused on children served through Medicaid. Most recently, Dr. Davey was the CEO of a telehealth platform that served members in over 40 countries.
In addition, Dr. Davey advocates for behavior analysis by supporting certification, practice standards, monitoring, developing legislation, policy at the state and national levels. Dr. Davey serves on the Arizona Governor's Autism Spectrum Disorder Committee and Telehealth Advisory Committee. He is a past Board Member and Public Policy Chair of CalABA, founding member of AZABA, a past Board Member and Past-President of APBA, and served on the National ABA CPT Code Steering Committee. He continues to serve as a subject matter expert to the BACB, CASP, health plans, and managed care organizations.
When asked about his addition to the team, Dr. Davey said "I am honored to join Bierman Autism Centers and I look forward to working alongside so many amazing clinicians and professionals as we support the families that trust us with their children's care and growth. Our mission is to Create Progress & Possibilities for Children with Autism, and I am thrilled to join a team that sets the standard in services and continues to achieve impactful outcomes for the families and individuals we serve."
By adding Dr. Davey as Chief Operating Officer, Bierman continues to focus on clinical excellence and quality of care.
Bierman Autism Centers is a place where kids up to 9 years of age acquire foundational skills they can build on such as self-advocacy and communication. To date they have graduated over 175 kids from their programs. They recognize that every kid's success is unique, and their one-on-one approach allows them to drive progress and measurable outcomes, ensuring each child is advancing on their own terms. Bierman currently has 14 centers, and is expanding in: Arizona, Indiana, Massachusetts, North Carolina, New Jersey, Rhode Island, and Ohio. For more about Bierman Autism Centers visit www.biermanautism.com or contact marketing@biermanautism.com.
View original content to download multimedia:
SOURCE Bierman Autism Centers | https://www.valleynewslive.com/prnewswire/2022/09/06/bierman-autism-centers-names-dr-bryan-davey-bcba-d-lba-chief-operating-officer/ | 2022-09-06T11:53:51Z | https://www.valleynewslive.com/prnewswire/2022/09/06/bierman-autism-centers-names-dr-bryan-davey-bcba-d-lba-chief-operating-officer/ | false |
A federal judge ruled in favor of former President Trump on Monday, ordering an independent review of materials seized by the FBI at Trump's Florida home. It's a temporary setback for investigators.
Copyright 2022 NPR
A federal judge ruled in favor of former President Trump on Monday, ordering an independent review of materials seized by the FBI at Trump's Florida home. It's a temporary setback for investigators.
Copyright 2022 NPR | https://www.wlrn.org/2022-09-06/a-judge-grants-trumps-special-master-request-to-review-mar-a-lago-materials | 2022-09-06T11:57:18Z | https://www.wlrn.org/2022-09-06/a-judge-grants-trumps-special-master-request-to-review-mar-a-lago-materials | false |
ISELIN, N.J., Sept. 6, 2022 /PRNewswire/ -- Hexaware Technologies, a fast-growing Global IT Consulting and Digital Solutions provider, today announced that it has achieved the Guidewire PartnerConnect specialization: Technical Upgrades.
Hexaware Technologies is a Guidewire PartnerConnect Consulting partner at the Advantage level and works with Guidewire in North America, EMEA, and Asia-Pacific.
Hexaware delivers state-of-the-art solutions to boost the digital capabilities of insurers and is a top choice for successful implementation with its customer-centric approach and domain expertise. The company offers quick, accurate, accessible, and reliable services at all touchpoints, exceeding user expectations. Hexaware always strives to provide tailor-made implementation and comprehensive management solutions for the Guidewire platform with its tools and technologies.
Specializations are both regionally and globally based and require partners to demonstrate skills, knowledge, and competency in a particular Guidewire product or solution area. The achievement of specializations enables insurers to have more clarity and insight into which partners have proven capabilities in a region. In addition, partners with specializations can better promote their capabilities across Guidewire products and solutions.
Molly Black, Senior Director, Partner Programs and Enablement, Global Alliances, Guidewire Software, says, "Congratulations to Hexaware on their most recent Technical Upgrades specialization within our PartnerConnect Consulting program. We're thrilled to recognize Hexaware for their expertise in Guidewire products and solutions and for continuing to provide successful implementations for our shared customers."
Milan Bhatt, Corporate Vice President, Healthcare & Insurance, Hexaware, said, "Hexaware believes in the 'Automation First Approach', and we have invested heavily in tools and technology to accelerate Guidewire upgrades. Hexaware is committed to helping customers take full advantage of the Guidewire platform for enhanced operational efficiencies. We already have multiple customer testimonials from Europe. Achieving the Guidewire Technical Upgrades specialization will be an important step in helping insurers around the world leverage our tools and services to bring down the upgrade-related cost significantly."
Please find more information about Guidewire specializations on the Guidewire website here.
About Hexaware
Hexaware is a global IT, BPS and consulting services company empowering businesses worldwide to realize digital transformation at scale and speed.
Learn more about Hexaware at http://www.hexaware.com. Take an immersive 360° virtual tour of our campuses worldwide at https://www.hexawareimmersive.com
Logo: https://mma.prnewswire.com/media/530945/Hexaware.jpg
View original content:
SOURCE Hexaware Technologies Ltd. | https://www.wlbt.com/prnewswire/2022/09/06/hexaware-achieves-guidewire-partnerconnect-program-specialization/ | 2022-09-06T11:58:35Z | https://www.wlbt.com/prnewswire/2022/09/06/hexaware-achieves-guidewire-partnerconnect-program-specialization/ | true |
WATERTOWN, Mass., Sept. 6, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the Company's participation at the H.C. Wainwright 24th Annual Global Investment Conference (the Conference). Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in person at the conference on Wednesday, September 14th at 12:00 p.m. EDT.
The Conference will be held at the Lotte New York Palace Hotel from September 12-14, during which Lyra will also host one-on-one meetings with investors.
The webcast of the fireside chat will be available on the Investor Relations section of the Company's website at https://investors.lyratherapeutics.com and will be available for at least 30 days following the event.
About Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches. Lyra's XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The Company's current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for up to six months following a single non-invasive, in-office administration. Lyra has two product candidates in late-stage development for CRS, a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities: LYR-210, for surgically naïve patients, is being evaluated in the ENLIGHTEN Phase 3 clinical program, and LYR-220, for patients who have recurrent symptoms despite surgery, is being evaluated in the BEACON Phase 2 clinical trial. These two product candidates are designed to treat the estimated four million CRS patients in the U.S. that fail medical management each year. For more information, please visit lyratherapeutics.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the dates and times of the investor conferences discussed in this press release, our pipeline and development of product candidates, including LYR 210 and LYR 220, and the progress and timing of clinical trials, and the anticipated success of leveraging the XTreo™ platform. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the Company has incurred significant losses since inception and expects to incur additional losses for the foreseeable future; the Company's need for additional funding, which may not be available; the Company's limited operating history; the fact that the Company has no approved products; the fact that the Company's product candidates are in various stages of development; or the fact that the Company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the Company's product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the Company's product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the Company's inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the Company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the Company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the Company's reliance on third parties to conduct its preclinical studies and clinical trials; the Company's inability to succeed in establishing and maintaining collaborative relationships; the Company's reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the Company's intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the Company's growth; effects of natural disasters, terrorism and wars (including the developing conflict between Ukraine and Russia); the fact that the global pandemic caused by COVID-19 could adversely impact the Company's business and operations, including the Company's clinical trials; the fact that the price of the Company's common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation. These and other important factors discussed under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities Exchange Commission (SEC) on August 9, 2022 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
Contact:
Kathryn Morris
The Yates Network LLC
914-204-6412
kathryn@theyatesnetwork.com
View original content to download multimedia:
SOURCE Lyra Therapeutics, Inc. | https://www.valleynewslive.com/prnewswire/2022/09/06/lyra-therapeutics-present-hc-wainwright-annualglobal-investment-conference-2022/ | 2022-09-06T11:58:40Z | https://www.valleynewslive.com/prnewswire/2022/09/06/lyra-therapeutics-present-hc-wainwright-annualglobal-investment-conference-2022/ | false |
375 Bitcoin mined, bringing reserves to 8,111
TORONTO, Sept. 6, 2022 /PRNewswire/ - Hut 8 Mining Corp. (Nasdaq: HUT) (TSX: HUT), ("Hut 8" or the "Company") one of North America's largest, innovation-focused digital asset mining pioneers and high performance computing infrastructure provider, increased its Bitcoin holdings by 375 in the period ending August 31, bringing its total self-mined holdings to 8,111 Bitcoin.
- 375 Bitcoin were generated, resulting in an average production rate of approximately 12.1 Bitcoin per day.
- Keeping with our longstanding HODL strategy, 100% of the self-mined Bitcoin in August were deposited into custody.
- Total Bitcoin balance held in reserve is 8,111 as of August 31, 2022.
- Installed ASIC hash rate capacity was 2.98 EH/s at the end of the month, which excludes certain legacy miners that the Company anticipates will be fully replaced by the end of the year.
- Hut 8 produced 125.8 BTC/EH in August.
- In late August, Hut 8 installed 180 NVIDIA GPUs in its flagship data centre in Kelowna, B.C. Currently mining Ethereum, the multi-workload machines will be designed to pivot on demand to provide Artificial Intelligence, Machine Learning, or VFX rendering services to customers.
- Hut 8 is partnering with Zenlayer to bring their on-demand high-performance computing to Canadian Web 3.0 and blockchain customers for the first time.
"Our team delivered very strong results across our mining and high performance infrastructure businesses in August, positioning us well for continued success," said Jaime Leverton, CEO. "We continue to receive and install our monthly shipments of new MicroBT miners on time, while actively adding to the suite of services we offer our data centre customers."
Hut 8 is one of North America's largest innovation-focused digital asset miners, led by a team of business-building technologists, bullish on bitcoin, blockchain, Web 3.0, and bridging the nascent and traditional high performance computing worlds. With two digital asset mining sites located in Southern Alberta and a third site in North Bay, Ontario, all located in Canada, Hut 8 has one of the highest capacity rates in the industry and one of the highest inventories of self-mined Bitcoin of any crypto miner or publicly-traded company globally. With 36,000 square feet of geo-diverse data centre space and cloud capacity connected to electrical grids powered by significant renewables and emission-free resources, Hut 8 is revolutionizing conventional assets to create the first hybrid data centre model that serves both the traditional high performance compute (Web 2.0) and nascent digital asset computing sectors, blockchain gaming, and Web 3.0. Hut 8 was the first Canadian digital asset miner to list on the Nasdaq Global Select Market. Through innovation, imagination, and passion, Hut 8 is helping to define the digital asset revolution to create value and positive impacts for its shareholders and generations to come.
This press release includes "forward-looking information" and "forward-looking statements" within the meaning of Canadian securities laws and United States securities laws, respectively (collectively, "forward-looking information"). All information, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company's businesses, operations, plans and other such matters is forward-looking information. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "allow", "believe", "estimate", "expect", "predict", "can", "might", "potential", "predict", "is designed to", "likely" or similar expressions. In addition, any statements in this press release that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information and include, among others, statements regarding: Bitcoin and Ethereum network dynamics; the Company's ability to advance its longstanding HODL strategy; the Company's ability to produce additional Bitcoin and maintain existing rates of productivity at all sites; the Company's ability to deploy additional miners; the Company's ability to continue mining digital assets efficiently; the Company's expected recurring revenue and growth rate from its high performance computing business; and the Company's ability to successfully navigate the current market.
Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates and projections regarding future events based on certain material factors and assumptions at the time the statement was made. While considered reasonable by Hut 8 as of the date of this press release, such statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to, security and cybersecurity threats and hacks, malicious actors or botnet obtaining control of processing power on the Bitcoin or Ethereum network, further development and acceptance of Bitcoin and Ethereum networks, changes to Bitcoin or Ethereum mining difficulty, loss or destruction of private keys, increases in fees for recording transactions in the Blockchain, erroneous transactions, reliance on a limited number of key employees, reliance on third party mining pool service providers, regulatory changes, classification and tax changes, momentum pricing risk, fraud and failure related to cryptocurrency exchanges, difficulty in obtaining banking services and financing, difficulty in obtaining insurance, permits and licenses, internet and power disruptions, geopolitical events, uncertainty in the development of cryptographic and algorithmic protocols, uncertainty about the acceptance or widespread use of cryptocurrency, failure to anticipate technology innovations, the COVID19 pandemic, climate change, currency risk, lending risk and recovery of potential losses, litigation risk, business integration risk, changes in market demand, changes in network and infrastructure, system interruption, changes in leasing arrangements, and other risks related to the cryptocurrency and data centre business. For a complete list of the factors that could affect the Company, please see the "Risk Factors" section of the Company's Annual Information Form dated March 17, 2022, and Hut 8's other continuous disclosure documents which are available on the Company's profile on the System for Electronic Document Analysis and Retrieval at www.sedar.com and on the EDGAR section of the U.S. Securities and Exchange Commission's website at www.sec.gov.
These factors are not intended to represent a complete list of the factors that could affect Hut 8; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described in this press release as intended, planned, anticipated, believed, sought, proposed, estimated, forecasted, expected, projected or targeted and such forward-looking statements included in this press release should not be unduly relied upon. The impact of any one assumption, risk, uncertainty, or other factor on a particular forward-looking statement cannot be determined with certainty because they are interdependent and Hut 8's future decisions and actions will depend on management's assessment of all information at the relevant time. The forward-looking statements contained in this press release are made as of the date of this press release, and Hut 8 expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
View original content to download multimedia:
SOURCE Hut 8 Mining Corp | https://www.wlbt.com/prnewswire/2022/09/06/hut-8-mining-production-operations-update-august-2022/ | 2022-09-06T11:58:48Z | https://www.wlbt.com/prnewswire/2022/09/06/hut-8-mining-production-operations-update-august-2022/ | false |
Fast implementation enables dramatic increase in referrer integration and loyalty.
WEST PALM BEACH, Fla., Sept. 6, 2022 /PRNewswire/ -- ScriptSender, a leader in enabling secure, one-click communication between healthcare providers, announced today that Chesapeake Medical Imaging has deployed its suite of solutions to optimize continuity of care.
Chesapeake Medical Imaging (CMI) operates 12 outpatient imaging centers in Maryland and integrated more than 85 referring practices within six months of the ScriptSender deployment. After a one-click integration, the referrer can transmit directly to CMI's server, using a virtual printer activated with a simple point-and-click. They can securely send any document—including prescriptions, clinical notes, insurance information, or even an entire patient folder—without the expense and complexity of setting up a VPN or HL7 connection to CMI, and without the inefficiency of faxing.
Tom Marshall, Director of Marketing and Practice Development for CMI, said, "With HL7, this would take years. Even a referrer who doesn't have an EMR can create web orders with ScriptSender technology. There is no cost to our referrers, and we tell them they can always go back to faxing. They never do."
ScriptSender also automates the process of sending for prior authorizations. Data on an order, received directly into CMI's system, triggers the authorization workflow. "This eliminates multiple steps that required manual entry before, and referrers can monitor their orders and authorizations," said Kristen Stokes, Global Project Manager for CMI. "This is a differentiator that enables us to stay competitive in our market."
Stokes also noted that ScriptSender's Image View / Image Share (IVIS) module is "another value-add." Images are embedded into CMI's reports and can be securely and instantly shared with other clinicians, on any platform, through IVIS. "IVIS is the only platform I've seen that enables secure access and image sharing in one click," said Stokes.
Chris Craft, CEO and founder of ScriptSender, said, "CMI understands that breaking down barriers to information sharing is absolutely central to patient care. By taking full advantage of our innovative technology, they are part of the revolution in healthcare. They are fostering a much cleaner, faster, and more accurate collaboration with their referring community, and we're proud to be part of their success."
Chesapeake Medical Imaging was established more than 20 years ago in Annapolis. The vision was to provide a higher quality of care and technology to the patient community, and that aim is now realized in 12 centers across the state. CMI is owned and operated by medical professionals, who leverage their expertise to deliver the most advanced insights to patients and referrers. CMI enjoys an extraordinary reputation, thanks to its commitment to innovative services. For more information, visit www.cmirad.net/
ScriptSender enables secure, one-click communication between healthcare providers. Integration is made easy—without the complexities and costs associated with new interfaces, site-to-site VPN issues, and lost faxes. With a portfolio that includes its flagship product, ScriptSender, plus Web Orders, ReportSender, Image Viewer, and other solutions, ScriptSender aims to enhance relationships among healthcare providers of every size. Our solutions are the result of years of executive leadership in healthcare along with hands-on technical expertise.
For more information, visit www.scriptsender.com.
View original content to download multimedia:
SOURCE ScriptSender | https://www.valleynewslive.com/prnewswire/2022/09/06/scriptsender-streamlines-referrals-prior-authorizations-chesapeake-medical-imaging/ | 2022-09-06T12:00:50Z | https://www.valleynewslive.com/prnewswire/2022/09/06/scriptsender-streamlines-referrals-prior-authorizations-chesapeake-medical-imaging/ | false |
KPI 360 combines multiple data sources into a single intuitive, visual dashboard so manufacturers can get actionable operating insights at all levels of a plant
WOBURN, Mass., Sept. 6, 2022 /PRNewswire/ -- SymphonyAI Industrial announced today the launch of KPI 360, an AI-driven solution that uses real-time data monitoring and prediction to help manufacturing companies view different operational data sources through a single, complete industrial intelligence dashboard that sets up in hours.
Backed by SymphonyAI's Eureka industrial AI platform, KPI 360 lets any type of user quickly set up monitoring for strategic KPIs through a visual, no-code builder interface. Leveraging SymphonyAI Industrial's proprietary domain knowledge engine, KPI 360 comes with pre-built KPIs for industrial assets and applications. The KPI 360 solution allows manufacturers to pull from data sources directly or through an application programming interface (API) such as Maximo, OSIsoft, SAP, and Siemens. These unique features make it easy to set up without a large project and maintain and expand over time without the need for any software expertise.
"KPI 360 is our first self-service product," said Dominic Gallello, CEO of SymphonyAI Industrial. "This approach enables our customers to set up everything from data pipelines to data visualization and allows everyone in a company to get a clear view of all business operations from the shop floor to the top floor. Flexibility and extensibility are built into KPI 360, so our customers can choose the visualization of their choice, link it to one or more KPIs, configure interactions with the visualizations, and change the visual appearance without writing a single line of code."
SymphonyAI Industrial, a SymphonyAI vertical, is an innovator in industrial insight, accelerating autonomous plant operations. The industry-leading Eureka AI/IoT platform and industrial optimization solutions connect tens of thousands of assets and workflows in manufacturing plants globally and process billions of data points daily, pushing new plateaus in operational intelligence.
- Digital manufacturing composable enterprise MOM/MES solutions can be operational in 90 days to connect devices, processes, people, and systems with harmonizing plant automation and control.
- Plant performance applications span asset predictive maintenance and process health and optimization, maintaining high availability of equipment, extending the life of capital assets, and reducing process variability.
- Connected worker solutions mobilize people to handle even their most complex processes with human-driven procedure and instruction support, using a combination of glasses, smartphones, tablets, and PCs.
SymphonyAI Industrial solutions provide high value to users by driving variability out of processes and optimizing operations for throughput, yield, energy efficiency, and sustainability.
SymphonyAI is building the leading enterprise AI company for digital transformation across the most important and resilient growth industries, including retail, consumer packaged goods, financial services, manufacturing, media, and IT service management. SymphonyAI businesses have many leading enterprises as clients in each of these industries. Since its founding in 2017, SymphonyAI has grown rapidly, approaching 2,000 talented leaders, data scientists, and other professionals. SymphonyAI is an SAIGroup company, backed by a $1 billion commitment from successful entrepreneur and philanthropist Dr. Romesh Wadhwani.
PR contact: Nicole Katzin – nicole@galestrategies.com
View original content:
SOURCE SymphonyAI Industrial | https://www.wlbt.com/prnewswire/2022/09/06/symphonyai-industrial-launches-kpi-360-optimize-manufacturing-operations-with-ai-physics-driven-kpis/ | 2022-09-06T12:02:59Z | https://www.wlbt.com/prnewswire/2022/09/06/symphonyai-industrial-launches-kpi-360-optimize-manufacturing-operations-with-ai-physics-driven-kpis/ | true |
SAN DIEGO, Sept. 6, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), today received a decision from the European Commission prohibiting the company's acquisition of GRAIL. The company is reviewing the Commission's order and intends to appeal the decision. The EC decision follows last week's ruling by US Federal Trade Commission judge in favor of Illumina's acquisition of GRAIL.
"We are disappointed with the European Commission's decision prohibiting us from acquiring GRAIL back to Illumina," said Charles Dadswell, General Counsel of Illumina. "Illumina can make GRAIL's life-saving multi-cancer early detection test more available, more affordable, and more accessible – saving lives and lowering healthcare costs. As we continue to believe, this merger is pro-competitive and will accelerate innovation. Last week the Chief Judge of the US Federal Trade Commission issued a decision supporting Illumina acquiring GRAIL."
In addition, to prepare for the anticipated divestment order from the European Commission in the coming months, the company will begin reviewing strategic alternatives for GRAIL in the event the divestiture is not stayed pending Illumina's appeal.
The merger of Illumina and GRAIL would usher in a transformational phase in the detection and treatment of cancer by facilitating equal and affordable access to the life-saving early cancer detection Galleri test.
With a single blood test, Galleri can screen asymptomatic patients for more than 50 types of cancer, many of which have no other form of screening and are often caught too late to treat effectively. In addition, Galleri can identify the tissue in which a cancer has developed. Galleri is unique as a multicancer early detection test suitable for general population screening. There is no other test available for this purpose. Galleri is available today in the US and the UK, but not in the European Union.
Illumina would accelerate GRAIL's commercial entry into the EU at scale by at least five years, saving tens of thousands of lives in the EU and billions of euros in healthcare costs.
A combined Illumina and GRAIL is key to helping the European Union achieve the goals outlined in Europe's Beating Cancer Plan, which states: "Early detection through screening offers the best chance of beating cancer and saving lives." Today, 71% of cancer-related deaths are in cancers with no recommended screening. With limited screening, cancer is more likely to be detected in late stages but when we diagnose cancer too late, less than 20% of patients will survive more than 5 years. In contrast, if we diagnose cancer early, approximately 90% of patients are expected to survive beyond five years.1 The GRAIL merger would not only accelerate multicancer early detection in the EU but would also reduce inequity in cancer care by making early diagnosis affordable and widespread, another key priority of Europe's Beating Cancer Plan.
Illumina is separately appealing a July 2022 decision by the General Court of the European Union regarding the European Commission's jurisdiction to challenge the GRAIL deal.
Cautionary Notes on Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "may," "target," similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the effects of the consummation of the transaction and the anticipated benefits thereof. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the terms and conditions of any required divestiture of GRAIL, and the timing of and the risks, costs and business disruptions (including the diversion of management's attention) associated with any such divestiture, the announcement, pendency or implementation thereof or any associated legal or regulatory proceedings or obligations, and other uncertainties related to Illumina's compliance (or ability to comply) with a divestment order, which may adversely affect Illumina and its business, including current plans and operations; (ii) the possibility of other adverse consequences to, among other things, Illumina's reputation, its relationships with governmental or regulatory authorities or its ability to successfully complete future acquisitions and/or divestitures as a result of the acquisition, the prohibition decision or a divestment order; (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, dis-synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of Illumina's business following or in connection with any divestiture of GRAIL; (iv) potential adverse reactions or changes to business relationships or our ability to attract and retain employees resulting from the announcement, pendency or implementation of the prohibition decision and/or legal, regulatory and other proceedings related thereto; (v) any negative effects of the announcement, pendency or implementation of the prohibition decision or a divestment order and/or of any divestiture of GRAIL on the market price of Illumina's common stock and on Illumina's operating results; (vi) risks associated with third-party contracts or other agreements containing provisions that might be implicated by any divestiture of GRAIL, including Illumina's obligations with respect to certain GRAIL contingent value rights and the risk that Illumina will be unable to fully discharge such obligations in connection with a divestiture of GRAIL; (vii) the risk that Illumina will be unable to recover the costs and/or realize the economic benefits associated with its efforts to develop and commercialize GRAIL's products, including Galleri, the cancer screening test developed by GRAIL; (viii) the risk that Illumina's appeals of the prohibition decision or a divestment order and the EU General Court's ruling on the European Commission's jurisdiction to review the Acquisition and impose any decisions with respect thereto are unsuccessful and of other negative outcomes of legal, regulatory and other proceedings related thereto; (ix) the risk of adverse effects resulting from additional potential litigation associated with the acquisition; (x) the other risks described in Illumina's most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and (xi) management's response to any of the aforementioned factors.
While the list of factors presented here is, and the list of factors presented in Illumina's public filings are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Illumina's financial condition, results of operations, credit rating or liquidity. Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:
Salli Schwartz
+1.858.291.6421
IR@illumina.com
Media:
Adi Raval
+1.202.629.8172
PR@illumina.com
1 Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov)
View original content:
SOURCE Illumina, Inc. | https://www.dakotanewsnow.com/prnewswire/2022/09/06/illumina-intends-appeal-european-commissions-decision-grail-deal/ | 2022-09-06T12:07:25Z | https://www.dakotanewsnow.com/prnewswire/2022/09/06/illumina-intends-appeal-european-commissions-decision-grail-deal/ | false |
Technology consultants who sought evidence that Donald Trump’s 2020 defeat was fraudulent made multiple visits to a county elections office in rural Georgia in the weeks after an alleged post-election breach of voting equipment there that is the subject of a criminal investigation.
The footage also shows that earlier in January, Cathy Latham, a teacher and then-chairwoman of the county Republican Party, was at the elections office and greeted the outsiders when they arrived shortly before noon to copy the data. Latham has said in sworn testimony that she taught a full day of school that day and visited the elections office briefly after classes ended. She was one of 16 Republicans who signed certificates declaring Trump the rightful winner of the 2020 election as part of the “fake elector” scheme now under investigation by federal and state prosecutors.
The new video adds to the picture of the alleged breach in Coffee County on Jan. 7, 2021, and reveals for the first time the later visits by Logan and Lenberg. It also provides further indications of links between various efforts to overturn the election, including what once appeared to be disparate attempts to access and copy election system data in the wake of Trump’s loss.
Experts have expressed concern that such efforts could expose details of voting systems’ hardware and software that are intended to be tightly controlled, potentially aiding hackers who might seek to alter the results of a future election. Data copied from elections systems in other states has been published online. Georgia state officials and voting-machine makers have downplayed the risk, pointing to safeguards that they say protect the systems from tampering.
The Post reported last month that a data forensics firm hired by the pro-Trump lawyer Sidney Powell copied software and data from the Dominion Voting Systems machines Coffee County uses to manage elections and tally ballots. The Georgia Bureau of Investigation has said it is investigating the matter.
Details of the Coffee County incident have come to light largely because of a flurry of subpoenas and depositions by plaintiffs in a long-running federal lawsuit against Georgia authorities over the security of the state’s elections. Emails and other records they obtained from the data forensics firm, Atlanta-based SullivanStrickler, showed that the Coffee episode was part of a coordinated multistate effort to access voting equipment in a hunt for evidence that the election was rigged.
The plaintiffs, including several Georgia voters and the nonprofit Coalition for Good Governance, obtained the new surveillance video in response to a subpoena to county authorities and provided it to The Post.
The security footage shows only the exterior of the office’s entrance area, and it is not clear what the consultants Logan and Lenberg did inside.
Latham “would not and has not knowingly been involved in any impropriety in any election,” said Robert D. Cheeley, her lawyer, in a statement to The Post. She “did not authorize or participate in any ballot scanning efforts, computer imaging or any similar activity in Coffee County in January 2021.”
Logan and Lenberg did not respond to messages seeking comment for this report.
David Cross, a lawyer who represents some of the plaintiffs in the civil case, said the additional visits raise questions about why the two men returned. “The biggest concern that we have is future elections,” said Cross, whose clients are pressing Georgia authorities to replace the state’s ballot-marking machines with hand-marked paper ballots.
Logan and Lenberg have played roles in the multistate pursuit of voting machines by Trump supporters. Michigan Attorney General Dana Nessel (D) has asked for a special prosecutor to decide whether to pursue charges against them and others for allegedly conspiring to unlawfully access elections equipment in three counties there last year. Logan and Lenberg also provided affidavits as expert witnesses in a post-election lawsuit in Antrim County, Mich., after a judge granted SullivanStrickler access to Dominion Voting Systems machines there.
SullivanStrickler previously said it would be “fully cooperative” with investigators examining the Coffee County matter and is confident it has done nothing wrong. The firm has said it acted in good faith and on instructions from licensed attorneys.
SullivanStrickler declined to comment for this story beyond its original statement.
The new surveillance footage shows three SullivanStrickler employees arriving at the Coffee elections office on at 11:42 a.m. on Jan. 7. Latham had arrived five minutes earlier, the footage shows. She greeted the SullivanStrickler team and led them inside.
In her deposition last month, taken by plaintiffs in the long-running civil case, Latham said she recalled having gone to the Coffee County elections office for “just a few minutes” that day, arriving sometime after 3:48 p.m. when she received a text from Misty Hampton, then the county elections supervisor, that said: “Going great so far.”
Asked during the deposition whether it would have been possible for her to go to the election office during work hours, Latham answered: “I mean, I taught a full schedule, I didn’t have a planning period, so I can’t remember.”
Records filed in the civil case last week also show that an attorney for SullivanStrickler described Latham as the “primary point of contact in coordinating and facilitating” the firm’s work in Coffee County.
The SullivanStrickler team brought a hard-shell rolling suitcase and a packed duffle bag into the office, the footage shows. Shortly before 1 p.m., a fourth employee arrived to join them. Latham left the office for about two and a half hours during the afternoon before returning and then finally departing after 6 p.m., the footage shows. The building has a side door that is not shown in the footage.
The SullivanStrickler team left the building at 7:43 p.m., more than two and a half hours after the office’s regular closing time, the footage shows. Hampton immediately followed.
The data obtained from Coffee County by SullivanStrickler included copies of virtually every component of the county voting system, including the central tabulation server, according to an inventory obtained by the plaintiffs through discovery. The firm billed Powell $26,000 for the day’s work, an invoice shows.
Hampton previously told The Post that she allowed a team of outsiders into her office after the 2020 vote so they could prove “that this election was not done true and correct.”
Hampton and attorneys for Coffee County did not respond to messages seeking comment.
The new surveillance footage shows that on Jan. 18, 11 days after SullivanStrickler completed its work in Coffee County, Logan and Lenberg arrived at the elections office with Hampton at 4:20 p.m.
Logan, 42, was chief executive of the security firm Cyber Ninjas, which was hired by Republican state lawmakers in Arizona to hunt for fraud in the 2020 vote there. The firm’s review found Trump had lost to Joe Biden in Arizona by an even greater margin than the certified result. Logan, of Sarasota, Fla., announced earlier this year that he had shuttered the company.
Lenberg, 66, lives in Tijeras, N.M., and previously worked in technical roles at a private laboratory operated for the National Nuclear Security Administration. A resume for Lenberg filed in the Antrim court case stated that he has held high-level security clearances and that his past work included “developing ways to break in (if possible) to what were considered to be secure systems.”
When the pair arrived at the Coffee County elections office on Jan. 18, both were carrying backpacks, and Lenberg brought snacks and energy drinks. Hampton and the two consultants were recorded leaving the building nearly four hours later. Logan and Lenberg returned to the elections office shortly before 9 a.m. the next morning, the footage shows, and exited after 6 p.m.
Six days later, Jan. 25, Lenberg was again recorded arriving at the elections office. He left nearly three hours later, then returned for shorter visits on each of the following four days, the video shows. On one occasion, he was carrying the box for a ring light system typically used to illuminate the subjects of video recordings.
Lenberg was part of an election review team in New Mexico that last month published a report featuring an image of what it called “a system log from a Dominion machine in Georgia.” At a public hearing of the Otero County Commission earlier this year, Lenberg said he had obtained “data from multiple counties” in Georgia and that he met with Hampton of Coffee County.
The Post has reported that, according to computer logs obtained by the plaintiffs, an account in Logan’s name had accessed Coffee County data on SullivanStrickler’s file-sharing system.
In spring 2021, after Hampton resigned, Logan’s business card was found on her desk by her successor, James Barnes. Barnes sent a copy of the card to the secretary of state’s office, expressing alarm in light of the fact that the Justice Department had raised concerns about the ballot review led by Cyber Ninjas in Arizona, according to an email obtained by The Post. An investigator in the secretary of state’s office was directed to follow up with county officials and “verify what if any contact cyber ninjas had with any election equipment,” emails show. Barnes said in a sworn deposition that state officials never contacted him.
Cross, the attorney for the plaintiffs, said at that point state authorities should have asked county officials for surveillance footage to determine who had been in the office and when. “They would have had a year and a half before a major midterm election to figure this out,” he said.
A spokesman for Secretary of State Brad Raffensperger (R) did not directly address questions from The Post about the agency’s response to Barnes’s concern or say whether the agency sought the security-camera footage at the time. Raffensperger has said publicly that after the election his staff devoted time to pursuing every tip of alleged voter fraud. Raffensperger’s office has told the court that it began investigating the Coffee County matter in February of this year, when allegations of the breach first became an issue in the long-running lawsuit. The Georgia Bureau of Investigation has been working with Raffensperger’s office and opened the criminal case on Aug. 15.
“We will hold all who acted in bad faith and broke the law to account,” said Gabriel Sterling, a spokesman for the secretary of state’s office.
The new court records show that local elections board official Eric Chaney acknowledged in a sworn deposition last month that he, too, was at the Coffee County elections office on Jan. 7, 2021. Chaney previously told The Post that he was not to his knowledge present when anyone “illegally accessed” the Coffee County server.
In the same deposition, Chaney responded to questions about the effort to copy Dominion Voting equipment by citing his Fifth Amendment right to avoid self-incrimination. The video footage shows that Chaney arrived at the elections office shortly before 11 a.m. that day and left shortly before 8 p.m.
Chaney and his lawyer did not respond to messages seeking comment.
Matthew Brown, Amy Gardner and Peter Stevenson contributed to this report. | https://www.washingtonpost.com/investigations/2022/09/06/coffee-county-georgia-breach-logan/ | 2022-09-06T12:07:42Z | https://www.washingtonpost.com/investigations/2022/09/06/coffee-county-georgia-breach-logan/ | true |
Reliable and cost-effective hybrid delivery of live sports, cultural events and breaking news with simplified production workflow to the widest global audience
LUXEMBOURG and HACKENSACK, N.J., Sept. 6, 2022 /PRNewswire/ -- SES, the leader in global content connectivity solutions, and LiveU, a leading provider of live video and remote production solutions, have partnered to offer an innovative end-to-end solution for live video contribution and distribution combined with premium content aggregation. Customers looking to broadcast live sports, news and other events from stadiums, sports facilities and remote sites now have access to the most reliable and cost-effective creation and delivery of live video to the widest audience – combining satellite, fibre, IP and cellular capabilities.
The fully integrated and turnkey solution based on the latest broadcast technologies gives global customers access to new services and levels of redundancy, including:
- Contribution: LiveU's cost-efficient mobile field units for live video transmission from outdoor locations and venues connected to SES teleports via 4G/5G. This direct connection offers an alternative to an on-site SNG truck or can be used as a redundant back-up feed.
- Aggregation: Customers now have the ability to instantly aggregate their content in the LiveU Matrix IP cloud live video service, including from LiveU's mobile field units and through SES's satellite and IP connections.
- Distribution: Customers can now reach widest possible audiences with simultaneous access to live video distribution over SES's global satellite and IP network and LiveU Matrix's global customers' endpoints.
Customers will also have access to leading sports brands using their preferred technology (IP or satellite) while benefiting from SES's dedicated project management team and LiveU's 24/7 support and service.
One of the first customers, Oranda Singapore, recently deployed the joint solution for live broadcasts of sports climbing in Korea to viewers across EMEA, Americas and Asia using LiveU's portable units with SES's satellite distribution. Floris Molijn, CEO, Oranda, said, "We are thrilled with the level of quality and flexibility that SES and LiveU have provided in finding a tailor-made solution for Oranda that combined SES's knowledge, reach and satellite capability with LiveU's production capabilities to deliver broadcast-quality signals over mobile data networks. Bringing it all together required out of the box thinking to turn around a project with very tight lead times, and SES and LiveU provided 100% reliability of signal distribution."
Michele Gosetti, Head of Sales, Sports & Events at SES, said, "LiveU is a leader in mobile and cloud-based broadcast video technologies, and they perfectly complement our vision of enabling our customers to broadcast live sports and events from nearly anywhere to the widest global audience possible. Combining our expertise in sports and events and our global reach with LiveU's mobile units and cellular technologies gives our customers the ability to deliver high-quality, professional broadcasts whether athletes are climbing up a remote mountain or competing in an urban professional sports stadium."
Ronen Artman, VP Marketing, LiveU said, "The synergy of our joint offering is clear. We are delighted to work with the SES team and already see the benefits, delivering connectivity for our global customers using optimised IP, cellular, satellite, and fibre. As well as delivering a highly cost-effective solution for all sports tiers for greater fan engagement, our solution provides robust broadcast-quality live coverage and back-up. There are also last mile benefits – customers can deliver the aggregated feeds easily in a direct seamless delivery to their Matrix account and receiver. Combining mobile and cloud, with satellite, fibre and IP offers the widest choice of technologies and remote production workflows to customers on a global scale."
An enabler of content and connectivity, SES reaches more than 366 million TV households and a billion people worldwide while broadcasting more than 700 hours of premium sports and live events every day. LiveU is recognised as the brand name in portable live video solutions, used by the world's top news broadcasters and sports organizations.
The joint offering will be presented at IBC2022 in Amsterdam (LiveU stand 7.C30 / SES Meeting Rooms at Hall 1, Balcony suites BS10-BS11).
For further information, please contact:
SES
Suzanne Ong
External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
LiveU
Joyce Essig
201-906-9367
joyce@liveu.tv
Joss Armitage (Int'l)
+44-7979-908-547
joss@jumppr.tv
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world's only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world's leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES's video network carries ~8,000 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
About LiveU
LiveU is shaping the future of live video, powering video production workflows and cloud services for news, sports, and other verticals. Building on our global market leadership and innovation, LiveU offers the highest quality, reliable and cost-effective end-to-end solutions for all types of live productions – producing more for less. Our broad portfolio ranges from our portable production-level field units and smartphone apps to satellite/cellular hybrid solutions and next-gen cloud-based IP management, orchestration, ingest and distribution solutions. With over 5,000 customers in 150 countries, LiveU's technology is the solution of choice for global broadcasters, sports, and other organizations (including government, education, public safety, enterprise, and production houses), streaming live video to TV, mobile, online, and social media. LiveU is a recipient of Frost & Sullivan's 2021 North America New Product Innovation Award for its LU800 unit and a winner of the 71st Annual Technology & Engineering Emmy® Awards in recognition of its innovation and achievement in Video over Cellular Internet Protocol (VoCIP) technology. For more information, visit www.liveu.tv, or follow us on Twitter, Facebook, YouTube, LinkedIn or Instagram.
View original content to download multimedia:
SOURCE LiveU | https://www.dakotanewsnow.com/prnewswire/2022/09/06/ses-liveu-launch-integrated-video-contribution-distribution-solution-global-live-events/ | 2022-09-06T12:09:35Z | https://www.dakotanewsnow.com/prnewswire/2022/09/06/ses-liveu-launch-integrated-video-contribution-distribution-solution-global-live-events/ | false |
Grant supports study of expanded HyBryte™ treatment, including in the Home Use Setting
PRINCETON, N.J., Sept. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has awarded an Orphan Products Development grant to support the evaluation of HyBryte™ (synthetic hypericin) for expanded treatment in patients with early-stage CTCL. The grant, totaling $2.6 million over 4 years, was awarded to a prestigious academic institution that was a leading enroller in the recently published positive Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in the treatment of early stage cutaneous T-cell lymphoma (CTCL).
"We are pleased the FDA is supporting the HyBryte™ program and giving patients an opportunity to access the therapy in an open-label setting," stated Christopher J. Schaber, President and CEO of Soligenix, Inc. "CTCL is an incredibly difficult to treat orphan disease and remains an area of unmet medical need with a very limited number of safe and effective treatment options. The Phase 3 results provide the basis for our upcoming marketing application and this study will serve to embark on potential home-use of the therapy, augment the safety database as well as provide further real-world evidence into the practical use of HyBryte™ once commercially available."
The clinical study RW-HPN-MF-01, "Assessment of Treatment with Visible Light Activated Synthetic Hypericin Ointment in Mycosis Fungoides Patients" is designed as an open-label, multicenter clinical trial enrolling approximately 50 patients at up to six of the highest enrolling clinical centers that participated in the Phase 3 FLASH study. Patients have the potential to be treated for up to 12 months with twice a week dosing (visible light activation to follow ointment application by 24 ± 6 hours). The primary endpoint for the study will be evaluating the number of treatment successes defined as ≥50% reduction in the cumulative CAILS (Composite Assessment of Index Lesion Severity) score from baseline to end of the treatment. Study initiation is planned for the fourth quarter of 2022.
About HyBryte™
HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light 16 to 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. In a published Phase 2 clinical study in CTCL, patients experienced a statistically significant (p=0.04) improvement with topical hypericin treatment whereas the placebo was ineffective. HyBryte™ has received orphan drug and fast track designations from the FDA, as well as orphan designation from the European Medicines Agency (EMA).
The recently published Phase 3 FLASH trial enrolled a total of 169 patients (166 evaluable) with Stage IA, IB or IIA CTCL. The trial consisted of three treatment cycles. Treatments were administered twice weekly for the first 6 weeks and treatment response was determined at the end of the 8th week of each cycle. In the first double-blind treatment cycle, 116 patients received HyBryte™ treatment (0.25% synthetic hypericin) and 50 received placebo treatment of their index lesions. A total of 16% of the patients receiving HyBryte™ achieved at least a 50% reduction in their lesions (graded using a standard measurement of dermatologic lesions, the CAILS score) compared to only 4% of patients in the placebo group at 8 weeks (p=0.04) during the first treatment cycle (primary endpoint). HyBryte™ treatment in the first cycle was safe and well tolerated.
In the second open-label treatment cycle (Cycle 2), all patients received HyBryte™ treatment of their index lesions. Evaluation of 155 patients in this cycle (110 receiving 12 weeks of HyBryte™ treatment and 45 receiving 6 weeks of placebo treatment followed by 6 weeks of HyBryte™ treatment), demonstrated that the response rate among the 12-week treatment group was 40% (p<0.0001 vs the placebo treatment rate in Cycle 1). Comparison of the 12-week and 6-week treatment groups also revealed a statistically significant improvement (p<0.0001) between the two groups, indicating that continued treatment results in better outcomes. HyBryte™ continued to be safe and well tolerated. Additional analyses also indicated that HyBryte™ is equally effective in treating both plaque (response 42%, p<0.0001 relative to placebo treatment in Cycle 1) and patch (response 37%, p=0.0009 relative to placebo treatment in Cycle 1) lesions of CTCL, a particularly relevant finding given the historical difficulty in treating plaque lesions in particular.
The third (optional) treatment cycle (Cycle 3) was focused on safety and all patients could elect to receive HyBryte™ treatment of all their lesions. Of note, 66% of patients elected to continue with this optional compassionate use / safety cycle of the study. Of the subset of patients that received HyBryte™ throughout all 3 cycles of treatment, 49% of them demonstrated a positive treatment response (p<0.0001 vs patients receiving placebo in Cycle 1). Moreover, in a subset of patients evaluated in this cycle, it was demonstrated that HyBryte™ is not systemically available, consistent with the general safety of this topical product observed to date. At the end of Cycle 3, HyBryte™ continued to be well tolerated despite extended and increased use of the product to treat multiple lesions.
Overall safety of HyBryte™ is a critical attribute of this treatment and was monitored throughout the three treatment cycles (Cycles 1, 2 and 3) and the 6-month follow-up period. HyBryte's™ mechanism of action is not associated with DNA damage, making it a safer alternative than currently available therapies, all of which are associated with significant and sometimes fatal, side effects. Predominantly these include the risk of melanoma and other malignancies, as well as the risk of significant skin damage and premature skin aging. Currently available treatments are only approved in the context of previous treatment failure with other modalities and there is no approved front-line therapy available. Within this landscape, treatment of CTCL is strongly motivated by the safety risk of each product. HyBryte™ potentially represents the safest available efficacious treatment for CTCL. With no systemic absorption, a compound that is not mutagenic and a light source that is not carcinogenic, there is no evidence to date of any potential safety issues.
The Phase 3 CTCL clinical study was partially funded by the National Cancer Institute via a Phase II SBIR grant (#1R44CA210848-01A1) awarded to Soligenix, Inc.
About Cutaneous T-Cell Lymphoma (CTCL)
CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs which generally involve B-cell lymphocytes (involved in producing antibodies), CTCL is caused by an expansion of malignant T-cell lymphocytes (involved in cell-mediated immunity) normally programmed to migrate to the skin. These malignant cells migrate to the skin where they form various lesions, typically beginning as patches and may progress to raised plaques and tumors. Mortality is related to the stage of CTCL, with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the disease has advanced. There is currently no cure for CTCL. Typically, CTCL lesions are treated and regress but usually return either in the same part of the body or in new areas.
CTCL constitutes a rare group of NHLs, occurring in about 4% of the approximate 700,000 individuals living with the disease. It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of CTCL that it affects over 25,000 individuals in the U.S., with approximately 3,000 new cases seen annually.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).
Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
View original content to download multimedia:
SOURCE Soligenix, Inc. | https://www.dakotanewsnow.com/prnewswire/2022/09/06/us-food-drug-administration-awards-26-million-orphan-products-development-grant-expanded-study-hybryte-treatment-cutaneous-t-cell-lymphoma/ | 2022-09-06T12:10:16Z | https://www.dakotanewsnow.com/prnewswire/2022/09/06/us-food-drug-administration-awards-26-million-orphan-products-development-grant-expanded-study-hybryte-treatment-cutaneous-t-cell-lymphoma/ | true |
LATHAM, N.Y. and RESEARCH TRIANGLE PARK, N.C., Sept. 6, 2022 /PRNewswire/ -- CommerceHub, an industry-leading commerce network connecting supply, demand and delivery for the world's leading retailers and brands, and ChannelAdvisor Corporation (NYSE: ECOM), a leading provider of cloud-based e-commerce solutions that enable brands and retailers to increase global sales, today announced they have entered into a definitive agreement for CommerceHub to acquire the outstanding shares of ChannelAdvisor in a transaction led by global software investor and current shareholder of CommerceHub, Insight Partners. Under the terms of the agreement, ChannelAdvisor stockholders will receive $23.10 per share in cash, representing a premium of approximately 57% over the company's closing stock price on September 2, 2022, the last full trading day prior to this announcement. The boards of directors of both companies have unanimously approved the transaction.
The complementary combination of CommerceHub and ChannelAdvisor expands capabilities for brands and retailers:
- Brands will be able to manage their public and private marketplaces alongside their retailer connections with a single vendor, improving efficiency by unifying first-party, dropship, and third-party integrations.
- Retailers will be able to access an even larger pool of brands, with over 18,000 customers transacting more than $50 billion in gross merchandise value (GMV) and more than $500 million in digital marketing and retail media ad spend annually across the combined network.
- Companies across the network will be able to save on delivery costs and improve delivery experiences with Delivery Suite, and improve their consumer experience with Shoppable Media and Brand Analytics.
"CommerceHub and ChannelAdvisor have both established themselves as leading solutions for different segments of online retailers and brands. By coming together, we can provide an even broader network, enabling our combined customers to grow their businesses by discovering new products, new brands, and new channels," said Bryan Dove, CEO, CommerceHub.
"This is a tremendous opportunity for our customers, for our team members and our shareholders. This transaction positions the combined company to accelerate innovation and help shape the future of commerce," said David Spitz, CEO, ChannelAdvisor.
Investors that participated in this transaction include Insight Partners, GTCR, Sycamore Partners, and Goldman Sachs Asset Management. Financing for the transaction is being provided by Sixth Street and Golub Capital LLC (the "Financing Sources").
The proposed transaction is not subject to a financing condition and is expected to close in 2022. The transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by ChannelAdvisor's stockholders. The companies will operate independently until the proposed transaction is finalized.
Upon completion of the transaction, ChannelAdvisor will become a privately held company and shares of ChannelAdvisor common stock will no longer be listed on any public market.
Advisors
Baird is serving as financial advisor to ChannelAdvisor and Cooley LLP is acting as legal counsel to ChannelAdvisor.
Stifel and District Capital Partners are serving as financial advisors to CommerceHub. Willkie Farr & Gallagher LLP is acting as legal advisor to CommerceHub and Paul, Weiss, Rifkind, Wharton & Garrison LLP are acting as debt financing legal advisor to CommerceHub. Kirkland & Ellis LLP served as legal advisor to GTCR and Sycamore Partners and Simpson Thacher & Barlett LLP served as legal advisor to Goldman Sachs Asset Management.
Latham & Watkins LLP are acting as legal advisors to the Financing Sources.
CommerceHub is a Software as a Service (SaaS) provider with a commerce network connecting the world's leading retailers and brands with drop ship, marketplace, and delivery solutions. Since 1997, CommerceHub has helped the largest retailers expand their online businesses to expand selection, meet consumer demand, and improve margins. For more information visit www. commercehub.com.
ChannelAdvisor (NYSE: ECOM) is a leading multichannel commerce platform whose mission is to connect and optimize the world's commerce. For over two decades, ChannelAdvisor has helped brands and retailers worldwide improve their online performance by expanding sales channels, connecting with consumers across the entire buying cycle, optimizing their operations for peak performance, and providing actionable analytics to improve competitiveness. Thousands of customers depend on ChannelAdvisor to securely power their e-commerce operations on channels such as Amazon, eBay, Google, Facebook, Walmart, and hundreds more. For more information, visit www.channeladvisor.com.
This communication is being made in respect of the proposed transaction involving ChannelAdvisor and CommerceHub, Inc. In connection with the proposed transaction, ChannelAdvisor will be filing documents with the SEC, including preliminary and definitive proxy statements relating to and describing the proposed transaction. The definitive proxy statement will be mailed to ChannelAdvisor stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov, on ChannelAdvisor's website at www.channeladvisor.com or by contacting ChannelAdvisor Investor Relations at (919) 228-4817.
This communication does not constitute a solicitation of proxy, an offer to purchase, or a solicitation of an offer to sell any securities. ChannelAdvisor and its respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from ChannelAdvisor stockholders in connection with the proposed transaction. Information about ChannelAdvisor's directors, executive officers and employees in the proposed transaction will be included in the proxy statements described above. Additional information regarding these individuals is set forth in ChannelAdvisor's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the definitive proxy statement on Schedule 14A for ChannelAdvisor's most recent Annual Meeting of Stockholders held on May 13, 2022, and ChannelAdvisor's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022. To the extent ChannelAdvisor's directors and executive officers or their holdings of ChannelAdvisor securities have changed from the amounts disclosed in those filings, to ChannelAdvisor's knowledge, such changes have been or will be reflected on initial statements of beneficial ownership on Form 3 or statements of change in ownership on Form 4 on file with the SEC. These documents are (or, when filed, will be) available free of charge at the SEC's website at www.sec.gov or at ChannelAdvisor's website at www.ChannelAdvisor.com.
This communication contains forward-looking statements which include, but are not limited to, all statements that do not relate solely to historical or current facts, such as statements regarding the Company's expectations, intentions or strategies regarding the future, or the completion or effects of the proposed transaction. In some cases, these statements include words like: "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. ChannelAdvisor's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed transaction, satisfaction of closing conditions precedent to the consummation of the proposed transaction, potential delays in consummating the proposed transaction, the ability of ChannelAdvisor to timely and successfully achieve the anticipated benefits of the transaction and the impact of health epidemics, including the COVID-19 pandemic, on the parties' respective businesses and the actions the parties may take in response thereto. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" and elsewhere in ChannelAdvisor's most recent filings with the SEC, including ChannelAdvisor's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. ChannelAdvisor assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
For Media and Analyst Inquiries:
Forrest Monroy
CommerceHub
fmonroy@commercehub.com
Caroline Riddle
ChannelAdvisor
caroline.riddle@channeladvisor.com
(919) 439-8026
View original content to download multimedia:
SOURCE ChannelAdvisor Corporation | https://www.wsaz.com/prnewswire/2022/09/06/commercehub-acquire-channeladvisor-2310-per-share/ | 2022-09-06T12:12:32Z | https://www.wsaz.com/prnewswire/2022/09/06/commercehub-acquire-channeladvisor-2310-per-share/ | true |
Fears grow for Ukraine nuke plant ahead of inspector report
By HANNA ARHIROVA
Associated Press
KYIV, Ukraine (AP) — Fears grew Tuesday for Europe’s largest nuclear power plant as shelling around it continued, a day after the facility was again knocked off Ukraine’s electricity grid and put in the precarious position of relying on its own power to run safety systems.
Repeated warnings from world leaders that fighting around the Zaporizhzhia plant has put it in an untenable situation that could lead to a nuclear catastrophe have done little to stem the hostilities. Russian-installed officials accused the Ukrainian forces of shelling the city where the plant is located on Tuesday, hours after the Ukrainians said Kremlin forces attacked a city across the river.
Both sides have traded such accusations since Russian troops seized the plant early in the war. With the danger rising, an International Atomic Energy Agency team finally traveled to the plant last week, and inspectors are expected to report what they found to the U.N. Security Council later in the day.
Two inspectors remain at the plant, which is run by Ukrainians workers, and Ukrainian presidential adviser Mykhailo Podolyak applauded that decision.
“There are Russian troops now who don’t understand what’s happening, don’t assess the risks correctly,” Podolyak said. “There is a number of our workers there, who need some kind of protection, people from the international community standing by their side and telling (Russian troops): ‘Don’t touch these people, let them work.’”
But that appears to have done little to lessen the risks. On Monday, the IAEA said Ukrainian authorities reported that the plant’s last transmission line was disconnected to allow workers to put out a fire caused by shelling.
“The line itself is not damaged, and it will be reconnected once the fire is extinguished,” the IAEA said.
In the meantime, the plant’s only remaining operational reactor would “generate the power the plant needs for its safety and other functions,” the agency said.
Mycle Schneider, an independent analyst in Canada on nuclear energy, said that means the plant was likely functioning in “island mode,” producing electricity just for its own operations.
“Island mode is a very shaky, unstable, and unreliable way to provide continuous power supply to a nuclear plant,” Schneider said.
It was just the latest incident that fueled fears of a potential nuclear disaster in a country still haunted by the world’s worst nuclear accident at Chernobyl. Experts say the reactors at Zaporizhzhia are designed to withstand natural disasters and even aircraft crashes, but the unpredictable fighting around the plant had repeatedly threatened to disrupt critical cooling systems, raising the risk of a meltdown.
Russian-installed officials in the Zaporizhzhia region on Tuesday accused the Ukrainian forces of shelling Enerhodar, the city where the plant is located, and damaging a power line close to the plant.
Russian state news agency RIA Novosti reported, citing its correspondent on the ground, that the power was off in Enerhodar on Tuesday and sounds of explosions could be heard.
Meanwhile, Ukraine’s presidential office said that Russian forces shelled residential buildings in Nikopol, a city across the Dnieper river from the Zaporizhzhia plant. Two people were wounded and a school, a kindergarten and some 30 buildings were damaged, the office said.
Russian shelling elsewhere killed at least three civilians, the statement said.
In the southern Kherson region, occupied by the Russians since early on in the war, the Ukrainian army continued its counteroffensive, destroying Russia’s logistical centers. A pontoon bridge was blown up overnight and a command center was hit, as well as two checkpoints.
In the eastern city of Sloviansk, workers with the Ukrainian Red Cross Society swept up debris Monday from a second rocket attack on its premises in a week. Nobody was hurt in either attack, said Taras Logginov, head of the agency’s rapid response unit. He blamed Russian forces and called the attacks war crimes.
In a row of apartment buildings across the road, the few residents who haven’t evacuated sawed sheets of plywood to board up their shattered windows.
Henadii Sydorenko sat on the porch of his apartment building for a break. He said he’s not sure whether to stay or leave, torn between his responsibility of taking care of three apartments whose owners have already evacuated and the increasing fear of the now frequent shelling.
“It’s frightening,” the 57-year-old said of the shelling. “I’m losing my mind, little by little.”
___
Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine | https://kion546.com/news/ap-national-news/2022/09/06/fears-grow-for-ukraine-nuke-plant-ahead-of-inspector-report-2/ | 2022-09-06T12:14:27Z | https://kion546.com/news/ap-national-news/2022/09/06/fears-grow-for-ukraine-nuke-plant-ahead-of-inspector-report-2/ | true |
WA Pendleton OR Zone Forecast for Monday, September 5, 2022
_____
457 FPUS56 KPDT 061058
ZFPPDT
Zone Forecast Product for Northeast Oregon and South Central Washington
National Weather Service Pendleton OR
358 AM PDT Tue Sep 6 2022
WAZ026-062300-
Kittitas Valley-
Including the cities of Ellensburg and Thorp
358 AM PDT Tue Sep 6 2022
.TODAY...Sunny. Highs in the mid to upper 80s. Northeast wind
5 to 10 mph.
.TONIGHT...Mostly clear. Lows in the upper 50s to mid 60s. East
wind 5 to 10 mph shifting to the northwest overnight.
.WEDNESDAY...Partly cloudy. Highs in the mid 80s to lower 90s.
Windy. Northwest wind 5 to 10 mph increasing to 15 to 25 mph in
the afternoon.
.WEDNESDAY NIGHT...Mostly clear. Lows in the upper 40s to mid
50s. Windy. Northwest wind 15 to 25 mph with gusts to around
40 mph.
.THURSDAY...Sunny. Highs in the upper 70s to lower 80s. Northwest
wind 5 to 15 mph.
.THURSDAY NIGHT THROUGH SATURDAY NIGHT...Mostly clear. Lows in
the upper 40s to upper 50s. Highs in the upper 70s to mid 80s.
.SUNDAY THROUGH MONDAY...Partly cloudy. Highs in the mid to upper
80s. Lows in the lower 50s to lower 60s.
$$
WAZ027-062300-
Yakima Valley-
Including the cities of Naches, Sunnyside, Toppenish, and Yakima
358 AM PDT Tue Sep 6 2022
.TODAY...Sunny. Highs in the mid to upper 80s. Northeast wind
5 to 10 mph.
.TONIGHT...Mostly clear. Lows in the mid 50s to lower 60s.
Southeast wind 5 to 10 mph in the evening, becoming light.
.WEDNESDAY...Partly cloudy. Highs in the upper 80s to lower 90s.
Northwest wind 5 to 15 mph. Gusts up to 25 mph in the afternoon.
.WEDNESDAY NIGHT...Mostly clear. Lows in the upper 40s to lower
50s. Northwest wind 5 to 15 mph with gusts to around 35 mph.
.THURSDAY...Sunny. Highs around 80. North wind 5 to 10 mph with
gusts to around 20 mph.
.THURSDAY NIGHT THROUGH SATURDAY NIGHT...Mostly clear. Lows in
the lower 50s to lower 60s. Highs in the upper 70s to mid 80s.
.SUNDAY THROUGH MONDAY...Partly cloudy. Highs in the mid 80s to
lower 90s. Lows in the lower 50s to lower 60s.
$$
WAZ028-062300-
Lower Columbia Basin of Washington-
Including the cities of Connell, Prosser, and Tri-Cities
358 AM PDT Tue Sep 6 2022
.TODAY...Sunny, haze. Highs in the upper 80s to lower 90s. North
wind 5 to 10 mph.
.TONIGHT...Mostly clear. Haze. Lows in the upper 50s to lower
60s. North wind 5 to 10 mph in the evening, becoming light.
.WEDNESDAY...Sunny in the morning, becoming partly cloudy. Haze
in the morning. Highs in the lower to mid 90s. Southwest wind
5 to 15 mph.
.WEDNESDAY NIGHT...Mostly clear. Lows in the upper 40s to lower
50s. West wind 5 to 15 mph with gusts to around 30 mph.
.THURSDAY...Sunny. Highs in the lower 80s. Northwest wind 5 to
10 mph.
.THURSDAY NIGHT THROUGH FRIDAY NIGHT...Clear. Lows in the upper
40s to mid 50s. Highs in the upper 70s to mid 80s.
.SATURDAY THROUGH MONDAY...Mostly clear. Highs in the mid 80s to
lower 90s. Lows in the 50s.
$$
WAZ029-062300-
Foothills of the Blue Mountains of Washington-
Including the cities of Dayton, Waitsburg, and Walla Walla
358 AM PDT Tue Sep 6 2022
.TODAY...Sunny. Haze through the day. Highs in the lower to mid
90s. East wind 5 to 10 mph shifting to the northwest in the
afternoon.
.TONIGHT...Mostly clear. Haze. Lows in the upper 50s to lower
60s. Southwest wind 5 to 10 mph.
.WEDNESDAY...Sunny. Haze in the morning. Highs in the lower 90s.
Breezy. Southwest wind 10 to 20 mph.
.WEDNESDAY NIGHT...Mostly clear. Lows in the lower 50s. West wind
5 to 15 mph.
.THURSDAY...Sunny. Highs around 80. West wind 5 to 15 mph.
.THURSDAY NIGHT THROUGH FRIDAY NIGHT...Clear. Lows in the upper
40s to lower 50s. Highs in the upper 70s to mid 80s.
.SATURDAY THROUGH SUNDAY...Mostly clear. Highs in the mid 80s to
lower 90s. Lows in the upper 40s to mid 50s.
.SUNDAY NIGHT AND MONDAY...Partly cloudy. Lows in the mid to
upper 50s. Highs in the mid 80s to lower 90s.
$$
WAZ030-062300-
Northwest Blue Mountains-
Including the city of Ski Bluewood Resort
358 AM PDT Tue Sep 6 2022
.TODAY...Sunny. Haze through the day. Areas of smoke in the
afternoon. Highs in the 80s.
.TONIGHT...Mostly clear. Haze and areas of smoke. Lows in the
60s.
.WEDNESDAY...Sunny. Haze and areas of smoke in the morning. Highs
in the mid 70s to lower 80s, except in the 80s valleys. West wind
5 to 15 mph with gusts to around 25 mph in the afternoon.
.WEDNESDAY NIGHT...Partly cloudy. Lows in the upper 40s to lower
50s. West wind 5 to 15 mph with gusts to around 25 mph.
.THURSDAY...Sunny. Highs in the lower to mid 60s, except in the
upper 60s to mid 70s valleys.
.THURSDAY NIGHT THROUGH FRIDAY NIGHT...Clear. Lows in the upper
40s to lower 50s. Highs in the 60s, except in the upper 60s to
mid 70s valleys.
.SATURDAY THROUGH SUNDAY...Mostly clear. Highs in the mid 70s to
lower 80s. Lows in the upper 40s to upper 50s.
.SUNDAY NIGHT AND MONDAY...Partly cloudy. Lows in the mid to
upper 50s. Highs in the lower 70s to lower 80s.
$$
WAZ520-062300-
East Slopes of the Washington Cascades-
Including the cities of Appleton, Cle Elum, and Cliffdell
358 AM PDT Tue Sep 6 2022
.TODAY...Sunny. Highs in the mid 70s to mid 80s.
.TONIGHT...Mostly clear. Lows in the lower 50s to lower 60s.
.WEDNESDAY...Mostly cloudy in the morning, becoming partly
cloudy. Highs in the lower 70s to lower 80s, except in the 80s
valleys. West wind 5 to 15 mph in the afternoon. Gusts up to
25 mph.
.WEDNESDAY NIGHT...Mostly clear. Lows in the lower 40s to lower
50s. Northwest wind 5 to 15 mph with gusts to around 30 mph.
.THURSDAY...Sunny. Highs in the upper 60s to upper 70s, except in
the mid 70s to lower 80s valleys.
.THURSDAY NIGHT THROUGH FRIDAY NIGHT...Clear. Lows in the mid 40s
to mid 50s. Highs in the mid 60s to mid 70s, except in the lower
70s to lower 80s valleys.
.SATURDAY THROUGH MONDAY...Mostly clear. Highs in the lower 70s
to lower 80s. Lows in the upper 40s to upper 50s.
$$
WAZ521-062300-
Simcoe Highlands-
Including the cities of Goldendale and Bickleton
358 AM PDT Tue Sep 6 2022
.TODAY...Sunny. Highs in the mid to upper 80s.
.TONIGHT...Mostly clear. Lows in the mid 50s to lower 60s.
.WEDNESDAY...Partly cloudy. Highs in the mid 80s to lower 90s.
West wind 5 to 15 mph with gusts to around 25 mph in the
afternoon.
.WEDNESDAY NIGHT...Mostly clear. Lows in the mid 40s to lower
50s. West wind 5 to 15 mph with gusts to around 30 mph.
.THURSDAY...Sunny. Highs in the mid 70s to lower 80s.
.THURSDAY NIGHT THROUGH FRIDAY NIGHT...Clear. Lows in the upper
40s to upper 50s. Highs in the lower 70s to lower 80s.
.SATURDAY THROUGH MONDAY...Partly cloudy. Highs in the upper 70s
to upper 80s. Lows in the lower 50s to lower 60s.
$$
_____
Copyright 2022 AccuWeather | https://www.sfchronicle.com/weather/article/WA-Pendleton-OR-Zone-Forecast-17421606.php | 2022-09-06T12:15:54Z | https://www.sfchronicle.com/weather/article/WA-Pendleton-OR-Zone-Forecast-17421606.php | true |
Flood warnings and watches are in effect in parts of Rhode Island and Massachusetts Tuesday as a weather system that paralyzed certain areas with heavy rains lingers over the region, according to the National Weather Service.
“Rounds of heavy rain could lead to localized flooding, especially across portions of Rhode Island and eastern Massachusetts, through this afternoon,” forecasters cautioned early Tuesday.
A flood warning, indicating elevated concerns among forecasters for the possibility of dangerous conditions, was issued around 4:42 a.m. Tuesday for northern Rhode Island, including Kent and Providence counties.
“Urban and small stream flooding caused by excessive rainfall continues,’' forecasters wrote, adding the warning is in effect until 11 a.m. Tuesday. “Between 3.5 and 9 inches of rain have fallen in the warned area since rain began yesterday. Local law enforcement reported that Industrial Road in Cumberland was closed due to flooding.”
Advertisement
The Woonasquatucket River near Centerdale is in minor flood stage at a level of 5.67 feet, forecasters wrote. The warning targets Providence, Warwick, Cranston, Pawtucket, East Providence, Woonsocket, Cumberland, North Providence, Smithfield, Lincoln, Central Falls, Burrillville, North Smithfield, Scituate, Glocester, Plainville and Foster.
In Rhode Island, Cranston was the heaviest hit with forecasters reporting the community received nearly 11 inches of rain followed by Providence (8.31), Smithfield (7.95) and North Providence (7.28).
In Massachusetts, North Attleborough and Attleboro were areas of concern to forecasters.
A flood watch is in effect until 5 p.m. Tuesday for most of Rhode Island and Massachusetts, forecasters wrote. The watch is focused on Block Island, Bristol, Kent, Newport, Providence and Washington counties in Rhode Island and Bristol, Eastern Hampden, Essex, Middlesex, Norfolk, Plymouth, Suffolk and Worcester counties.
The weather service said that rainfall totaled between 3 and 9 inches on Labor Day and that the meandering weather system could bring up to 4 inches more. Isolated thunderstorms are possible, forecasters said.
Advertisement
The once-parched region was overwhelmed in some communities by the rain that arrived relentlessly Monday, generating flash flooding of Interstate 95 in Providence, trapping some drivers for several hours until the flooding receded, officials said.
By Monday night, traffic was moving in both directions of I-95 The impacted section of the interstate was completely cleared by about 7:15 p.m., officials said.
A building at 215 Peace St. in Providence collapsed during the flooding. It was unoccupied at the time, and no injuries were reported, officials said
Rhode Island Department of Transportation Director Peter Alviti told reporters on Monday that drainage systems had not become blocked during the flash flooding, which dumped more than 4 inches of rain on Providence and surrounding areas in a short period of time.
“It was simply that the rain came down at an intensity that exceeded its capacity to accept it,” he said during the press conference.
Forecasters said some rain will persist into Wednesday and the wet conditions will be followed by dry weather into next week.
This is developing story.
Material from earlier Globe coverage was used in this report.
John R. Ellement can be reached at john.ellement@globe.com. Follow him on Twitter @JREbosglobe. | https://www.bostonglobe.com/2022/09/06/metro/no-rest-soaken-more-rain-flood-warnings-ri-mass-tuesday/ | 2022-09-06T12:16:45Z | https://www.bostonglobe.com/2022/09/06/metro/no-rest-soaken-more-rain-flood-warnings-ri-mass-tuesday/ | true |
Canadian police are hunting for the remaining suspect over the fatal stabbing of 10 people in an indigenous community and a nearby town in the province of Saskatchewan after finding the body of his brother amid a massive manhunt for the pair.
Damien Sanderson, 31, was found dead on Monday near the stabbing sites and authorities believe his brother and fellow suspect, Myles Sanderson, 30, is injured, on the run and likely to be in the provincial capital of Regina, said police chief Evan Bray.
Royal Canadian Mounted Police commanding officer Assistant Commissioner Rhonda Blackmore said authorities are not sure of the cause of Damien Sanderson’s death yet but the injuries were not self-inflicted.
His “body was located outdoors in a heavily grassed area in proximity to a house that was being examined. We can confirm he has visible injuries,” she said.
Asked if Myles Sanderson was responsible for his brother’s death, Ms Blackmore said police are investigating that possibility, but “we can’t say that definitively at this point in time″.
Eighteen other people were injured in the series of stabbings.
Leaders of the James Smith Cree Nation, where most of the stabbing attacks took place, blamed the killings on the drug and alcohol abuse plaguing the community, which they said was a legacy of the colonization of indigenous people.
Resident Darryl Burns and his brother, Ivor Wayne Burns, said their 62-year-old sister, Gloria Lydia Burns, was a first responder who was killed while responding to a call.
“She went on a call to a house and she got caught up in the violence,” Darryl Burns said. “She was there to help. She was a hero.”
He blamed drugs and pointed to colonisation for the rampant drug and alcohol use on reserves.
“We had a murder-suicide here three years ago. My granddaughter and her boyfriend. Last year we had a double homicide. Now this year we have 10 more that have passed away and all because of drugs and alcohol.”
Ivor Wayne Burns also blamed drugs for his sister’s death and said the suspect brothers should not be hated.
“We have to forgive them boys,” he said. “When you are doing hard drugs, when you are doing coke, and when you are doing heroin and crystal meth and those things, you are incapable of feeling. You stab somebody and you think it’s funny. You stab them again and you laugh.”
Ms Blackmore said police are still determining the motive, but the chief of the Federation of Sovereign Indigenous Nations echoed suggestions that the stabbings could be drug-related.
“This is the destruction we face when harmful illegal drugs invade our communities, and we demand all authorities to take direction from the chiefs and councils and their membership to create safer and healthier communities for our people,” said Chief Bobby Cameron.
Ms Blackmore said Myles Sanderson’s criminal record dates back years and includes violence. Last May, Saskatchewan Crime Stoppers issued a wanted list that included him writing that he was “unlawfully at large”.
While authorities believe Myles Sanderson is in Regina, about 210 miles (335km) south of where the stabbings happened, they have issued alerts in Canada’s three vast prairie provinces — which also include Manitoba and Alberta — and contacted US border officials. The manhunt entered its third day on Tuesday.
Before Damien Sanderson’s body was found, arrest warrants were issued for the suspects and both men faced at least one count each of murder and attempted murder.
The stabbing attack was among the deadliest mass killings in Canada, where such crimes are less common than in the United States. The deadliest gun rampage in Canadian history happened in 2020, when a man disguised as a police officer shot people in their homes and set fires across the province of Nova Scotia, killing 22 people. In 2019, a man used a van to kill 10 pedestrians in Toronto.
Police in Saskatchewan got their first call about a stabbing at 5.40am on Sunday, and within minutes heard about several more. In all, dead or injured people were found at 13 different locations on the sparsely populated reserve and in the town, Ms Blackmore said.
James Smith Cree Nation is about 20 miles (30km) from Weldon.
Among the 10 killed was Lana Head, who is the former partner of Michael Brett Burns and the mother of their two daughters.
“It’s sick how jail time, drugs and alcohol can destroy many lives,” Mr Burns told the Aboriginal Peoples Television Network. “I’m hurt for all this loss.”
Weldon residents identified one of the dead as Wes Petterson, a retired widower who made coffee every morning at the senior centre. He loved gardening, picking berries, canning, and making jam and cakes, recalled William Works, 47, and his mother, Sharon Works, 64.
“He would give you the shirt off his back if he could,” William Works said, describing his neighbour as a “gentle old fellow” and “community first”.
Sharon Works was baffled: “I don’t understand why they would target someone like him anyway, because he was just a poor, helpless little man, 100lb soaking wet. And he could hardly breathe because he had asthma and emphysema and everybody cared about him because that’s the way he was. He cared about everybody else. And they cared about him.” | https://www.thecourier.co.uk/news/uk-world/3665581/canadian-police-hunt-remaining-stabbings-suspect-after-brother-found-dead/ | 2022-09-06T12:16:50Z | https://www.thecourier.co.uk/news/uk-world/3665581/canadian-police-hunt-remaining-stabbings-suspect-after-brother-found-dead/ | true |
An entertainment page and an updated People You Should Know format are among several changes to the News-Graphic as the Fall season begins.
Starting in this edition, our popular People You Should Know will evolve from a question-and-answer format to feature interview format. The feature will focus on people who may be in the background, but have a significant influence on the community.
Replacing the People You Should Know feature on page two of each edition will be a regular listing of public meetings for the Georgetown City Council, Scott County Fiscal Court, Scott County Board of Education, school site-based councils and other meetings of importance.
Starting with the Sept. 9 edition, we will launch a new entertainment page called Weekend. The page will on focus events and activities in the area. Jen Tackett will provide a weekly listing of live music events, as well as a monthly musical artist feature.
The page will also include a revolving schedule of features from the Scott County Library, Scott County Extension Office, as well as movie reviews and features on school and community plays.
An extensive Community Directory, sort of an online telephone directory, is now available on our website at www.news-graphic.com.
The News-Graphic’s weekly sports show is now online on the website and features interviews with our community’s finest athletes and Kal Oakes. Each Thursday is a new edition of the show.
The newspaper is also partnering with Scott County Schools Athletic Department and Bird’s Nest Productions to audio cast each week’s football games and some of the biggest games during the basketball season.
These new features will join a lineup of award-winning community sports and news coverage. | https://www.news-graphic.com/news/gng-to-launch-entertainment-page-new-pysk-features/article_887b5e7a-2b04-11ed-a9df-93cdc2b96251.html | 2022-09-06T12:17:00Z | https://www.news-graphic.com/news/gng-to-launch-entertainment-page-new-pysk-features/article_887b5e7a-2b04-11ed-a9df-93cdc2b96251.html | true |
BERLIN (AP) — Swiss retailer Migros said Tuesday that it is launching a coffeemaking system designed to replace capsules that produce thousands of tons of waste worldwide each year.
The cooperative said its spherical capsules — described as “coffee balls” — are fully compostable, unlike the plastic and aluminum containers popularized by its rival Nestle under the brand Nespresso 36 years ago.
Migros said its coffee balls are encased in a thin, flavorless, seaweed-based cover that can be discarded with the spent coffee after use.
The company said the CoffeeB system, which also features a special coffeemaker, will be rolled out first in Switzerland and France this year, followed by Germany in 2023. | https://www.kxnet.com/news/business-beat/ap-business/ap-swiss-retailer-rolls-out-coffee-balls-to-replace-capsules/ | 2022-09-06T12:18:42Z | https://www.kxnet.com/news/business-beat/ap-business/ap-swiss-retailer-rolls-out-coffee-balls-to-replace-capsules/ | false |
PLAINFIELD, Ind. – A blood drive in Plainfield on Tuesday will be dedicated to fallen Elwood Officer Noah Shahnavaz.
The Indiana Law Enforcement Academy is hosting the event at its facility in Plainfield, commemorating Indiana police officers who have died in the line of duty. The event will specifically memorialize Shahnavaz, who just recently died in the line of duty.
Shahnavaz was gunned down during a traffic stop on July 31 and later laid to rest by his family and community members on Aug. 6.
“Please raise your sleeve in honor of the Indiana police officers who have made the ultimate sacrifice in the line of duty and for those officers who bravely serve their communities today,” Indiana Law Enforcement Academy Executive Director Tim Horty said in a news release.
The event also comes days after Richmond Police Officer Seara Burton was taken off of life support and moved to a hospice care facility back in Indiana. Burton was shot during a traffic stop that took place on Aug. 10. She had been in the intensive care unit at Miami Valley Hospital in Dayton, Ohio since the shooting.
The Richmond Police Department said her condition has not changed much since she was taken off of life support but is closely monitoring her condition. The city will provide updates.
Tuesday’s blood drive in Plainfield will take place from 4 p.m. until 8 p.m. inside the gymnasium of the Indiana Law Enforcement Academy located at 5402 S. CR 700 East in Plainfield.
Organizers say appointments are encouraged, but walk-ins are welcome. You can call 317-916-5150 to make an appointment or do so online. | https://fox59.com/morning-news/blood-drive-in-plainfield-dedicated-to-fallen-elwood-officer-noah-shahnavaz/ | 2022-09-06T12:19:11Z | https://fox59.com/morning-news/blood-drive-in-plainfield-dedicated-to-fallen-elwood-officer-noah-shahnavaz/ | true |
With the Giants set to begin the season Sunday at the Titans, let’s bring you our game-by-game predictions for coach Brian Daboll’s first year.
Here goes ...
• Week 1 (Sept. 11): at Titans
Loss, 28-17 (0-1)
A.J. Brown is gone — though he’s in Philadelphia, which doesn’t really help the Giants — yet the Titans and Ryan Tannehill are clearly better.
BUY GIANTS TICKETS: STUBHUB, VIVID SEATS, TICKETSMARTER, TICKETMASTER
• Week 2 (Sept. 18): vs. Panthers
Win, 21-20 (1-1)
It’ll be fascinating to see how Baker Mayfield, this early on with the Panthers, handles Wink Martindale’s defensive pressure. But we’ll take the Giants in a low-scoring squeaker in Daboll’s first home game.
• Week 3 (Sept. 26, Monday): vs. Cowboys
Loss, 35-20 (1-2)
The Cowboys’ roster is vastly better than the Giants’ roster at this point. It’s just that simple.
• Week 4 (Oct. 2): vs. Bears
Win, 38-28 (2-2)
Battle of two rebuilding teams. The Giants should be able to beat Justin Fields and Co. at home. This is one of several winnable home games for Daboll and Co.
• Week 5 (Oct. 9): at Packers (in London)
Loss, 42-14 (2-3)
It would be a shocker if the Giants won this game, even though it’s not a true road game in Green Bay. Ultimately, too much Aaron Rodgers, as he picks apart the Giants’ overhauled secondary.
• Week 6 (Oct. 16): vs. Ravens
Loss, 34-28 (2-4)
No bye for the Giants coming off the London trip. Martindale will be fired up to face his old team, but that alone won’t be enough to stop Lamar Jackson.
• Week 7 (Oct. 23): at Jaguars
Loss, 31-27 (2-5)
This feels like a swing game for the rebuilding Giants. We initially saw it as a win, but after watching this team this summer, we’re flipping it the other way.
• Week 8 (Oct. 30): at Seahawks
Loss, 38-28 (2-6)
Yes, Russell Wilson is gone. Yes, Seattle is also still a very tough place to win. No, the Giants will not win this game, as their pre-bye, midseason losing streak continues and the realities of this rebuilding process begin to set in.
• Week 9 (Nov. 6): Bye
Want to bet on the NFL?
See the best NJ Sports Betting sites
• Week 10 (Nov. 13): vs. Texans
Win, 41-27 (3-6)
Like the Giants, the Texans are one of the NFL’s worst teams. This is a game Daboll should win at home, coming off his bye week.
• Week 11 (Nov. 20): vs. Lions
Win, 17-14 (4-6)
All things considered, the Giants have a fairly favorable home schedule in 2022. And this is yet another winnable home game.
• Week 12 (Nov. 24, Thanksgiving): at Cowboys
Loss, 48-20 (4-7)
The Giants lose in Dallas for the sixth straight year. Entering 2022, the Giants are 5-15 against the Cowboys since their most recent Super Bowl win.
• Week 13 (Dec. 4): vs. Commanders
Win, 28-27 (5-7)
This is absolutely a winnable home game for the Giants. Entering 2022, the Giants are 13-7 against the Commanders since their most recent Super Bowl win.
• Week 14 (Dec. 11): vs. Eagles
Loss, 35-32 (5-8)
This will be a close game at MetLife Stadium, but Jalen Hurts and Co. get the edge.
• Week 15 (Dec. 17 or 18): at Commanders
Loss, 20-10 (5-9)
Carson Wentz isn’t great, but he’s an upgrade for the Commanders at quarterback.
• Week 16 (Dec. 24, Saturday): at Vikings
Loss, 40-27 (5-10)
Will Kirk Cousins benefit from his new, offensive-minded head coach, Kevin O’Connell? Because of injury attrition, it’s hard to forecast a lot of these late-season games. But the Vikings are clearly better than the Giants.
• Week 17 (Jan. 1): vs. Colts
Loss, 38-14 (5-11)
Matt Ryan isn’t what he once was, but he’s a savvy enough veteran to handle the Giants’ young defense.
• Week 18 (Jan. 7 or 8): at Eagles
Loss, 27-17 (5-12)
This will be the Giants’ ninth straight loss in Philadelphia — and fifth straight loss to end the season, as things fall off a cliff for Daboll and Co. against better competition. Entering 2022, the Giants are 5-15 against the Eagles since their most recent Super Bowl win, after the 2011 season.
• FINAL RECORD: 5-12
This is going to be a long first season for Daboll, whose roster is still a mess from the Dave Gettleman era. Yes, there are some winnable home games on the schedule, and the Giants will take advantage of some of those opportunities. But this team is still very thin on talent in key spots.
Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription.
Darryl Slater may be reached at dslater@njadvancemedia.com. | https://www.nj.com/giants/2022/09/giants-2022-game-by-game-predictions-how-many-wins-will-brian-daboll-have-in-year-1-slater.html | 2022-09-06T12:20:31Z | https://www.nj.com/giants/2022/09/giants-2022-game-by-game-predictions-how-many-wins-will-brian-daboll-have-in-year-1-slater.html | false |
Sister Wives: ‘There's So Much More to the Story’ says Meri Brown
In a recent Instagram post, Kody Brown’s ex-wife Meri Brown confirms there’s a lot more to discover about the Sister Wives Fam.
Sister Wives is a controversial American reality television show on TLC. The reality show follows the life of Kody Brown, his four wives (Meri, Janelle, Christine, and Robyn), and their 18 children. It’s primarily centered around the subject of polygamy.
'Sister Wives’ star Meri Brown shared
Kody Brown’s ex-wife, Meri Brown, 51 recently shared an Instagram photo of her half-covered face with what looks like a journal along with the caption "There's so much more to the story....#Ready."
Fan speculations
Although there’s no straightforward statement by the Sister Wives lead fans made multiple speculations like, "Oohhhh I hope you left Cody!!!! You deserve someone who loves you!!" Fans also questioned if Meri is coming up with a new book.
Sister Wives Season 17
The long-running TLC reality show premiered on September 26, 2010. The reality show called Sister Wives revolves around the controversial life of Kody Brown steering through the world of polygamy. The Season 17 of Sister Wives will premiere on Sunday, September 11, at 10 pm EST on TLC.
Sister Wives: Cast
Kody Brown along with his four wives Meri Brown, Janelle Brown, Christine Brown, and Robyn Brown along with their 18 children.
Sister Wives: Kody Brown
Born on January 17, 1969, Kody Winn Brown popularly known as Kody Brown. Brown is featured on the controversial TLC show Sister Wives. He has 4 wives and eighteen children, along with three grandchildren.
Sister Wives - Where to watch online?
Sister Wives is a TLC show that’s available on TLC and Hulu. Viewers can also stream the episodes on iTunes, Google Play, VUDU, and Amazon Prime Video.
Although it seems like an illegal concept in the United Sates Brown claims that his polygamist arrangement is completely legal because he is legally married only to Robyn Brown. His three other marriages are spiritual unions.
Also read: Sister Wives stars Kody and Christine Brown SPLIT after 25 years: We ask for your kindness
Will there be a third Bad Seed movie? Here’s what Mckenna Grace says | https://www.pinkvilla.com/entertainment/hollywood/sister-wives-1188460 | 2022-09-06T12:20:34Z | https://www.pinkvilla.com/entertainment/hollywood/sister-wives-1188460 | true |
Mokhtar Jabli is founder and CEO of The Nightfall Group, California’s premiere luxury rental and travel concierge service.
Thoughtful, tactical marketing can be a highly effective way to primely position your business to potential clients and partners. Research from the Content Marketing Institute shows that 75% of marketers increased their brand’s credibility and trust through digital marketing tactics. Without a successful marketing strategy, businesses may find it difficult to navigate the right avenues to market their products and services and cut through the clutter of competition.
How To Make Your Marketing More Intentional
Many companies have an idea of base-level marketing, but in order to go from good to great, they need to learn strategies they can use to get to the next level. With these three tactics, businesses can grow their presence to increase their client base, name recognition and revenue.
1. Research your competitors.
One way to gain the upper hand in your business’ market is to research the competition. As an example, as the leader of a rental and travel concierge service, I might look into luxury travel companies, concierge companies, real estate companies, luxury goods and services and other topics related to my business. Keep a list of these companies so you can watch how they grow and how their marketing changes over time, and be sure to add new companies to the list when they enter the market.
After compiling your list, determine how they are marketing themselves by looking at how they are highlighted in search results. For instance, if a company is displayed at the top of a search page, it’s likely utilizing Google Ads. You will likely notice the word “Ad” appears in front of the hyperlink. If a company shows up several times in recent news results, it likely has a public relations team that is securing media placements.
Once you find out how your competitors are utilizing marketing, you can make informed decisions about the opportunities you want to pursue.
2. Develop personalized marketing collateral.
Studies have shown that personalization is the key to returning clients, and this extends to the business’ marketing strategy. In order to successfully gain new clients or retain existing ones, consider customizing your marketing approach to better suit their needs.
First, you need to understand the different types of marketing collateral and what makes sense for your business. Every business should have an eye-catching website that highlights its products or services and any other relevant information. Having a blog on your website can be an effective tool for generating leads as well; Hubspot research shows that 56% of marketers who leverage blogging say it is effective.
Social media pages are necessary for today’s market, and you will want to determine which platforms are appropriate for your business. Facebook is the most popular social media platform for marketers, with 1.8 billion active daily users; Instagram is a short second, with more than 500 million active daily users. Newsletters and email marketing are effective marketing tools—Campaign Monitor estimates that half of the global population uses email. Even with the rise of digital marketing strategies and users, print collateral is still popular with potential and existing clients. In fact, marketing campaigns that combine print and digital advertisements are 400% more effective than campaigns with just one or the other.
Once you determine and start implementing the best marketing strategies for your business, analyze how those strategies are performing. For example, with social media, you can customize ad campaigns to provide a personalized experience to potential clients. It’s also important to place a focus on user experience to ensure your website is performing well. According to an Amazon report, 88% of online shoppers say they wouldn’t return to a website after having a bad user experience. Focusing on your clients’ experience and prioritizing personalization will result in increased marketing success for your business.
3. Gain client feedback and read reviews.
One of the most important ways you can ensure marketing success is through client feedback. Intaking and analyzing client feedback can help you make more informed decisions for your business and, when used correctly, can position you to provide better service for clients through increased personalization.
There are numerous ways a business can gather client feedback. Asking for reviews, either on a specific platform like Facebook or through your website, is a quick and effective way to gain insight into what your business is doing well or where it needs to improve. With newsletter marketing, you can conduct a survey among your current client base to find out key areas where you can grow. Offering incentives like gift cards or discounts on future products or services may get more clients to fill out the survey.
Another avenue is social listening, which Hubspot notes is the number one tactic used by marketers. With it, brands can be attentive to what others are saying about them on social media and in online reviews. This feedback can help businesses learn more about how clients perceive the products and services they offer and market those offerings more effectively.
Scaling your marketing approach should be a priority if you want to see your business grow. By utilizing these marketing strategies, you can help your business become more attractive to existing clients, increase your new client base and positively impact your bottom line.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify? | https://www.forbes.com/sites/forbesbusinesscouncil/2022/09/06/3-tips-to-ensure-business-success-with-thoughtful-tactical-marketing/ | 2022-09-06T12:29:08Z | https://www.forbes.com/sites/forbesbusinesscouncil/2022/09/06/3-tips-to-ensure-business-success-with-thoughtful-tactical-marketing/ | false |
BEIJING (AP) — Asian stock markets were mixed Tuesday after China promised to speed up the rollout of policy changes to boost anemic economic growth and Australia’s central bank raised its benchmark interest rate.
Shanghai, Tokyo and Seoul gained while Hong Kong declined.
The Chinese Cabinet’s planning agency promised Monday to accelerate easier lending and other policies but announced no new spending. Economic growth sank to 2.5% over a year earlier in the first half, less than half the official annual target.
The announcement might “provide a short-term uplift” to sentiment, but investors “ultimately want to see a stronger recovery,” said Yeap Jun Rong of IG in a report.
The Shanghai Composite Index gained 1.1% to 3,235.57 while the Nikkei 225 in Tokyo added 0.1% to 27,643.06. The Hang Seng in Hong Kong shed 0.2% to 19,177.70.
Sydney’s S&P-ASX 200 lost 0.3% to 6,833.80 after Australia’s central bank raised its benchmark lending rate by 0.5 percentage points to 2.35%, its highest level since 2015, and said more rate hikes were planned.
Investors worry repeated rate hikes by the U.S. Federal Reserve and central banks in Asia and Europe to cool inflation that is at multi-decade highs might derail global economic growth. Central banks say they must slow business and consumer activity to get prices under control.
The Kospi in Seoul advanced 0.2% to 2,408.55 while India’s Sensex opened down less than 0.1% at 59,230.54. New Zealand retreated while Southeast Asian markets gained.
U.S. markets were closed Monday for a holiday.
European markets sank following Friday’s announcement by Russian gas giant Gazprom that a suspension of supplies through the Nord Stream 1 pipeline would be extended indefinitely. That adds to shortages in Germany and other economies.
The deputy director of China’s National Development and Reform Commission, Yang Yinkai, said the agency will “speed up the release of policy effectiveness” to “make up for losses caused by the epidemic in the second quarter,” according to news reports.
The government has trimmed interest rates, given entrepreneurs a break on rent and promised other aid to revive the economy after Shanghai and other industrial centers temporarily shut down to fight virus outbreaks. But it is avoiding major spending, possibly for fear of reigniting a rise in housing costs and debt that Chinese leaders worry is dangerously high.
Also Monday, Beijing freed up more foreign currency holdings of Chinese commercial banks for lending and trading by lowering the amount they must hold in reserve. The move rolls back an increase imposed last year to limit speculative trading and restrain the rise of the exchange rate of China’s yuan, which has since declined.
In energy markets, benchmark U.S. crude gained $1.78 to $88.65 per barrel in electronic trading on the New York Mercantile Exchange. Brent crude, used to price international oils, lost 70 cents to $95.04 per barrel in London.
The dollar advanced to 141.12 yen from Monday’s 140.46 yen. The euro gained to 99.55 cents from 99.31 cents. | https://www.myarklamiss.com/news/business/ap-business/ap-asian-stocks-mixed-after-china-promises-to-boost-growth/ | 2022-09-06T12:30:04Z | https://www.myarklamiss.com/news/business/ap-business/ap-asian-stocks-mixed-after-china-promises-to-boost-growth/ | true |
DALLAS, Sept. 6, 2022 /PRNewswire/ -- Generation Hemp, Inc., a Dallas/Fort Worth based midstream hemp company (OTCQB: GENH), and its wholly-owned subsidiary, GENH Halcyon Acquisition, LLC (collectively the "Company") in collaboration with Richard Rawlings' Gas Monkey Garage, today announced the official launch of its Gas Monkey Spill-Jack consumer goods hemp product line. Gas Monkey Spill-Jack is an all-natural, plant-based, sustainable, and biodegradable loose absorbent made from the hemp hurd byproduct that is produced by the Company's hemp processing operations. This is the second consumer goods product produced by Generation Hemp, adding to its hemp animal bedding line called Rowdy Rooster Hemp. Gas Monkey Spill-Jack is now being sold on spilljackusa.com and will soon be offered on Amazon.
There are several types of spill absorbents with varying characteristics within three general categories – mineral based, animal or vegetable based, and synthetic or organic polymers. The challenge in choosing an absorbent is finding an effective material that does not pose a threat to either health or the environment, whether that threat is posed when that material is procured or used. For example, a widely used spill absorbent material in products is Bentonite Clay. This is often a very dusty material and has warnings of containing unsafe levels of lead (FDA) and has been associated with a number of health complaints in humans.
When Generation Hemp's processing facility operations often led to thick and sticky hemp oil messes similar to spills in an automotive garage, the facility managers started to use hemp hurd to soak up those spills, because kitty litter and other chemical based products could not be used around the crops being processed. When they saw how well it worked, they took it to neighboring businesses to try out further. They found that it worked faster and better than the kitty litter stand by in other applications. Chairman and CEO of Generation Hemp, Inc. commented, "We began experimenting and testing hemp hurd's efficacy against all the industrial absorbent standard go-tos. Spill-Jack performed as well or better against every other material. Most of the current products used are not the best environmental options, and other eco-friendly options just don't perform as well. When we brought the milled hemp stalks to Richard Rawlings' Gas Monkey Garage, I think everyone was somewhat stunned at Spill-Jack's performance." Evans continued, "Our team was very excited to collaborate with Richard and Gas Monkey. Getting the stamp of approval from such a well known automotive brand is one thing, but to then have the founder put his brand behind our product was just unexpected. In fact, it was our visit to Gas Monkey Garage that inspired our product's name, Spill-Jack. If you can jack up a car, you can jack up a spill!"
The initial products in the Gas Monkey Spill-Jack line will come in three different sizes: a large 20 pound bag that can absorb approximately 24 gallons of oil, a medium sized bag that can absorb approximately 9 liters of oil, and mini-bag singles sold individually or in six-packs and can be kept in the purse or glove box to clean up any spills on the go, including pet messes.
Generation Hemp, Inc. is a Dallas/Fort Worth based hemp company that operates in the midstream sector. With operations in western Kentucky and Denver, Colorado, the company uses its proprietary technology to dry, clean, process and store hemp. In addition, Generation Hemp also owns and leases real estate to companies needing seed storage facilities located within the greater Denver area.
Richard Rawlings, owner and founder of Gas Monkey Garage, is the star of the international hit series "Fast N' Loud," "Garage Rehab," "Demolition Theatre," and more. Since the inception of Gas Monkey Garage in 2004, Richard Rawlings continues to be anything except ordinary. Having built two commissioned custom cars for Hot Wheels, setting numerous world records, and cementing Gas Monkey Garage as a household name, Richard does anything but blend in! Aside from his garage and television shows, Richard Rawlings is an innovative entrepreneur, turning Gas Monkey Garage into a household name and worldwide brand. Between owning multiple restaurants/venues, having his own Tequila and Energy Drink, selling merchandise worldwide, and sponsoring some of the top names in automotive racing, Richard Rawlings only knows one speed and its full throttle. You can learn more about Richard Rawlings and the Gas Monkey crew at GasMonkeyGarage.com, and see what the Monkeys are up to every Monday night at 8pm CDT on their YouTube Channel.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as "believes", "expects", "anticipates", "intends", "plans", "estimates," "projects", "forecasts", "proposes", "should", "likely" or similar expressions, indicates a forward-looking statement. These statements and all the projections in this press release are subject to risks and uncertainties and are based on the beliefs and assumptions of management, and information currently available to management. The actual results could differ materially from a conclusion, forecast or projection in the forward-looking information. The identification in this press release of factors that may affect the company's future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive.
Contact:
Melissa M. Pagen
Generation Hemp, Inc.
Phone: (310) 628-2062
Email: mpagen@genhempinc.com
View original content:
SOURCE Generation Hemp Inc. | https://www.kmvt.com/prnewswire/2022/09/06/generation-hemp-officially-launches-gas-monkey-spill-jack-hemp-product-line/ | 2022-09-06T12:35:20Z | https://www.kmvt.com/prnewswire/2022/09/06/generation-hemp-officially-launches-gas-monkey-spill-jack-hemp-product-line/ | true |
MINNEAPOLIS, Sept. 6, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 12:50 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.
View original content to download multimedia:
SOURCE Bio-Techne Corporation | https://www.wistv.com/prnewswire/2022/09/06/bio-techne-present-baird-2022-global-healthcare-conference/ | 2022-09-06T12:37:36Z | https://www.wistv.com/prnewswire/2022/09/06/bio-techne-present-baird-2022-global-healthcare-conference/ | false |
A three-person team of University of Georgia undergraduates from both the Terry College of Business and the College of Agricultural and Environmental Sciences claimed the top prize in an annual competition that challenged students to design the ideal campus workspace.
ATHENS — The Summer Design Sprint was sponsored by the College of Family and Consumer Sciences, Terry College of Business and the UGA Entrepreneurship Program in partnership with Cox Enterprises.
A design sprint encourages students to practice human-centered design methods to create an innovative solution to a complex problem with the help of industry partners, Dee Warmath, a faculty member in FACS, said.
“It was wonderful to see these students engage with the human-centered design process to produce very thoughtful solutions to improving the workspace and classroom experiences,” Warmath said. “Every time we give our students the opportunity, they exceed our expectations.”
Following a six-week program in which the teams worked closely with industry partners on designing the project, the students presented their ideas to a panel of judges on Aug. 15 at UGA’s Delta Innovation Hub.
Four teams of three students competed in the final event.
The team of Sejal Khanna and Shourya Seth from the Terry College of Business and Conner Dunahoo from CAES took first place and a $1,500 prize for their project, MINT (mutualism, integration, nonlinearity and thoughtfulness).
MINT envisioned an industry partner creating a course offering students real-world experience, an internship and potentially an offer of full-time employment.
The judges said they were impressed by the potential impact of the idea and how it would address the needs of students, the university and industry partners.
“While we were all from different majors, different backgrounds and did not have too much in common at first, we realized we were all passionate about heightening university-student-corporation relationships,” Khanna, a management information systems major in the Terry College of Business, said. “Together, we believed that students would greatly benefit from a program that was based on catering to different learning styles, providing work experience and focusing on relevant, up-to-date techniques and technologies.”
Cox Enterprise representatives who also served as judges were Brian Anderson, senior director of Enterprise, Human-Centered Design; Amy Lin, senior manager, Human-Centered Design and User Experience; and Amit Vyas, vice president, Team Member Experience.
Andrew Potter, the director of Experiential Learning at UGA, and Don Chambers, an associate director of UGA Entrepreneurship, also served as judges.
The second-place team of Milan Richard (School of Social Work), Catalina Giang (Franklin College of Arts and Sciences) and Maggie Wang (Terry College of Business) took home a $750 prize for their Study Space Hub app idea that would allow students to quickly find their own personalized study space.
The team of Joyce Anne Shepherd and Shweta Sainathan from the Terry College of Business and Shanne Low from the University of Wisconsin placed third and claimed a $250 prize for their project, LiveLearning, a platform for students to connect with professionals via a university-sponsored entity.
“I was really impressed with the level of rigor of the research conducted considering the short timeline for the project,” Anderson said. “The teams didn’t propose just one solution, and I liked the flexibility of options presented, ranging from a low-tech approach that could be implemented almost right away to more sophisticated options that you can plan budget and resources to make happen.”
The design sprint was funded by a gift from Cox Enterprises and facilitated by Camryn Cobb, a doctoral student in FACS.
“It was wonderful partnering with Cox and giving the students an opportunity to share their ideas in a professional setting,” Cobb said. “This design sprint allowed us all to share ideas and make new connections, which is crucial to the college experience.”
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article. | https://www.albanyherald.com/news/design-sprint-challenges-students-to-use-creative-thinking-to-solve-problems/article_1574fba8-2a4a-11ed-8c08-ef3cef5d35de.html | 2022-09-06T12:37:52Z | https://www.albanyherald.com/news/design-sprint-challenges-students-to-use-creative-thinking-to-solve-problems/article_1574fba8-2a4a-11ed-8c08-ef3cef5d35de.html | true |
DENVER, Sept. 6, 2022 /PRNewswire/ - Ovintiv Inc. (NYSE: OVV) (TSX: OVV) ("Ovintiv" or the "Company") today announced that Ralph Izzo has been named as an independent member of its Board of Directors, effective September 6, 2022, and that Bruce Waterman will retire from the Board of Directors effective December 31, 2022.
Mr. Izzo, 64, currently serves as the Executive Chair of Public Service Enterprise Group Incorporated ("PSEG"), having recently retired as their Chair, President and CEO. PSEG is a publicly traded diversified energy holding company, founded in 1903 and has a long history of providing infrastructure to access safe, affordable, reliable, and cleaner energy to customers in New Jersey and Long Island. Since joining PSEG in 1992, Mr. Izzo has held several significant executive positions within the PSEG family of companies. Mr. Izzo also serves on the Board of Directors of the Bank of New York Mellon.
Mr. Izzo is a member of the U.S. Department of Energy's Fusion Energy Sciences Advisory Committee and the former chair of the Nuclear Energy Institute. He is also on the Board of Directors for the Edison Electric Institute, Nuclear Electric Insurance Limited, the New Jersey Chamber of Commerce, the Liberty Science Center and the New Jersey Performing Arts Center. Mr. Izzo is on the advisory board for the University of Pennsylvania's School of Engineering and Applied Sciences Mechanical Engineering and Applied Mechanics Department, a member of the Board of Trustees of the Peddie School and Princeton University's Andlinger Center for Energy and the Environment Advisory Council, as well as a member of the Visiting Committee for the Department of Nuclear Engineering at Massachusetts Institute of Technology, the Columbia University School of Engineering Board of Visitors, and of the CEO Action for Diversity and Inclusion. In addition, he is a former chair of the Rutgers University Board of Governors and the New Jersey Chamber of Commerce.
Mr. Izzo received his Bachelor of Science and Master of Science degrees in mechanical engineering and his Doctor of Philosophy degree in applied physics from Columbia University. He also received a Master of Business Administration degree, with a concentration in finance, from the Rutgers Graduate School of Management.
"We are excited that Ralph is joining our Board. His significant senior leadership experience in operations, strategic planning, finance, risk management, environmental stewardship, and diversity leadership will enhance the board's strengths," said Ovintiv's Chair Peter Dea. "Mr. Izzo is a well-known leader within the utility industry, as well as the national energy policy arena and represents our ongoing Board refreshment process as our third new Director in the past 18-months."
Mr. Waterman joined the board in 2010 and served on various committees over his tenure including Audit Committee Chair from 2017 until 2022. Mr. Waterman's wealth of finance, energy industry and government relations experience benefited the Company immensely. "On behalf of the Board and leadership team, I would like to thank Bruce for his many contributions and wise counsel over the last 12 years," said Mr. Dea. Brendan McCracken, Ovintiv's President and CEO noted "the Company is grateful for Mr. Waterman's years of service and dedication and we wish him well in retirement."
Further information on Ovintiv Inc. is available on the Company's website, www.ovintiv.com, or by contacting:
View original content to download multimedia:
SOURCE Ovintiv Inc. | https://www.kmvt.com/prnewswire/2022/09/06/ovintiv-names-ralph-izzo-its-board-directors/ | 2022-09-06T12:39:15Z | https://www.kmvt.com/prnewswire/2022/09/06/ovintiv-names-ralph-izzo-its-board-directors/ | false |
Awarded 2022 Clinical Education Hall of Fame Award from Mercy College
MELVILLE, N.Y., Sept. 6, 2022 /PRNewswire/ -- Professional Physical Therapy, a leading provider of outpatient physical therapy and rehabilitation services in the Northeast, is proud to celebrate the recognition of their Clinical Affiliation Program. Now expanded to over 100 College and University partners, the program offers undergraduate students the opportunity to gain hands-on experience and receive mentorship with Professional's renowned clinical instructors.
The expansion has been recognized by a long-standing Clinical Affiliate, Mercy College. On July 21, 2022, Mercy College awarded Professional with the prestigious Hall of Fame award for exceptional clinical education for Physical Therapy. The award recognizes Professional's lifelong commitment to clinical education and mentorship of future professionals.
The Director of Clinal Affiliations, Kim Ciprian, was recognized for her hard work and dedication to the growth of the Clinical Affiliation Program. Kim has been with Professional since 2001, starting as a Certified Athletic Trainer and working in various departments learning all aspects of the business. After taking over the Clinical Affiliation Program in 2018, she developed a new internal management system to grow the program to what it is today.
Kim states, "Professional PT has some of the best clinicians in the Northeast. I am grateful for such an amazing Clinical team to work with. Professional prides itself in education, not only of our employees but in future clinicians as well."
For more information about participating in a clinical affiliation with Professional Physical Therapy, contact Professional at CAP@professionalpt.com or click here to learn more about the program.
Professional's Clinical Affiliation Program offers students an opportunity to gain hands-on experience with our patients and receive mentorship with our clinical instructors. Many of our instructors are Credentialed Clinical Instructors by the American Physical Therapy Association (APTA) and all are dedicated to ensuring that the student's experience at Professional is a rewarding one.
Students of the program often return to become a full-time member of our clinical staff, and many are now Clinical Directors and Partners in the company. We currently have contracts with over 100 colleges and universities that participate in our Clinical Affiliation Program.
View original content to download multimedia:
SOURCE Professional Physical Therapy | https://www.kmvt.com/prnewswire/2022/09/06/professional-physical-therapy-celebrates-successful-growing-clinical-affiliation-program/ | 2022-09-06T12:39:34Z | https://www.kmvt.com/prnewswire/2022/09/06/professional-physical-therapy-celebrates-successful-growing-clinical-affiliation-program/ | false |
WATSONVILLE, Calif., Sept. 6, 2022 /PRNewswire/ -- The MILPA Collective releases "Truth Telling and Palabra: A Project at Rikers Island," a report that memorializes a transformative project that brought safety, stability, and healing to incarcerated young people [ages 18-21] and correctional staff at the RNDC jail at Rikers Island in Queens, New York.
From June 2021 through January 2022, at the request of Commissioner Vincent Schiraldi, MILPA and a team of expert consultants led a project at Rikers Island to stabilize conditions for incarcerated young adults and frontline staff. Like most jurisdictions across the country, rates of violence are nine times higher among young adults than any other group, making a focus on young adults key to stabilizing conditions agency-wide.
The MILPA approach of working in community and carceral settings across the U.S via the leadership of formerly incarcerated Chicano Indigenous and Black relatives uniquely positioned them to guide this project. "Our work wasn't about flooding Rikers with more programs. Our work was about making systemic change. Organizing with those who live and work inside, to challenge the systemic racism and toxic culture that sustains the status quo at Rikers," says Juan Gomez, Executive Director of MILPA. "And while we always try to balance urgency with the process, at Rikers, we had to treat every day like a war zone with a disaster relief mission."
In just seven months MILPA led a team of expert consultants and accomplished the following:
- Completed a participatory planning process in partnership with frontline staff and incarcerated young adults
- Designed a new model of jail operations for young adults
- Opened four transformed pilot living units using the new operations model
- Trained upwards of 50 correctional staff to work in the units
- Facilitated healing-engaged workshops
- Crafted a new antiracist policy to codify the new model with an eye toward scale.
Planning and preparation began in June 2021, and on November 1st the first pilot units opened, with the second two opening in mid-December 2021. From then through January 2022, only one fight occurred, while the other RNDC units experienced a total of 47 stabbings and slashings during the same period. Using a unique combination of facility-based organizing tactics, a participatory planning process, and a disaster relief approach, the team built an "inside" coalition of Black and Chicano Indigenous frontline staff and incarcerated people aligned in purpose, process, and hope for the future.
In January 2022, the project ended when Commissioner Schiraldi and his administration were ousted by the incoming Mayor. "While this story has an equivocal ending, the report has been written to memorialize the heart and hard work that staff and incarcerated people put into making this vision a reality while reflecting on its implications for the field."
You can access the full report, "Truth Telling and Palabra: A Project at Rikers Island," here and the Executive Summary here.
About MILPA: MILPA is a non-profit organization that is founded and led by formerly incarcerated Chicano Indigenous people. MILPA is a movement space dedicated to Cultivating Change Makers for The Next Seven Generations. For more, visit milpacollective.org
MEDIA CONTACT:
Dayanna Macias- Carlos
Email: pressoffice@milpacollective.org
Phone: (559)289-9885
View original content to download multimedia:
SOURCE MILPA Collective | https://www.wafb.com/prnewswire/2022/09/06/truth-telling-palabra-project-rikers-island-report-released-by-milpa-collective/ | 2022-09-06T12:41:11Z | https://www.wafb.com/prnewswire/2022/09/06/truth-telling-palabra-project-rikers-island-report-released-by-milpa-collective/ | true |
Victims of earthquakes or other disasters could one day find themselves being rescued by an army of solar-powered cyborg cockroaches.
A team of scientists led by Dr Kenjiro Fukuda, from the Riken Cluster for Pioneering Research in Japan, has added tiny electronic control circuits and a flexible solar panel to cockroaches’ bodies to create a robotic remote-controlled insect with almost limitless stamina.
“Body-mounted energy-harvesting devices are critical for expanding the range of activity and functionality of cyborg insects,” Dr Fukuda said.
READ MORE: Conspiracy theorists think scientists accidentally transferred us into a new Universe
He says that swarms of his tiny insectile cyborgs could play a valuable role in search and rescue operations. Asked if it's cruel to customise the insects' bodies in this way, Dr Fukuda says: “It depends on how much we care for the ethics of insects.”
Dr Fukuda’s work is discussed in the latest issue of scientific journal NPJ Flexible Electronics.
Bearing in mind how notoriously hard the cockroach is to kill, the robotic bugs could explore areas contaminated with radioactive waste or other hazards.
The technology that controls the bugs is almost brutally simple. A mild electric shock on one side of its body temporarily disables its legs on that side - causing the bug to turn in the desired direction.
The idea has been discussed in scientific circles for some time, but now that Dr Fukuda’s team has managed to create a miniature solar cell small enough, and flexible enough, to be carried by the cyborg cockroach - the robot bug is now at last a practical possibility.
The body-mounted ultra-thin organic solar cell module achieves a power output over 17 times greater than the power sources fitted to previous experimental cyborg insects.
Disaster recovery is just one application for the undead bugs. The Pentagon has already conducted experiments to see if flying insects could be used to carry a miniature video camera into enemy territory for undetectable surveillance.
A working prototype of DARPA’s Hybrid Insect Micro-Electro-Mechanical System was demonstrated in 2008, and while little has been since been heard publicly, there could well be tiny remote controlled flies buzzing around your home right now.
READ NEXT:
- Parallel universes exist and we will soon explore them, physicist says
- New film sparks fears Moon could be pushed from orbit in doomsday event
- Fears aliens could rearrange solar system's planets to send Earth 'a message'
- China to use lunar satellites to discover secrets of universe and cosmic dark ages | https://www.dailystar.co.uk/news/latest-news/cyborg-zombie-cockroaches-solar-panels-27919900 | 2022-09-06T12:42:33Z | https://www.dailystar.co.uk/news/latest-news/cyborg-zombie-cockroaches-solar-panels-27919900 | true |
DENVER, Sept. 6, 2022 /PRNewswire/ - Ovintiv Inc. (NYSE: OVV) (TSX: OVV) ("Ovintiv" or the "Company") today announced that Ralph Izzo has been named as an independent member of its Board of Directors, effective September 6, 2022, and that Bruce Waterman will retire from the Board of Directors effective December 31, 2022.
Mr. Izzo, 64, currently serves as the Executive Chair of Public Service Enterprise Group Incorporated ("PSEG"), having recently retired as their Chair, President and CEO. PSEG is a publicly traded diversified energy holding company, founded in 1903 and has a long history of providing infrastructure to access safe, affordable, reliable, and cleaner energy to customers in New Jersey and Long Island. Since joining PSEG in 1992, Mr. Izzo has held several significant executive positions within the PSEG family of companies. Mr. Izzo also serves on the Board of Directors of the Bank of New York Mellon.
Mr. Izzo is a member of the U.S. Department of Energy's Fusion Energy Sciences Advisory Committee and the former chair of the Nuclear Energy Institute. He is also on the Board of Directors for the Edison Electric Institute, Nuclear Electric Insurance Limited, the New Jersey Chamber of Commerce, the Liberty Science Center and the New Jersey Performing Arts Center. Mr. Izzo is on the advisory board for the University of Pennsylvania's School of Engineering and Applied Sciences Mechanical Engineering and Applied Mechanics Department, a member of the Board of Trustees of the Peddie School and Princeton University's Andlinger Center for Energy and the Environment Advisory Council, as well as a member of the Visiting Committee for the Department of Nuclear Engineering at Massachusetts Institute of Technology, the Columbia University School of Engineering Board of Visitors, and of the CEO Action for Diversity and Inclusion. In addition, he is a former chair of the Rutgers University Board of Governors and the New Jersey Chamber of Commerce.
Mr. Izzo received his Bachelor of Science and Master of Science degrees in mechanical engineering and his Doctor of Philosophy degree in applied physics from Columbia University. He also received a Master of Business Administration degree, with a concentration in finance, from the Rutgers Graduate School of Management.
"We are excited that Ralph is joining our Board. His significant senior leadership experience in operations, strategic planning, finance, risk management, environmental stewardship, and diversity leadership will enhance the board's strengths," said Ovintiv's Chair Peter Dea. "Mr. Izzo is a well-known leader within the utility industry, as well as the national energy policy arena and represents our ongoing Board refreshment process as our third new Director in the past 18-months."
Mr. Waterman joined the board in 2010 and served on various committees over his tenure including Audit Committee Chair from 2017 until 2022. Mr. Waterman's wealth of finance, energy industry and government relations experience benefited the Company immensely. "On behalf of the Board and leadership team, I would like to thank Bruce for his many contributions and wise counsel over the last 12 years," said Mr. Dea. Brendan McCracken, Ovintiv's President and CEO noted "the Company is grateful for Mr. Waterman's years of service and dedication and we wish him well in retirement."
Further information on Ovintiv Inc. is available on the Company's website, www.ovintiv.com, or by contacting:
View original content to download multimedia:
SOURCE Ovintiv Inc. | https://www.wistv.com/prnewswire/2022/09/06/ovintiv-names-ralph-izzo-its-board-directors/ | 2022-09-06T12:43:47Z | https://www.wistv.com/prnewswire/2022/09/06/ovintiv-names-ralph-izzo-its-board-directors/ | true |
New apprenticeship software, Apprentix, can track and manage multiple programs and expand offerings to even more employees.
DENVER, Sept. 6, 2022 /PRNewswire/ -- Serial entrepreneur Andy Seth is excited to announce his latest initiative, Apprenticeships for All, by way of his two B corporations – Flow and Ravience.
Seth is expanding apprenticeship offerings in Flow, his content marketing business, and Ravience, his customer service business, to entry-level workers and existing managers interested in furthering their careers and skillsets.
The programs will run through Seth's newest startup, Apprentix, an online platform that helps companies create and manage their own apprenticeships. Business owners interested in creating their own apprenticeship program can contact an Apprenticeship Expert here or at support@apprentix.io for a free one-hour consultation.
Apprenticeships at Flow and Ravience are available for positions in Content Marketing and Quality Assurance for entry-level employees and Business Development and Operations for existing employees. All roles are 100% remote and apprentices are paid to learn.
"I want to inspire other modern leaders to take their existing training programs, make some tweaks, and turn them into apprenticeships," says Seth. "There are so many incredible business benefits to implementing this structure – including diversifying your candidate pool, lowering recruiting costs, and developing your employees' skills to your company's exact needs."
Seth developed Apprentix after organically offering apprenticeships in all of his businesses. He always intended on expanding his programs but needed capable software to manage and track their progress. After realizing such a product didn't exist, he set out to code one himself.
Apprentix allows users to design programs from scratch or select one of the 50,000 existing apprenticeships for their own use. Business owners can also designate appropriate wage schedules and register their program with the federal government, if they choose.
"Not everyone can take on debt to go to college, but that doesn't make them less deserving of a good job or less hard-working. In fact, 94% of apprentices continue their employment after graduating. That's something a four-year degree can't guarantee," says Seth.
Apprentix is the only apprenticeship platform that allows organizations to create apprenticeships from scratch and manage them, all in one tool.
Flow is one of the world's leading personal branding agencies and rated top 10% of all B-Corps worldwide. Flow delivers brand strategy, websites, content marketing, and book marketing.
Ravience is a US-based customer experience services company providing online businesses with responsive, affordable, and highly-skilled agents to turn customers into raving fans.
Contact Information:
Olivia Mancuso
Flow Marketing
olivia@feelmeflow.com
View original content to download multimedia:
SOURCE Apprentix | https://www.wistv.com/prnewswire/2022/09/06/serial-entrepreneur-andy-seth-launches-apprenticeships-all-via-new-apprenticeship-software/ | 2022-09-06T12:44:45Z | https://www.wistv.com/prnewswire/2022/09/06/serial-entrepreneur-andy-seth-launches-apprenticeships-all-via-new-apprenticeship-software/ | true |
- Proposal does not apply to Eurodollar futures and options that expire before June 30, 2023
- Conversion date aligns with OTC market plans
- Market participants invited to provide feedback until September 30
- SOFR options to be added to portfolio margining solution
CHICAGO, Sept. 6, 2022 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that based on initial client feedback, it is proposing to convert Eurodollar futures and options open interest into corresponding SOFR contracts on April 14, 2023, under the company's previously adopted fallbacks plan. Eurodollar futures and options contracts that expire before June 30, 2023 are excluded from this proposal and will continue to trade until their expiry.
"Our proposed conversion date will help our clients complete their operational work as early as possible in the transition process, while closely aligning with the recently published industry timelines for over-the-counter interest rate swaps," said Agha Mirza, CME Group Global Head of Rates and OTC Products. "SOFR futures and options are now the leading liquidity pool, as open interest has reached 19 million contracts and volume has significantly outpaced Eurodollars. Based on this growth, today's announcement provides a practical timeline by which clients can bring remaining Eurodollar contracts into the SOFR market."
In the month of August, CME Group reported record average daily volume of nearly 2.5 million contracts and record open interest of 19 million contracts for SOFR futures and options contracts. SOFR options had record volume and open interest in August and SOFR futures had record open interest during the same period. Additional highlights include:
Ahead of the final conversion under fallbacks, liquid standard and reduced-tick Inter-Commodity Spread (ICS) instruments are available to facilitate the voluntary conversion of Eurodollar open interest via the SED Spread for futures and the LS Spread for options.
In addition, to further support the deepening of SOFR markets, CME Group plans to add SOFR options to its portfolio margining solution for cleared products in December 2022, subject to regulatory approval. Portfolio margining enables clients to reduce margin requirements by offsetting their exposure on cleared swaps versus interest rate futures and options.
Now among the world's deepest and most consistently liquid markets, SOFR futures and options have broad participation from global banks, hedge funds, asset managers, principal trading firms and other types of traders.
SOFR futures and options are listed with and subject to the rules of CME. For more information, please visit www.cmegroup.com/sofr.
About CME Group
As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and, E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec and EBS are trademarks of BrokerTec Europe LTD and EBS Group LTD, respectively. Dow Jones, Dow Jones Industrial Average, S&P 500 and S&P are service and/or trademarks of Dow Jones Trademark Holdings LLC, Standard & Poor's Financial Services LLC and S&P/Dow Jones Indices LLC, as the case may be, and have been licensed for use by Chicago Mercantile Exchange Inc. All other trademarks are the property of their respective owners.
CME-G
View original content:
SOURCE CME Group | https://www.kalb.com/prnewswire/2022/09/06/cme-group-proposes-april-14-2023-fallbacks-conversion-eurodollar-futures-options-contracts/ | 2022-09-06T12:44:51Z | https://www.kalb.com/prnewswire/2022/09/06/cme-group-proposes-april-14-2023-fallbacks-conversion-eurodollar-futures-options-contracts/ | false |
Karen Cohen Khazon, "Turpaz's double-digit growth and strong profit, profitability, and EBITDA stem from our combined growth strategy, which proves effective despite challenging macroeconomic conditions"
Company completes three acquisitions YTD, reaching a total of six acquisitions since it's IPO in May 2021
HOLON, Israel, Sept. 6, 2022 /PRNewswire/ -- Turpaz Industries (Turpaz) (TASE: TRPZ), the developer, manufacturer, and marketer of fragrance and flavor extracts, intermediates for the pharma industry, specialty ingredients for the agrochemical and fine chemicals industries, as well as citrus products and aroma chemicals for the flavor and fragrance industry., reported its financial results for the second quarter of the year, today. The Q2 and H2 results set new records thanks to high growth rates in sales, gross profit, operating profit, and adjusted EBITDA.
Karen Cohen Khazon, Turpaz's CEO, commented on the results, "the record results we reported today reflect double-digit revenues and profit growth stemming from the company's growth strategy. Our strategy combines organic growth and acquisitions. The strong capital structure, low leveraging, and the experienced global management team allow Turpaz to deal effectively with challenging global macroeconomic conditions and persist with our acquisition strategy."
The double-digit growth presented by Turpaz was evident in all parameters reviewed, reflecting the management's global growth strategy. The sales in Q2 2022 grew by 50% to $30.3 million compared with $20.2 million in the same quarter of last year. The sales in the first half of 2022 grew by 46.3% to $57.7 million compared with $39.4 million in the same period last year. The growth is due to acquisitions completed during 2021 and 2022 as well as from organic growth net of currency fluctuations impact that accounted for 11% in the second quarter of 2022 and 10.3% in the first half of the year. These financial outcomes were achieved despite currency fluctuations, particularly in the markets in which the company trades in US$. These fluctuations impaired the sales in the second quarter by 7.7% and 5% in the first half of the year.
The gross profit in the first quarter of 2022 grew by 40.7% to $11.7 million, compared with $8.3 million in the same quarter of last year. The gross profit grew by 41.7% in the first half of 2022 to $22.4 million compared with $15.8 million in the same period last year. The growth in the gross profit and the stability of the gross profitability occurred despite the global increase in raw material and shipping costs.
The adjusted EBITDA grew by 34.7% in the first quarter of 2022 to $7 million, compared with $5.2 million in the same quarter of last year. The adjusted EBITDA grew to $13.3 million, compared with $9.9 million in the same period last year, an increase of 35%. The operating profit in the second quarter of 2022 has expanded by 19.8% to $5 million, as compared with $4.1 in the same quarter of last year. The operating profit in the first half of 2022 grew by 18.8% to $9.5 million, compared with $8 million in the same period of last year.
The net profit in the second quarter of 2022 grew by 32.7% to a total of $ 4.2 million, compared with $ 3.2 million in the same quarter last year. The net profit in the first half of 2022 grew by 29.8%, totaling $8.2 million, as opposed to $6.3 million in the same period of last year.
For more information about Turpaz, and the full financial report, visit ir.turpaz.co.il
Contact:
Yoni Adini
Yoni@turpaz.co.il
View original content:
SOURCE Turpaz Industries Ltd. | https://www.wistv.com/prnewswire/2022/09/06/turpaz-reports-record-results-q22022-sales-grow-by-50-303-million-net-profit-increased-by-327-42-million/ | 2022-09-06T12:45:44Z | https://www.wistv.com/prnewswire/2022/09/06/turpaz-reports-record-results-q22022-sales-grow-by-50-303-million-net-profit-increased-by-327-42-million/ | true |
Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
© 2022 Good Karma Brands Milwaukee, LLC. | https://wtmj.com/ap-news/2022/09/06/ap-top-business-news-at-618-a-m-edt-4/ | 2022-09-06T12:46:41Z | https://wtmj.com/ap-news/2022/09/06/ap-top-business-news-at-618-a-m-edt-4/ | false |
As one year anniversary passes, Gaylord's marijuana economy is thriving
GAYLORD — When the Gaylord City Council approved an ordinance allowing marijuana enterprises to operate in the city in May of 2021, the council was mainly focused on two goals: adding jobs and tax revenue.
By most accounts the ordinance has delivered on those objectives.
Gaylord began granting licenses to marijuana business a little over a year ago and at the end of August, 27 licenses had been approved by council. Of those, 22 are for retail outlets, two are for micro-retail operations, one is for a transportation business and two are for growing facilities.
A rough estimate shows that anywhere from 70 to over 100 jobs have been added to the city's economy by the cannabis businesses. Next year, Gaylord and Otsego County will share in the distribution of adult-use marijuana tax revenue. This year, more than $42 million was distributed to 163 municipalities and counties as a part of the Michigan Regulation and Taxation of Marijuana Act.
There have been other economic benefits. Many vacant commercial properties have experienced six-figure investments and in some cases blighted property has been eliminated. All of this has bolstered local real estate and building materials companies and eventually will result in additional property tax revenue.
"I think the ordinance has worked out fine and exactly liked we hoped it would," said Gaylord City Attorney Paul Slough.
In his research in writing up the marijuana ordinance, Slough discovered that some municipalities attracted litigation when they rejected license applications, especially if the ordinance called on applicants to meet specific criteria such as giving local applicants an advantage.
Litigation can be expensive and time consuming for local governments. To avoid that, Slough proposed the city only limit the geographic areas where the businesses can operate and basically grant a license to all who meet state and city rules and regulations.
His philosophy was the market will decide how many is enough.
"We have not had any threats of litigation and the entire process of working with the (license) applicants has been smooth," Slough said. "Through the special use process from the planning commission and city council we have been able to address the public's concerns and work with the applicants to set reasonable restrictions on a case-by-case basis."
Going back to the 1960s, Gaylord has carefully crafted an image of a friendly community with a distinctive Alpine motif. It has served the area well helping to build the tourism business into a year-round economic generator.
So far, it doesn't appear that the marijuana enterprises have affected the city's image.
"The (marijuana businesses) tend to fly low and under the radar," said Gaylord City Manager Kim Awrey. "The (businesses) are not in your face that they are marijuana establishments. We have less marijuana establishments than ones that sell alcohol."
"We have had a lot of response from (marijuana businesses) that are established in other parts of the state," Awrey added. "They were eager to come to Gaylord and its crossroads location with M-32 and I-75."
How many is enough?
By far, retail licenses are the most popular option for investors in the city's cannabis industry. The vast majority of licenses have been for stores selling marijuana and its byproducts to consumers.
Even though the city has approved over 20 licenses, right now only seven are open for business and there could be another two or three by the end of the year. That could give the city 10 retail outlets.
"I was concerned that with the amount of licenses that were applied for we would have 20 retail stores open by now," Awrey said. "We have not seen that. The market is deciding as a handful of licenses were applied for and people placed purchase agreements on property and some have fallen through. They are not purchasing them anymore and the market is dictating that."
Subscribe:Check out our offers and read the local news that matters to you
More:First marijuana store to open in Gaylord on Tuesday
Awrey believes that city is still benefitting even if all of the licenses fail to open a store right away.
"Even if the stores opening don't make it they are rehabbing those buildings. One store took down an old gas station (on Main Street) that had been an eyesore for years," she said.
Gaylord Police Chief Frank Claeys isn't sure if the proliferation of retail stores is too much for the city.
"I understand people's concerns — we don't want to see a million of anything in our town whether it's pizza shops or marijuana businesses. I think the market will sort this out," he said.
Awrey believes that the market will be hard pressed to absorb more than 10 retail stores.
Paul Schmitz Jr. is the president and CEO of Core Investment. His company was just granted a retail license by council at the end of August and he is not worried about having nine or 10 competitors by the time he opens his store sometime next year.
"The beauty of the capitalistic society is the consumer determines that and I think nine isn't a bad number. I know of different municipalities that probably share a similar population number when you take into account Gaylord's tourism that have stores in the double digits and they are all successful," said Schmitz.
Nick Piedmonte is the CEO of Dunegrass, which opened a store on South Otsego Avenue in the spring.
"Dunegrass Gaylord is absolutely meeting our expectations. Locating on the south side of town near the south I-75 exit ramp and in close proximity to tourist homes and RV parks near Otsego Lake was a highly strategic decision for us. We had an excellent response from both locals and visitors to the Gaylord area, keeping us in line with our brand strategy as Northern Michigan's cannabis outfitter," he said.
Piedmonte believes that the market may be at its limit right now.
"The market likely cannot service anymore dispensaries. Effectively, the customer base has been usurped by the existing stores and any new competitors will need to draw customers from existing businesses versus entering an under-serviced market. Our theory that most competitors would set up shop on (or) around Main Street has proven true while our south-side location remains underserved," he said.
Schmitz and his company's involvement in Gaylord illustrate how the city is benefiting from cannabis-related development even without the store actually being open. They have acquired a vacant building at 1523 S. Otsego Ave.
"We will be doing quite a bit of remodeling, including adding a drive-thru window for express pick-up," said Schmitz, who added that his firm will be making a six-figure investment in the project. "It's been vacant a long time and that is part of the reason we were attracted to it."
Schmitz said his company will be looking to hire 18 employees for the store.
"They will have a starting salary of $16 an hour with full benefits," he added.
Next year, the city and the county will share in the tax revenue derived from the marijuana sales. In 2022, local governments earned about $56,000 for each retail operation. Assuming Gaylord has nine or 10 stores operating by the end of the year, the city and Otsego County each will receive over $500,000 if the payout stays at $56,000 per outlet.
"I was afraid (tax sharing) was going to get watered down so when I made my projection for the city budget I didn't go as high as $56,000," Awrey said. "I was between $25,000 and $50,000. Now I see there were record (marijuana) sales in the state for the month of July."
Claeys said his department has adjusted to the demands from the ordinance and he hasn't noticed an increase in crime.
"We haven't seen a lot of change in our day-to-day operations over it. We haven't been swamped with calls. We had one incident at a store (a break-in) which would be on par for this many buildings anyways," Claeys said.
He also said he hasn't noticed an increase in the so-called nuisance crimes like loitering, littering and graffiti.
"I had some concerns about that after speaking to other communities and I don't think we have seen an increase yet," said Claeys.
Claeys also said his department's role in the license application process has gone well so far.
"There is a vetting process by the state and then a vetting process for us. We review their site plan and make sure their security plan is safe for the employees and the public," he said. "The ordinance has worked as intended. We now have enough stores that at this point the ordinance has provided us with what we wanted, which was to allow access to our market and to keep our community safe. We haven't had any violations or reports of violations."
More:Michigan cannabis companies struggle to survive in increasingly competitive market
The state outlook
In July, the Detroit Free Press published a report and noted that the state marijuana industry was going through a shakeup. The price of cannabis flower had declined, making it difficult for growers to turn a profit, and at the same time, new companies continued to open grow operations, processing facilities and retail stores, leading to an increasingly competitive marketplace.
Piedmonte said Dunegrass is a stand alone multi-location retail business.
"We have no grow or processing operation. The biggest challenge as I see it exists for mid-sized, vertically integrated companies who're dealing with a plummeting price in cannabis flower. The price per pound will continue to decrease through the fall and winter," he said when asked to assess the state's cannabis industry.
"I think (the industry) is now at an inflection point when you look at supply and quality," said Schmitz of Core Investment. "I think now is the point where quality starts to show through when there is an overabundance of supply out there. It gives customers a better choice of premium products at a more reasonable price." | https://www.petoskeynews.com/story/business/economy/2022/09/06/as-one-year-anniversary-passes-gaylords-marijuana-economy-is-thriving/65460702007/ | 2022-09-06T12:46:41Z | https://www.petoskeynews.com/story/business/economy/2022/09/06/as-one-year-anniversary-passes-gaylords-marijuana-economy-is-thriving/65460702007/ | true |
Micro Focus Enterprise Suite on Google Cloud accelerates organizations' digital transformation journey
SANTA CLARA, Calif., Sept. 6, 2022 /PRNewswire/ -- Micro Focus (LSE: MCRO; NYSE: MFGP) announced today the availability of its Enterprise Suite for application modernization on Google Cloud Marketplace. With this new Marketplace availability, organizations can more quickly deploy an enterprise-grade mainframe infrastructure solution on Google Cloud at a time when companies are seeking new and cost-effective ways to deliver on IT strategies through continuous modernization and digital transformation initiatives.
The announcement brings together Micro Focus' application modernization capabilities with the powerful security, availability, scalability, and administration features Google Cloud offers as well as Google Compute Engine (GCE) services.
"Moving critical workloads from legacy infrastructure and onto a flexible, scalable, and innovative platform like Google Cloud is an important step in digital transformation. It is imperative that organizations ensure their core business applications can meet the demands of today's ever-changing technology and business needs. Because of this, research shows that 72 percent of COBOL application owners are considering modernization as the best way to digitally transform their strategic core business systems," said Neil Fowler, General Manager and VP of the Application Modernization and Connectivity business at Micro Focus. "The availability of Micro Focus' proven modernization solutions, deployed easily on Google Cloud's trusted infrastructure via the Google Cloud Marketplace, can provide organizations with an easier path to begin their digital transformation journey."
"Legacy infrastructure should not be a barrier to innovation," said Howard Weale, Director, Transformation Practice at Google Cloud. "Bringing Micro Focus to Google Cloud Marketplace will accelerate and simplify organizations' ability to modernize some of the most common mainframe infrastructure in use today, helping them achieve their cloud agendas more quickly while benefiting from leading security, data management, and workload administration capabilities."
Enterprise Suite is a Micro Focus product line that enables modernization of IBM mainframe PL/I and COBOL applications, processes and infrastructure, enabling greater efficiency and time to market. Last month, Micro Focus released the enhanced version of the Enterprise Suite, version 8.0, in conjunction with Visual COBOL 8.0. With this announcement, customers now have the choice and flexibility to deploy their mainframe applications with Micro Focus to any of the major clouds.
The Enterprise Suite of solutions includes:
More Information
Find detailed information about Enterprise Suite 8.0 here or access a free trial.
Explore Micro Focus products on the Google Cloud Marketplace.
Read the blog post "Micro Focus Visual COBOL and Enterprise Suite are now available on the Google Cloud Platform (GCP)!"
Join Micro Focus on LinkedIn and follow @MicroFocus on Twitter.
Micro Focus is one of the world's largest enterprise software providers, focused on solving the IT dilemma—how to balance today's needs with tomorrow's opportunities. We deliver mission-critical technology that helps tens of thousands of customers worldwide manage core IT elements of their business. Strengthened by our strategic services and support organizations, and an extensive partner network, our broad set of technologies for security, IT operations, application delivery, governance, modernization, and analytics provides the innovative solutions organizations need to run and transform— at the same time.
Contact: microfocus@pancomm.com
View original content to download multimedia:
SOURCE Micro Focus | https://www.wafb.com/prnewswire/2022/09/06/micro-focus-extends-its-application-modernization-cloud-solutions-google-cloud-marketplace/ | 2022-09-06T12:47:13Z | https://www.wafb.com/prnewswire/2022/09/06/micro-focus-extends-its-application-modernization-cloud-solutions-google-cloud-marketplace/ | false |
Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combination's Potential Across Difficult-to-Treat Cancers
Post-Hoc, Pooled Analysis of Three Pivotal Phase 3 Studies on Eribulin's Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisai's Commitment to Advancing Understanding of Our Medicines
NUTLEY, N.J., Sept. 6, 2022 /PRNewswire/ -- Eisai announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13.
A late-breaking oral presentation of detailed results from the LEAP (LEnvatinib And Pembrolizumab) clinical program including the final analysis of the Phase 3 LEAP-002 trial will be featured in a Proffered Paper session (NCT03713593; Presentation: #LBA34). The study evaluated the combination of lenvatinib plus Merck's anti-PD-1 antibody pembrolizumab versus lenvatinib monotherapy as a first-line treatment for patients with unresectable hepatocellular carcinoma. Additionally, two mini-oral presentations will feature updated efficacy and safety data from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial evaluating the combination in patients with advanced renal cell carcinoma (NCT02811861; Presentation: #1449MO) and Phase 3 Study 309/KEYNOTE-775 trial evaluating the combination in patients with advanced endometrial carcinoma (NCT03517449; Presentation: #525MO).
In addition, a new post-hoc analysis of three pivotal Phase 3 studies (Study 301/NCT00337103, Study 304/NCT02225470 and the EMBRACE trial/Study 305/NCT00388726) evaluating the efficacy of eribulin mesylate (HALAVEN®) versus other chemotherapies (capecitabine, vinorelbine and Treatment of Physician's Choice [TPC], respectively) in patients living with metastatic breast cancer whose tumors have low or no HER2-expression will be presented during a poster session (Presentation: #259P).
"We look forward to presenting data at ESMO, showcasing Eisai's latest research on both lenvatinib and eribulin, with the goal of continuing to help people living with various types of cancer," said Dr. Takashi Owa, Chief Scientific Officer, Deep Human Biology Learning, Senior Vice President, Eisai Co., Ltd. "Presentations on the LEAP clinical program as well as new analyses for eribulin reinforce our commitment to the ongoing research of our portfolio in an effort to better serve patients and healthcare providers."
In March 2018, Eisai and Merck (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with pembrolizumab. To date, more than 15 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
The full list of Eisai presentations is included below. All regular abstracts are available. All late-breaking abstracts will be made available Wednesday, September 7, 2022, at 6:05 PM EDT (Thursday, September 8, 2022, at 12:05 AM CEST).
LENVIMA is indicated:
- For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)
- In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC)
- In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
- For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
- In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by an FDA-approved test, or not microsatellite instability-high (MSI-H), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
LENVIMA, discovered and developed by Eisai, is a multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with a concurrent inhibition of FGF-receptor substrate 2α (FRS2α) phosphorylation. The combination of LENVIMA and everolimus showed increased anti-angiogenic and anti-tumor activity as demonstrated by decreased human endothelial cell proliferation, tube formation, and VEGF signaling in vitro and tumor volume in mouse xenograft models of human renal cell cancer greater than each drug alone. In syngeneic mouse tumor models, the combination of lenvatinib with an anti-PD-1 monoclonal antibody decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity compared to either treatment alone.
Warnings and Precautions
Hypertension. In DTC (differentiated thyroid cancer), hypertension occurred in 73% of patients on LENVIMA (44% grade 3-4). In RCC (renal cell carcinoma), hypertension occurred in 42% of patients on LENVIMA + everolimus (13% grade 3). Systolic blood pressure ≥160 mmHg occurred in 29% of patients, and 21% had diastolic blood pressure ≥100 mmHg. In HCC (hepatocellular carcinoma), hypertension occurred in 45% of LENVIMA-treated patients (24% grade 3). Grade 4 hypertension was not reported in HCC.
Serious complications of poorly controlled hypertension have been reported. Control blood pressure prior to initiation. Monitor blood pressure after 1 week, then every 2 weeks for the first 2 months, and then at least monthly thereafter during treatment. Withhold and resume at reduced dose when hypertension is controlled or permanently discontinue based on severity.
Cardiac Dysfunction. Serious and fatal cardiac dysfunction can occur with LENVIMA. Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of LENVIMA-treated patients. Monitor for clinical symptoms or signs of cardiac dysfunction. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Arterial Thromboembolic Events. Among patients receiving LENVIMA or LENVIMA + everolimus, arterial thromboembolic events of any severity occurred in 2% of patients in RCC and HCC and 5% in DTC. Grade 3-5 arterial thromboembolic events ranged from 2% to 3% across all clinical trials.
Among patients receiving LENVIMA with pembrolizumab, arterial thrombotic events of any severity occurred in 5% of patients in CLEAR, including myocardial infarction (3.4%) and cerebrovascular accident (2.3%).
Permanently discontinue following an arterial thrombotic event. The safety of resuming after an arterial thromboembolic event has not been established, and LENVIMA has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.
Hepatotoxicity. Across clinical studies enrolling 1327 LENVIMA-treated patients with malignancies other than HCC, serious hepatic adverse reactions occurred in 1.4% of patients. Fatal events, including hepatic failure, acute hepatitis, and hepatorenal syndrome, occurred in 0.5% of patients. In HCC, hepatic encephalopathy occurred in 8% of LENVIMA-treated patients (5% grade 3-5). Grade 3-5 hepatic failure occurred in 3% of LENVIMA-treated patients; 2% of patients discontinued LENVIMA due to hepatic encephalopathy, and 1% discontinued due to hepatic failure.
Monitor liver function prior to initiation, then every 2 weeks for the first 2 months, and at least monthly thereafter during treatment. Monitor patients with HCC closely for signs of hepatic failure, including hepatic encephalopathy. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Renal Failure or Impairment. Serious including fatal renal failure or impairment can occur with LENVIMA. Renal impairment was reported in 14% and 7% of LENVIMA-treated patients in DTC and HCC, respectively. Grade 3-5 renal failure or impairment occurred in 3% of patients with DTC and 2% of patients with HCC, including 1 fatal event in each study. In RCC, renal impairment or renal failure was reported in 18% of LENVIMA + everolimus–treated patients (10% grade 3).
Initiate prompt management of diarrhea or dehydration/hypovolemia. Withhold and resume at reduced dose upon recovery or permanently discontinue for renal failure or impairment based on severity.
Proteinuria. In DTC and HCC, proteinuria was reported in 34% and 26% of LENVIMA-treated patients, respectively. Grade 3 proteinuria occurred in 11% and 6% in DTC and HCC, respectively. In RCC, proteinuria occurred in 31% of patients receiving LENVIMA + everolimus (8% grade 3). Monitor for proteinuria prior to initiation and periodically during treatment. If urine dipstick proteinuria ≥2+ is detected, obtain a 24-hour urine protein. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Diarrhea. Of the 737 LENVIMA-treated patients in DTC and HCC, diarrhea occurred in 49% (6% grade 3). In RCC, diarrhea occurred in 81% of LENVIMA + everolimus–treated patients (19% grade 3). Diarrhea was the most frequent cause of dose interruption/reduction, and diarrhea recurred despite dose reduction. Promptly initiate management of diarrhea. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Fistula Formation and Gastrointestinal Perforation. Of the 799 patients treated with LENVIMA or LENVIMA + everolimus in DTC, RCC, and HCC, fistula or gastrointestinal perforation occurred in 2%. Permanently discontinue in patients who develop gastrointestinal perforation of any severity or grade 3-4 fistula.
QT Interval Prolongation. In DTC, QT/QTc interval prolongation occurred in 9% of LENVIMA-treated patients and QT interval prolongation of >500 ms occurred in 2%. In RCC, QTc interval increases of >60 ms occurred in 11% of patients receiving LENVIMA + everolimus and QTc interval >500 ms occurred in 6%. In HCC, QTc interval increases of >60 ms occurred in 8% of LENVIMA-treated patients and QTc interval >500 ms occurred in 2%.
Monitor and correct electrolyte abnormalities at baseline and periodically during treatment. Monitor electrocardiograms in patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or those who are taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. Withhold and resume at reduced dose upon recovery based on severity.
Hypocalcemia. In DTC, grade 3-4 hypocalcemia occurred in 9% of LENVIMA-treated patients. In 65% of cases, hypocalcemia improved or resolved following calcium supplementation with or without dose interruption or dose reduction. In RCC, grade 3-4 hypocalcemia occurred in 6% of LENVIMA + everolimus–treated patients. In HCC, grade 3 hypocalcemia occurred in 0.8% of LENVIMA-treated patients. Monitor blood calcium levels at least monthly and replace calcium as necessary during treatment. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS). Across clinical studies of 1823 patients who received LENVIMA as a single agent, RPLS occurred in 0.3%. Confirm diagnosis of RPLS with MRI. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity and persistence of neurologic symptoms.
Hemorrhagic Events. Serious including fatal hemorrhagic events can occur with LENVIMA. In DTC, RCC, and HCC clinical trials, hemorrhagic events, of any grade, occurred in 29% of the 799 patients treated with LENVIMA as a single agent or in combination with everolimus. The most frequently reported hemorrhagic events (all grades and occurring in at least 5% of patients) were epistaxis and hematuria. In DTC, grade 3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage. In HCC, grade 3-5 hemorrhage occurred in 5% of LENVIMA-treated patients, including 7 fatal hemorrhagic events. Serious tumor-related bleeds, including fatal hemorrhagic events, occurred in LENVIMA-treated patients in clinical trials and in the postmarketing setting. In postmarketing surveillance, serious and fatal carotid artery hemorrhages were seen more frequently in patients with anaplastic thyroid carcinoma (ATC) than other tumors. Safety and effectiveness of LENVIMA in patients with ATC have not been demonstrated in clinical trials.
Consider the risk of severe or fatal hemorrhage associated with tumor invasion or infiltration of major blood vessels (eg, carotid artery). Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction. LENVIMA impairs exogenous thyroid suppression. In DTC, 88% of patients had baseline thyroid stimulating hormone (TSH) level ≤0.5 mU/L. In patients with normal TSH at baseline, elevation of TSH level >0.5 mU/L was observed post baseline in 57% of LENVIMA-treated patients. In RCC and HCC, grade 1 or 2 hypothyroidism occurred in 24% of LENVIMA + everolimus–treated patients and 21% of LENVIMA-treated patients, respectively. In patients with normal or low TSH at baseline, elevation of TSH was observed post baseline in 70% of LENVIMA-treated patients in HCC and 60% of LENVIMA + everolimus–treated patients in RCC.
Monitor thyroid function prior to initiation and at least monthly during treatment. Treat hypothyroidism according to standard medical practice.
Impaired Wound Healing. Impaired wound healing has been reported in patients who received LENVIMA. Withhold LENVIMA for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of LENVIMA after resolution of wound healing complications has not been established.
Osteonecrosis of the Jaw (ONJ). ONJ has been reported in patients receiving LENVIMA. Concomitant exposure to other risk factors, such as bisphosphonates, denosumab, dental disease, or invasive dental procedures, may increase the risk of ONJ.
Perform an oral examination prior to treatment with LENVIMA and periodically during LENVIMA treatment. Advise patients regarding good oral hygiene practices and to consider having preventive dentistry performed prior to treatment with LENVIMA and throughout treatment with LENVIMA.
Avoid invasive dental procedures, if possible, while on LENVIMA treatment, particularly in patients at higher risk. Withhold LENVIMA for at least 1 week prior to scheduled dental surgery or invasive dental procedures, if possible. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ.
Withhold LENVIMA if ONJ develops and restart based on clinical judgement of adequate resolution.
Embryo-Fetal Toxicity. Based on its mechanism of action and data from animal reproduction studies, LENVIMA can cause fetal harm when administered to pregnant women. In animal reproduction studies, oral administration of lenvatinib during organogenesis at doses below the recommended clinical doses resulted in embryotoxicity, fetotoxicity, and teratogenicity in rats and rabbits. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception during treatment with LENVIMA and for at least 30 days after the last dose.
Adverse Reactions
In DTC, the most common adverse reactions (≥30%) observed in LENVIMA-treated patients were hypertension (73%), fatigue (67%), diarrhea (67%), arthralgia/myalgia (62%), decreased appetite (54%), decreased weight (51%), nausea (47%), stomatitis (41%), headache (38%), vomiting (36%), proteinuria (34%), palmar-plantar erythrodysesthesia syndrome (32%), abdominal pain (31%), and dysphonia (31%). The most common serious adverse reactions (≥2%) were pneumonia (4%), hypertension (3%), and dehydration (3%). Adverse reactions led to dose reductions in 68% of LENVIMA-treated patients; 18% discontinued LENVIMA. The most common adverse reactions (≥10%) resulting in dose reductions were hypertension (13%), proteinuria (11%), decreased appetite (10%), and diarrhea (10%); the most common adverse reactions (≥1%) resulting in discontinuation of LENVIMA were hypertension (1%) and asthenia (1%).
In RCC, the most common adverse reactions (≥20%) observed in LENVIMA + pembrolizumab-treated patients were fatigue (63%), diarrhea (62%), musculoskeletal pain (58%), hypothyroidism (57%), hypertension (56%), stomatitis (43%), decreased appetite (41%), rash (37%), nausea (36%), decreased weight (30%), dysphonia (30%), proteinuria (30%), palmar-plantar erythrodysesthesia syndrome (29%), abdominal pain (27%), hemorrhagic events (27%), vomiting (26%), constipation (25%), hepatotoxicity (25%), headache (23%), and acute kidney injury (21%). The most common serious adverse reactions (≥2%) were hemorrhagic events (5%), diarrhea (4%), hypertension (3%), myocardial infarction (3%), pneumonitis (3%), vomiting (3%), acute kidney injury (2%), adrenal insufficiency (2%), dyspnea (2%), and pneumonia (2%). Fatal adverse reactions occurred in 4.3% of patients receiving LENVIMA in combination with pembrolizumab, including cardio-respiratory arrest (0.9%), sepsis (0.9%), and one case (0.3%) each of arrhythmia, autoimmune hepatitis, dyspnea, hypertensive crisis, increased blood creatinine, multiple organ dysfunction syndrome, myasthenic syndrome, myocarditis, nephritis, pneumonitis, ruptured aneurysm and subarachnoid hemorrhage. Serious adverse reactions occurred in 51% of patients receiving LENVIMA and pembrolizumab. Serious adverse reactions in ≥2% of patients were hemorrhagic events (5%), diarrhea (4%), hypertension (3%), myocardial infarction (3%), pneumonitis (3%), vomiting (3%), acute kidney injury (2%), adrenal insufficiency (2%), dyspnea (2%), and pneumonia (2%). Permanent discontinuation of LENVIMA, pembrolizumab, or both due to an adverse reaction occurred in 37% of patients; 26% LENVIMA only, 29% pembrolizumab only, and 13% both drugs. The most common adverse reactions (≥2%) leading to permanent discontinuation of LENVIMA, pembrolizumab, or both were pneumonitis (3%), myocardial infarction (3%), hepatotoxicity (3%), acute kidney injury (3%), rash (3%), and diarrhea (2%). Dose interruptions of LENVIMA, pembrolizumab, or both due to an adverse reaction occurred in 78% of patients receiving LENVIMA in combination with pembrolizumab. LENVIMA was interrupted in 73% of patients and both drugs were interrupted in 39% of patients. LENVIMA was dose reduced in 69% of patients. The most common adverse reactions (≥5%) resulting in dose reduction or interruption of LENVIMA were diarrhea (26%), fatigue (18%), hypertension (17%), proteinuria (13%), decreased appetite (12%), palmar-plantar erythrodysesthesia (11%), nausea (9%), stomatitis (9%), musculoskeletal pain (8%), rash (8%), increased lipase (7%), abdominal pain (6%), and vomiting (6%), increased ALT (5%), and increased amylase (5%).
In RCC, the most common adverse reactions (≥30%) observed in LENVIMA + everolimus–treated patients were diarrhea (81%), fatigue (73%), arthralgia/myalgia (55%), decreased appetite (53%), vomiting (48%), nausea (45%), stomatitis (44%), hypertension (42%), peripheral edema (42%), cough (37%), abdominal pain (37%), dyspnea (35%), rash (35%), decreased weight (34%), hemorrhagic events (32%), and proteinuria (31%). The most common serious adverse reactions (≥5%) were renal failure (11%), dehydration (10%), anemia (6%), thrombocytopenia (5%), diarrhea (5%), vomiting (5%), and dyspnea (5%). Adverse reactions led to dose reductions or interruption in 89% of patients. The most common adverse reactions (≥5%) resulting in dose reductions were diarrhea (21%), fatigue (8%), thrombocytopenia (6%), vomiting (6%), nausea (5%), and proteinuria (5%). Treatment discontinuation due to an adverse reaction occurred in 29% of patients.
In HCC, the most common adverse reactions (≥20%) observed in LENVIMA-treated patients were hypertension (45%), fatigue (44%), diarrhea (39%), decreased appetite (34%), arthralgia/myalgia (31%), decreased weight (31%), abdominal pain (30%), palmar-plantar erythrodysesthesia syndrome (27%), proteinuria (26%), dysphonia (24%), hemorrhagic events (23%), hypothyroidism (21%), and nausea (20%). The most common serious adverse reactions (≥2%) were hepatic encephalopathy (5%), hepatic failure (3%), ascites (3%), and decreased appetite (2%). Adverse reactions led to dose reductions or interruption in 62% of patients. The most common adverse reactions (≥5%) resulting in dose reductions were fatigue (9%), decreased appetite (8%), diarrhea (8%), proteinuria (7%), hypertension (6%), and palmar-plantar erythrodysesthesia syndrome (5%). Treatment discontinuation due to an adverse reaction occurred in 20% of patients. The most common adverse reactions (≥1%) resulting in discontinuation of LENVIMA were fatigue (1%), hepatic encephalopathy (2%), hyperbilirubinemia (1%), and hepatic failure (1%).
In EC, the most common adverse reactions (≥20%) observed in LENVIMA and pembrolizumab–treated patients were hypothyroidism (67%), hypertension (67%), fatigue (58%), diarrhea (55%), musculoskeletal disorders (53%), nausea (49%), decreased appetite (44%), vomiting (37%), stomatitis (35%), decreased weight (34%), abdominal pain (34%), urinary tract infection (31%), proteinuria (29%), constipation (27%), headache (26%), hemorrhagic events (25%), palmar‐plantar erythrodysesthesia (23%), dysphonia (22%), and rash (20%). Fatal adverse reactions occurred in 4.7% of those treated with LENVIMA and pembrolizumab, including 2 cases of pneumonia, and 1 case of the following: acute kidney injury, acute myocardial infarction, colitis, decreased appetite, intestinal perforation, lower gastrointestinal hemorrhage, malignant gastrointestinal obstruction, multiple organ dysfunction syndrome, myelodysplastic syndrome, pulmonary embolism, and right ventricular dysfunction. Serious adverse reactions occurred in 50% of patients receiving LENVIMA and pembrolizumab. Serious adverse reactions with frequency ≥3% were hypertension (4.4%), and urinary tract infection (3.2%). Discontinuation of LENVIMA due to an adverse reaction occurred in 26% of patients. The most common (≥1%) adverse reactions leading to discontinuation of LENVIMA were hypertension (2%), asthenia (1.8%), diarrhea (1.2%), decreased appetite (1.2%), proteinuria (1.2%), and vomiting (1.2%). Dose reductions of LENVIMA due to adverse reactions occurred in 67% of patients. The most common (≥5%) adverse reactions resulting in dose reduction of LENVIMA were hypertension (18%), diarrhea (11%), palmar-plantar erythrodysesthesia syndrome (9%), proteinuria (7%), fatigue (7%), decreased appetite (6%), asthenia (5%), and weight decreased (5%). Dose interruptions of LENVIMA due to an adverse reaction occurred in 58% of these patients. The most common (≥2%) adverse reactions leading to interruption of LENVIMA were hypertension (11%), diarrhea (11%), proteinuria (6%), decreased appetite (5%), vomiting (5%), increased alanine aminotransferase (3.5%), fatigue (3.5%), nausea (3.5%), abdominal pain (2.9%), decreased weight (2.6%), urinary tract infection (2.6%), increased aspartate aminotransferase (2.3%), asthenia (2.3%), and palmar-plantar erythrodysesthesia (2%).
Use in Specific Populations
Because of the potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for at least 1 week after the last dose. LENVIMA may impair fertility in males and females of reproductive potential.
No dose adjustment is recommended for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe (CLcr 15-29 mL/min) renal impairment. Reduce the dose for patients with DTC, RCC, or EC and severe renal impairment. There is no recommended dose for patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end-stage renal disease.
No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dose adjustment is recommended for patients with DTC, RCC, or EC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe hepatic impairment. Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment.
LENVIMA (lenvatinib) is available as 10 mg and 4 mg capsules.
Please see Prescribing information for LENVIMA (lenvatinib) at http://www.lenvima.com/pdfs/prescribing-information.pdf.
HALAVEN® (eribulin mesylate) is a microtubule dynamics inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. First in the halichondrin class, eribulin is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells.
Warnings and Precautions
Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.
Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.
Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.
QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.
Adverse Reactions
In patients with mBC receiving HALAVEN, the most common adverse reactions (≥25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).
Use in Specific Populations
Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose.
Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.
For more information about HALAVEN, click here for the full Prescribing Information.
In March 2018, Eisai and Merck, known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA.
In addition to ongoing clinical studies evaluating the KEYTRUDA plus LENVIMA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in multiple different tumor types across more than 15 clinical trials.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.
For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on Twitter (U.S. and global) and LinkedIn (for U.S. and EMEA).
LENVIMA® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
HALAVEN® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
# # #
View original content to download multimedia:
SOURCE Eisai Inc. | https://www.wkyt.com/prnewswire/2022/09/06/eisai-presents-new-data-its-oncology-portfolio-pipeline-esmo-congress-2022/ | 2022-09-06T12:47:25Z | https://www.wkyt.com/prnewswire/2022/09/06/eisai-presents-new-data-its-oncology-portfolio-pipeline-esmo-congress-2022/ | false |
Sitio Royalties to buy oil & gas rights firm Brigham Minerals in $4.8-bln deal
Sept 6 (Reuters) - Sitio Royalties Corp said on Tuesday it would buy oil and gas rights company Brigham Minerals Inc in a $4.8-billion deal, as it looks to capitalise on the uptick in the energy markets following Russia's invasion of Ukraine.
Minerals companies such as Brigham sign agreements with landowners for the right to drill and keep any hydrocarbons they find, often paying an upfront fee and subsequent royalty payments to the landowner.
The equity value of the all-stock deal is $1.73 billion and it is expected to close by the first quarter of 2023.
Sitio and Brigham shareholders will own about 54% and 46% of the company, respectively. (Reporting by Arunima Kumar in Bengaluru; Editing by Vinay Dwivedi) | https://www.dailymail.co.uk/wires/reuters/article-11185107/Sitio-Royalties-buy-oil--gas-rights-firm-Brigham-Minerals-4-8-bln-deal.html?ns_mchannel=rss&ns_campaign=1490&ito=1490 | 2022-09-06T12:47:35Z | https://www.dailymail.co.uk/wires/reuters/article-11185107/Sitio-Royalties-buy-oil--gas-rights-firm-Brigham-Minerals-4-8-bln-deal.html?ns_mchannel=rss&ns_campaign=1490&ito=1490 | false |
SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executive Officer Piers Ingram, Ph.D., and Chief Financial Officer Josh House will participate in one-on-one investor meetings at Morgan Stanley's 20th Annual Global Healthcare Conference (September 12-14, 2022), held at the Sheraton New York Hotel in New York City.
About Hummingbird Bioscience
Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. We are currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase 1 studies. At Hummingbird Bioscience, our commitment to rigorous science, teamwork and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.
For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, Twitter, and YouTube.
View original content:
SOURCE Hummingbird Bioscience | https://www.kwch.com/prnewswire/2022/09/06/hummingbird-bioscience-participate-morgan-stanley-20th-annual-global-healthcare-conference/ | 2022-09-06T12:50:52Z | https://www.kwch.com/prnewswire/2022/09/06/hummingbird-bioscience-participate-morgan-stanley-20th-annual-global-healthcare-conference/ | false |
WASHINGTON, Sept. 6, 2022 /PRNewswire/ -- A brand new, 7-part podcast miniseries about the lived experience of Parkinson's disease is now available.
The whole series can be found on all major podcast platforms.
The Parkinson's Disease Podcast is a short-format, narrative miniseries that shares important insights and information for the millions of people affected by this condition.
It is part of the Health Unmuted audio library by Mission Based Media, and joins other titles including Alzheimer's Disease Podcast and COPD Podcast. Each miniseries in Health Unmuted focuses on a specific health topic and features the voices of medical professionals, caregivers and, importantly, people living with the condition.
"Parkinson's disease affects over 8 million people worldwide, and advances in diagnostics and treatments can have a tremendous impact on the course of the disease. Our mission is to help people have a deeper understanding about their health, and creating accessible, engaging content is a key part of fulfilling that mission," said Dan Kendall, founder of Mission Based Media and executive producer of Health Unmuted.
The podcast is available for free for listeners and was made possible with support from Altoida, a leading platform to improve drug development, research, and care for patients with neurological diseases including Parkinson's.
"Our team at Altoida is delighted to partner with Mission Based Media to make the Parkinson's Disease Podcast a reality," said Travis Bond, CEO at Altoida. "Our vision to unlock neurology diagnostics at scale and revolutionize brain health management aligns with the podcast's goal of equipping listeners with the information and resources necessary to make informed health decisions. We are thrilled to collaborate with forward thinking partners to share the important stories behind neurological disease, and help pioneer innovative technologies in support."
"Effective and accessible health education is critically important, particularly at the early stages of living with a chronic condition," added Kendall. "Health Unmuted podcasts cover topics ranging from symptoms and diagnosis, through to lifestyle changes and treatment options. Each episode helps combat the misinformation that can lead to confusion, anxiety and poor outcomes."
Find Health Unmuted podcasts on major podcast platforms including Apple Podcasts, Google Podcasts, Amazon Music and Spotify, as well as HealthUnmuted.com. More than 50 other health conditions are planned for Health Unmuted including diabetes, multiple sclerosis, breast cancer and gastrointestinal conditions. Healthcare providers and patient-focused organizations can learn about distribution opportunities by visiting https://partners.healthunmuted.com or emailing partners@healthunmuted.com
About Mission Based Media Ltd.
Mission Based Media is a digital media company and podcast network creating and sharing trustworthy podcasts about health, care and well-being. We have a comprehensive library of podcasts across a broad scope of health topics, conditions and therapies. Our content features insights and information from top health professionals and organizations, and highlights engaging patient stories and perspectives. For more information, visit Health Podcast Network, Digital Health Today and Health Unmuted.
About Altoida, Inc.
Altoida is building the world's leading platform to accelerate and improve drug development, research, and care for patients with neurological diseases. The company's innovative AI-driven approach leverages immersive augmented reality (AR) to evaluate the brain in a comprehensive, real-world mode of functioning using data captured with a standard smartphone or tablet. Altoida's validated and evidence-based digital biomarker platform received FDA Breakthrough Device Designation and is supported by more than 20 years of scientific research and publications in journals like Nature Digital Medicine. Altoida is based in Washington, DC. For more information, visit www.altoida.com. Follow us on LinkedIn and Twitter at @altoida.
View original content to download multimedia:
SOURCE Mission Based Media Ltd. | https://www.wkyt.com/prnewswire/2022/09/06/new-health-education-podcast-breaks-down-barriers-people-with-parkinsons-disease/ | 2022-09-06T12:51:17Z | https://www.wkyt.com/prnewswire/2022/09/06/new-health-education-podcast-breaks-down-barriers-people-with-parkinsons-disease/ | true |
BERLIN (AP) — Israel's president addressed Germany's parliament on Tuesday about atrocities committed during the Third Reich, while at the same time praising the close and friendly relations that have emerged between the two countries since the end of the Holocaust.
Six million European Jews were murdered by Germany's Nazis and their henchmen during World War II.
“Never in human history was there a campaign like the one the Nazis and their accomplices conducted to annihilate the Jewish people,” Israeli President Isaac Herzog told lawmakers at the Bundestag.
“Never in history was a state responsible, as Nazi Germany was responsible, for the loss of all semblance of humanity, for the erasure of all mercy, for the pursuit of the worldwide obliteration, with such awful cruelty, of an entire people.”
Herzog also spoke about his father, former Israeli President Chaim Herzog, who was among the liberators of the concentration camp of Bergen-Belsen in northern Germany in April 1945, as an officer of the British forces.
“I shall never forget how he described to me the horrors he witnessed. The stench. The human skeletons in striped pajamas, the piles of corpses, the destruction, the hell on earth,” the Israeli president told German lawmakers.
After his speech, Herzog and Steinmeier, accompanied by their wives, went to Berlin's Memorial to the Murdered Jews — a field of 2,700 gray concrete slabs near the the city's landmark Brandenburg Gate — where they laid two wreaths for the victims of the Holocaust.
On Tuesday afternoon, the two presidents are set to visit the site of the former concentration camp. After a tour of the memorial site, they are expected to meet with survivors and German high school students.
The Israeli president arrived for a state visit to Germany earlier this week that also included a trip to Munich on Monday where he participated in the 50-year anniversary ceremony for the 11 Israeli athletes murdered by Palestinian militants at the 1972 Olympic Games.
Looking forward, Herzog praised close relations between the two countries and their joint commitment to fight antisemitism.
“The partnership between Israel and Germany has achieved global renown, and we must continue deepening and cultivating it, for the benefit of a brilliant future not only for our countries but for the whole of humanity," he said in parliament.
___
Tia Goldberg contributed to this report from Jerusalem.
Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. | https://www.mynews13.com/fl/orlando/ap-top-news/2022/09/06/israeli-president-gives-broad-speech-to-germanys-parliament | 2022-09-06T12:51:52Z | https://www.mynews13.com/fl/orlando/ap-top-news/2022/09/06/israeli-president-gives-broad-speech-to-germanys-parliament | true |
Animals Make the Best Friends!
MAZATLÁN, Mexico, Sept. 6, 2022 /PRNewswire/ -- Mexican-based indie game developer and publisher EnsenaSoft is proud to announce the worldwide release of ISLA SINALOA, a relaxing open-ended social simulation game set on an island retreat inhabited by fun and engaging animal characters in a peaceful universe full of fun activities. Over two years in the making, ISLA SINALOA is available as a FREE-TO-PLAY download on iOS®, Android™, and the Windows® Store.
Launch Trailer: https://www.youtube.com/watch?v=XEnusZsAGNQ
ISLA SINALOA features a large cast of colorful, friendly neighbors and animal characters. Your character is fully customizable, and 100s of options are available from the clothing store. You can tailor the look, features, and body expressions as desired, and when you are ready, exciting adventures and exploration await.
ISLA SINALOA challenges you to complete a series of fun and rewarding tasks. In return, you are given fascinating attractions to place, such as the Zoo, the Museum, and the Botanical Garden, collectively featuring more than 500 items to collect and learn from. Donate the fish you catch to the Zoo and watch them swim in the aquarium. Visit a remote island by talking to Dolly Dolphin, who, in exchange for a ticket, will grant you access to unique locations with mines to scavenge, pyramids with underground temples to explore, and even volcanic caves with rare gems and gold to mine. Items you collect can be donated to the exhibits or sold for profit in the games store, from where you can buy and sell 100s of items over time. The Museum has a rather large collection of fun and unique artifacts that you need to collect. They provide entertaining stories and historical nuggets guaranteed to make you smile. A large painting room with world-famous artists eventually opens, but it is your task to populate it by digging up treasure on remote islands, treasures that you trade for artistic loot with the local pirate! When you need a break, you can visit the Botanical Garden and smell the beautiful and colorful flowers you have collected during your adventures.
ISLA SINALOA would not be complete without a farm from where you can plant crops and manage the garden. Harvest your crops for assigned tasks or resell your items and take care of the cows and chickens. No retreat is complete without great food and entertainment! Visit the restaurant and purchase the ingredients needed for tasty recipes. The disco sells delicious ice cream and has a dancing floor with different genres of music hosted by the fabulous Alex DJ. You can even go on a Hot Air Balloon ride and visit other players' islands, and when fatigue sets in, call Byron Bat for a ride home to take a well-deserved siesta.
ISLA SINALOA is a paradise for casual gamers with more than 15+ mini-games to try out: How about a solitaire game? Or mahjong with Piao Panda? Why not build your very own arcade cabinet and try it out? You can cook and serve food by running a food truck owned by Nacho Dog! When you are not playing, you can build upon and expand your house by decorating each room with interesting wall decor, rugs, and unique furniture you craft or purchase when available.
ISLA SINALOA celebrates your birthday, and the islanders will host you a party. 10 major international holidays like Christmas, Halloween and Cinco de Mayo are given special treatment in the game as buildings and houses are decorated according to season.
KEY FEATURES
- 15+ mini-games, including a food truck that you get to run
- Over 30+ animal characters to get to know and become friends with
- Over 500+ items to collect and donate for island building exhibits
- Beautiful and vibrant zoo, museum, and botanical gardens
- Customize your character with 100s of outfit and character combinations
- 100s of craft-able items to decorate your island and home
- Many holidays are celebrated on your island
- You can share your island with your friends
- Full of love and little surprises!
ISLA SINALOA supports English and Spanish with French, German, Italian and Portuguese translations in the works. There is even an excellent merchandise shop on ZAZZLE offering fantastic items featuring the characters expressing their personalities.
Isla Sinaloa is available from here:
Journalists interested in further information or additional assets may contact indie PR specialist Hans Olsen by sending an email to hans@hansfrederikolsen.dk. Members of the press are encouraged to check out the following Hotlinks for recent news and updates.
About EnsenaSoft
EnsenaSoft is an award-winning game developer and publisher founded in Mazatlán, Sinaloa, Mexico in 2009, and consists of a talented group of designers, artists, programmers (and musicians from around the world) all committed to creating high-quality digital games content across all major gaming platforms and technologies. With a portfolio spanning hundreds of released titles, it is our continued promise to produce entertaining digital games to audiences of all ages and gaming preferences.
View original content:
SOURCE EnsenaSoft | https://www.kwch.com/prnewswire/2022/09/06/live-harmony-with-nature-adventure-relaxation-await-you-tropical-island-paradise-isla-sinaloa/ | 2022-09-06T12:51:53Z | https://www.kwch.com/prnewswire/2022/09/06/live-harmony-with-nature-adventure-relaxation-await-you-tropical-island-paradise-isla-sinaloa/ | false |
VANCOUVER, BC, Sept. 6, 2022 /PRNewswire/ - PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) ("PlantX" or the "Company"), the digital face of the plant-based community, operating a one-stop shop for plant-based products, today announced unaudited monthly financial metrics for August 2022.
PlantX generated monthly gross revenue of $1.381 million in August 2022, an increase of 32% compared to $1.048 million in August 2021. The increase was driven primarily by expansion of our distribution channels and retail footprint. Gross profit for August 2022 was $525,000, or 38% gross margin, compared to gross profit of $367,000, or 35% gross margin in August 2021. Notably, the Little West cold-pressed juice brand continues to generate strong sell-through across its retail distribution partners. Additionally, the Chicago Uptown location had its best month since it was acquired by PlantX in December 2021. This growth was driven by expanded selection and special events.
"PlantX continues to generate significant year-over-year growth, driven by positive market reception to the Little West cold-pressed juice brand and the success of live events at our retail locations to drive store traffic as we build loyal customers," said PlantX CEO, Lorne Rapkin. "Consumers increasingly see PlantX as the first stop for all things involved with the plant-based lifestyle, and this growing presence is resulting in revenue acceleration."
The financial metrics disclosed in this press release are management prepared and have not been audited or reviewed by the Company's auditors. Unless otherwise indicated, all amounts are expressed in Canadian dollars.
As the digital face of the plant-based community, PlantX's platform is a one-stop shop for plant-based products. With its fast-growing category verticals, the Company offers customers across North America more than 5,000 plant-based products. In addition to offering delivery service for meals and indoor plants, the Company currently has plans underway to expand its product lines to include a juice and coffee company. The Company uses its digital platform to build a community of likeminded consumers and, most importantly, to provide education. Its successful enterprise is being built and fortified on partnerships with the top nutritionists, chefs, and brands. The Company's digital presence works to eliminate the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier, and happier life.
Connect with PlantX: Email | Website | Facebook | LinkedIn | Twitter | Instagram | YouTube | TikTok
This press release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may," "will," "expect," "likely", "should," "would," "plan," "anticipate," "intend," "potential," "proposed," "estimate," "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, statements regarding the business and strategic plans of the Company.
By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: receiving sufficient demand for the Offering; the Company's ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; the conflict in eastern Europe; having a limited operating history; the ability of the Company to access capital to meet future financing needs; the Company's reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.
Additional risk factors can also be found in the Company's continuous disclosure documents, which have been filed on SEDAR and can be accessed at www.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
View original content to download multimedia:
SOURCE PlantX Life Inc. | https://www.kwch.com/prnewswire/2022/09/06/plantx-announces-monthly-gross-revenue-14-million-august-2022-up-32-year-over-year/ | 2022-09-06T12:53:01Z | https://www.kwch.com/prnewswire/2022/09/06/plantx-announces-monthly-gross-revenue-14-million-august-2022-up-32-year-over-year/ | false |
- Executive Chairman of the Board, Jeremy Frommer will assume the CEO seat.
- Creatd's board significantly amplifies its capabilities with the addition of Justin Maury, Creatd's COO and Co-founder.
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Creatd, Inc. (Nasdaq CM: CRTD) ("Creatd" or the "Company"), a creator-first holding company, and the parent company of Vocal, is pleased to announce a new appointment to its board of directors, Justin Maury, Creatd COO and co-founder, as well as the appointment of current Executive Chairman, Jeremy Frommer to the position of Chairman and CEO.
Justin Maury is Creatd's Chief Operating Officer and co-founder. Maury is a full-stack designer and product developer by training who first partnered with Creatd's Executive Chairman of the Board, Jeremy Frommer, in 2013 after building a decade of experience at numerous global creative agencies. Maury is credited with leading the early vision, design, and architecture of Vocal, the Company's flagship platform, which he brought to launch in 2016. Beyond Vocal, Maury oversees Creatd's broader technology roadmap and is instrumental in the creation and scale of Creatd's subsequent business segments, which encompass technology, agency partnership, e-commerce, and production activities.
Commented Creatd Executive Chairman Jeremy Frommer, "This addition to our board marks a significant boost to our company's collective strength on both a professional and personal level. As head of product, COO, and now, a member of Creatd's board, Justin has remained instrumental in leading the platform and the entire company. Our board will greatly benefit from his unique product perspective, and his direct input will be invaluable as we refine our technology roadmap and progress our Web 3.0 strategy."
Creatd, Inc. (Nasdaq CM: CRTD) is a company dedicated to unlocking creativity for creators, brands, and consumers. We accomplish this through Creatd's four business pillars: Creatd Labs, Creatd Partners, Creatd Ventures, and Creatd Studios.
Creatd: https://creatd.com;
Creatd IR: https://investors.creatd.com;
Vocal Platform: https://vocal.media;
Investor Relations Contact: ir@creatd.com
Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings.
View original content to download multimedia:
SOURCE Creatd, Inc. | https://www.kxii.com/prnewswire/2022/09/06/executive-chairman-jeremy-frommer-assume-chairman-ceo-position-additionally-creatd-inc-welcomes-founder-coo-justin-maury-board-directors/ | 2022-09-06T12:57:47Z | https://www.kxii.com/prnewswire/2022/09/06/executive-chairman-jeremy-frommer-assume-chairman-ceo-position-additionally-creatd-inc-welcomes-founder-coo-justin-maury-board-directors/ | true |
Canada police hunt remaining suspect in stabbing attacks
WELDON, Saskatchewan (AP) — Canadian police hunted for the remaining suspect in the stabbing deaths of 10 people in an Indigenous community and nearby town in the province of Saskatchewan after finding the body of his brother amid a massive manhunt for the pair.
Damien Sanderson, 31, was found dead Monday near the stabbing sites and authorities believe his brother and fellow suspect, Myles Sanderson, 30, is injured, on the run and likely in the provincial capital of Regina, said police chief Evan Bray. The series of stabbings also wounded 18 people.
RCMP Commanding Officer Assistant Commissioner Rhonda Blackmore said authorities are not sure of the cause of death yet but the injuries were not self-inflicted.
Damien Sanderson’s “body was located outdoors in a heavily grassed area in proximity to a house that was being examined. We can confirm he has visible injuries,” said Blackmore. Asked if Myles Sanderson was responsible for his brother’s death, Blackmore said police are investigating that possibility, but “we can’t say that definitively at this point in time.″
Leaders of the James Smith Cree Nation, where most of the stabbing attacks took place, blamed the killings on the drug and alcohol abuse plaguing the community, which they said was a legacy of the colonization of Indigenous people.
James Smith Cree Nation resident Darryl Burns and his brother, Ivor Wayne Burns, said their sister, Gloria Lydia Burns, was a first responder who was killed while responding to a call. Burns said his 62-year-old sister was on a crisis response team.
“She went on a call to a house and she got caught up in the violence,” he said. “She was there to help. She was a hero.”
He blamed drugs and pointed to colonization for the rampant drug and alcohol use on reserves.
“We had a murder-suicide here three years ago. My granddaughter and her boyfriend. Last year we had a double homicide. Now this year we have 10 more that have passed away and all because of drugs and alcohol,” Darryl Burns said.
Ivor Wayne Burns also blamed drugs for his sister’s death and said the suspect brothers should not be hated.
“We have to forgive them boys,” he said. “When you are doing hard drugs, when you are doing coke, and when you are doing heroin and crystal meth and those things, you are incapable of feeling. You stab somebody and you think it’s funny. You stab them again and you laugh.”
Blackmore said police were still determining the motive, but the chief of the Federation of Sovereign Indigenous Nations echoes suggestions the stabbings could be drug-related.
“This is the destruction we face when harmful illegal drugs invade our communities, and we demand all authorities to take direction from the chiefs and councils and their membership to create safer and healthier communities for our people,” said Chief Bobby Cameron.
Blackmore said the criminal record of Myles Sanderson dates back years and includes violence. Last May, Saskatchewan Crime Stoppers issued a wanted list that included him writing that he was “unlawfully at large.”
While authorities believe Myles Sanderson is in Regina, about 335 kilometers (210 miles) south of where the stabbings happened, they have issued alerts in Canada’s three vast prairie provinces — which also include Manitoba and Alberta — and contacted U.S. border officials. The manhunt entered its third day Tuesday.
Before Damien’s body was found, arrest warrants were issued for the suspects and both men faced at least one count each of murder and attempted murder.
The stabbing attack was among the deadliest mass killings in Canada, where such crimes are less common than in the United States. The deadliest gun rampage in Canadian history happened in 2020, when a man disguised as a police officer shot people in their homes and set fires across the province of Nova Scotia, killing 22 people. In 2019, a man used a van to kill 10 pedestrians in Toronto.
Deadly mass stabbings are rarer than mass shootings, but have happened around the world. In 2014, 29 people were slashed and stabbed to death at a train station in China’s southwestern city of Kunming. In 2016, a mass stabbing at a facility for the mentally disabled in Sagamihara, Japan, left 19 people dead. A year later, three men killed eight people in a vehicle and stabbing attack at London Bridge.
Police in Saskatchewan got their first call about a stabbing at 5:40 a.m. on Sunday, and within minutes heard about several more. In all, dead or wounded people were found at 13 different locations on the sparsely populated reserve and in the town, Blackmore said. James Smith Cree Nation is about 30 kilometers (20 miles) from Weldon.
Among the 10 killed was Lana Head, who is the former partner of Michael Brett Burns and the mother of their two daughters.
“It’s sick how jail time, drugs and alcohol can destroy many lives,” Burns told the Aboriginal Peoples Television Network. “I’m hurt for all this loss.”
Weldon residents have identified one of the dead as Wes Petterson, a retired widower who made he coffee every morning at the senior center. He loved gardening, picking berries, canning, and making jam and cakes, recalled William Works, 47, and his mother, Sharon Works, 64.
“He would give you the shirt off his back if he could,” William Works said, describing his neighbor as a “gentle old fellow” and “community first.”
Sharon Works was baffled: “I don’t understand why they would target someone like him anyway, because he was just a poor, helpless little man, 100 pounds soaking wet. And he could hardly breathe because he had asthma and emphysema and everybody cared about him because that’s the way he was. He cared about everybody else. And they cared about him.”
____
Gillies reported from Toronto.
Copyright 2022 The Associated Press. All rights reserved. | https://www.wafb.com/2022/09/06/canada-police-hunt-remaining-suspect-stabbing-attacks/ | 2022-09-06T12:58:14Z | https://www.wafb.com/2022/09/06/canada-police-hunt-remaining-suspect-stabbing-attacks/ | true |
Sapiens Reinsurance solution will improve efficiency and enable auditable processing to better serve partners
RALEIGH, N.C., Sept. 6, 2022 /PRNewswire/ -- Sapiens International Corporation (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, announced today that AEGIS, a leading mutual insurance company, has selected Sapiens ReinsurancePro to enhance their internal controls processes, automated calculations and reporting. Sapiens ReinsurancePro replaces AEGIS' complex combination of disparate custom applications and spreadsheets to streamline and optimize processes.
"Implementing Sapiens Reinsurance solution will help us manage the increasing volume and complexity of our ceded reinsurance strategy and quickly respond to new reinsurance offerings," said Scott Schenker, AEGIS Senior VP & CIO. "Sapiens' solution stands out in the industry for its proven ability to automate complex reinsurance requirements and improve efficiency. The solution will expand our capabilities to manage complex structures and total capacity, within a competitive cost structure."
"We are very pleased to empower AEGIS in their quest for full financial control of the reinsurance processes and to enable them to increase efficiency by streamlining the process," said Jamie Yoder, Sapiens North America President & General Manager. "Our platform enables AEGIS to take ownership of their data and proactively conduct analysis on that data instead of relying on IT or external parties, so they can better serve their customers."
Sapiens ReinsurancePro supports all types of reinsurance processing, regardless of volume, in one comprehensive and powerful reinsurance system, empowering insurance companies to manage and automate the underwriting and administration of reinsurance, including treaty and facultative, ceded, assumed and retroceded reinsurance.
About AEGIS
AEGIS is a leading mutual insurance company that provides liability and property coverage, as well as related risk management services, to the energy industry. Its policyholders represent virtually the entire energy infrastructure in North America, including electric and natural gas utilities, related energy companies, oil & gas exploration and production companies, water utilities, and transmission & distribution companies. For more information, visit www.aegislink.com/
About Sapiens
Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative, and agile. Backed by 40 years of industry expertise, Sapiens offers a complete insurance platform, with pre-integrated, low-code solutions and a cloud-first approach that accelerates customers' digital transformation. Serving over 600 customers in 30 countries, Sapiens offers insurers across property and casualty, workers' compensation and life markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management. For more information, visit www.sapiens.com or follow us on LinkedIn.
Media Contact
Shay Assaraf
Chief of Marketing, Sapiens
Shay.assaraf@sapiens.com
Investor's Contact
Dina Vince
Head of Investor Relations, Sapiens
dina.vince@sapiens.com
Forward Looking Statements
Certain matters discussed in this press release that are incorporated herein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words "anticipate," "believe," "estimate," "expect," "may," "will," "plan" and similar expressions. Such statements reflect our current views with respect to future events and are subject to pandemic risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers' systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.
While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.
Logo: http://mma.prnewswire.com/media/585787/Sapiens_Logo.jpg
View original content:
SOURCE Sapiens International Corporation | https://www.kswo.com/prnewswire/2022/09/06/aegis-selects-sapiens-automate-modernize-its-reinsurance-processes/ | 2022-09-06T12:59:50Z | https://www.kswo.com/prnewswire/2022/09/06/aegis-selects-sapiens-automate-modernize-its-reinsurance-processes/ | true |
WAXAHACHIE, Texas, Sept. 6, 2022 /PRNewswire/ -- The board of directors and management team of Minority Equality Opportunities Acquisition Inc. (NASDAQ: MEOA), the first minority-led special purpose acquisition company, or SPAC, listed on the Nasdaq Capital Market ("NASDAQ"), announced today that it had signed a definitive business combination agreement to merge with Digerati Technologies, Inc. (OTCQB: DTGI) ("Digerati"), a Hispanic-led and founded provider of cloud services specializing in UCaaS (Unified Communications as a Service) solutions for the small to medium-sized business market.
Digerati and MEOA will merge to create a combined company listed on NASDAQ. The all-stock transaction forms a company with an initial equity value of approximately $228 million translating into an enterprise value of approximately $145 million, assuming no redemptions from MEOA's shareholders.
The current Digerati management team, led by Arthur L. Smith, will continue to run the Company. Corporate directors for the new entity are current Digerati directors and two new directors, including Shawn D. Rochester, President and CEO of MEOA.
"MEOA's merger announcement with Digerati personifies our mission, vision and purpose," Mr. Rochester said. "Digerati is a minority founded and led business with (1) a very diverse management team (with its CEO, CFO, and EVP of Sales being of Hispanic ethnicity) that has developed great products and solutions, and staked out a strong competitive position in the marketplace, (2) an employee base that is almost 50% minority and (3) a UCaaS platform that has the ability to help empower over 20 million minority and women owned small businesses through its first-class suite of communications products. In addition to our proposed business combination with Digerati, MEOA's deep commitment to equity, inclusion, diverse representation and maximizing shareholder value is further exemplified by our use of a diverse spectrum of extraordinary third-party service providers (and teams within service providers) that are owned and or led by African Americans, Asian Americans, Hispanic Americans, and Women."
"Our merger with MEOA positions Digerati for continued growth in a rapidly expanding and highly fragmented market," said Arthur L. Smith, CEO of Digerati. "We believe a business combination with MEOA will facilitate the acceleration of our M&A strategy in a market with a healthy pipeline of acquisition targets and contribute to the combined company's organic growth as we continue providing small to medium-sized businesses with solutions and superior customer service."
PGP Capital Advisors, LLC and Vaughan Capital Advisors, LLC acted as financial advisors to MEOA and Pryor Cashman LLP acted as legal counsel for MEOA. Maxim Group LLC acted as financial advisor and Lucosky Brookman acted as legal counsel to Digerati in connection with the transaction.
Minority Equality Opportunities Acquisition Inc. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, organized under the laws of Delaware and formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with companies that are minority owned, led or founded.
Digerati Technologies, Inc. (OTCQB: DTGI) is a provider of cloud services specializing in UCaaS (Unified Communications as a Service) solutions for the business market. Through its operating subsidiaries NextLevel Internet (NextLevelinternet.com), T3 Communications (T3com.com), Nexogy (Nexogy.com), and SkyNet Telecom (Skynettelecom.net), Digerati is meeting the global needs of small businesses seeking simple, flexible, reliable, and cost-effective communication and network solutions including, cloud PBX, cloud telephony, cloud WAN, cloud call center, cloud mobile, and the delivery of digital oxygen on its broadband network. Digerati has developed a robust integration platform to fuel mergers and acquisitions in a highly fragmented market. as it delivers business solutions on its carrier-grade network and Only in the Cloud™. For more information, please visit www.digerati-inc.com and follow DTGI on LinkedIn, Twitter and Facebook.
INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
This press release is being made in respect of the proposed business combination transaction involving MEOA and Digerati. The parties intend to file a registration statement on Form S-4 (or such other form as they might determine to be applicable) with the SEC, which will include a proxy statement for MEOA and Digerati shareholders and which will also serve as a prospectus related to offers and sales of the securities of the combined entity ("Pubco"). MEOA will also file other documents regarding the proposed transaction with the SEC. A definitive proxy statement/prospectus will also be sent to the stockholders of MEOA and Digerati, seeking required stockholder approval. Before making any voting or investment decision, investors and security holders of MEOA and Digerati are urged to carefully read the entire registration statement and proxy statement/prospectus, when they become available, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed transaction. The documents filed with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
In addition, the documents filed with the SEC may be obtained free of charge from MEOA's website at https://www.meoaus.com and from Digerati's website at https://digerati-inc.com.
MEOA, Digerati and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders, in favor of the approval of the merger. Information regarding MEOA's and Digerati's directors and executive officers and other persons who may be deemed participants in the solicitation may be obtained by reading the registration statement and the proxy statement/prospectus and other relevant documents filed with the SEC when they become available. Free copies of these documents may be obtained as described above.
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the applicable securities laws. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.
These forward-looking statements include, but are not limited to, statements regarding the terms and conditions of the proposed business combination and related transactions disclosed herein, the timing of the consummation of such transactions, assumptions regarding shareholder redemptions and the anticipated benefits and financial position of the parties resulting therefrom. These statements are based on various assumptions and/or on the current expectations of MEOA or Digerati's management. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor or other person as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of MEOA and/or Digerati. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the amount of redemption requests made by MEOA's public shareholders; NASDAQ's approval of MEOA's initial listing application; changes in the assumptions underlying Digerati's expectations regarding its future business; the effects of competition on Digerati's future business; and the outcome of judicial proceedings to which Digerati is, or may become a party.
If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Digerati and MEOA presently do not know or currently believe are immaterial that could also cause actual results to differ materially from those contained in the forward-looking statements. In addition, forward-looking statements reflect expectations, assumptions, plans or forecasts of future events and views as of the date of this press release. Digerati and MEOA anticipate that subsequent events and developments will cause these assessments to change. However, while Digerati and/or MEOA may elect to update these forward-looking statements at some point in the future, each of Digerati and MEOA specifically disclaims any obligation to do so, except as required by applicable law. These forward-looking statements should not be relied upon as representing Digerati's or MEOA (or their respective affiliates') assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
View original content:
SOURCE Minority Equality Opportunities Acquisition Inc. | https://www.kait8.com/prnewswire/2022/09/06/minority-equality-opportunities-acquisition-inc-announces-merger-with-hispanic-led-founded-cloud-services-company-digerati-technologies/ | 2022-09-06T13:00:38Z | https://www.kait8.com/prnewswire/2022/09/06/minority-equality-opportunities-acquisition-inc-announces-merger-with-hispanic-led-founded-cloud-services-company-digerati-technologies/ | false |
Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combination's Potential Across Difficult-to-Treat Cancers
Post-Hoc, Pooled Analysis of Three Pivotal Phase 3 Studies on Eribulin's Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisai's Commitment to Advancing Understanding of Our Medicines
NUTLEY, N.J., Sept. 6, 2022 /PRNewswire/ -- Eisai announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13.
A late-breaking oral presentation of detailed results from the LEAP (LEnvatinib And Pembrolizumab) clinical program including the final analysis of the Phase 3 LEAP-002 trial will be featured in a Proffered Paper session (NCT03713593; Presentation: #LBA34). The study evaluated the combination of lenvatinib plus Merck's anti-PD-1 antibody pembrolizumab versus lenvatinib monotherapy as a first-line treatment for patients with unresectable hepatocellular carcinoma. Additionally, two mini-oral presentations will feature updated efficacy and safety data from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial evaluating the combination in patients with advanced renal cell carcinoma (NCT02811861; Presentation: #1449MO) and Phase 3 Study 309/KEYNOTE-775 trial evaluating the combination in patients with advanced endometrial carcinoma (NCT03517449; Presentation: #525MO).
In addition, a new post-hoc analysis of three pivotal Phase 3 studies (Study 301/NCT00337103, Study 304/NCT02225470 and the EMBRACE trial/Study 305/NCT00388726) evaluating the efficacy of eribulin mesylate (HALAVEN®) versus other chemotherapies (capecitabine, vinorelbine and Treatment of Physician's Choice [TPC], respectively) in patients living with metastatic breast cancer whose tumors have low or no HER2-expression will be presented during a poster session (Presentation: #259P).
"We look forward to presenting data at ESMO, showcasing Eisai's latest research on both lenvatinib and eribulin, with the goal of continuing to help people living with various types of cancer," said Dr. Takashi Owa, Chief Scientific Officer, Deep Human Biology Learning, Senior Vice President, Eisai Co., Ltd. "Presentations on the LEAP clinical program as well as new analyses for eribulin reinforce our commitment to the ongoing research of our portfolio in an effort to better serve patients and healthcare providers."
In March 2018, Eisai and Merck (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with pembrolizumab. To date, more than 15 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
The full list of Eisai presentations is included below. All regular abstracts are available. All late-breaking abstracts will be made available Wednesday, September 7, 2022, at 6:05 PM EDT (Thursday, September 8, 2022, at 12:05 AM CEST).
LENVIMA is indicated:
- For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)
- In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC)
- In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
- For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
- In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by an FDA-approved test, or not microsatellite instability-high (MSI-H), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
LENVIMA, discovered and developed by Eisai, is a multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with a concurrent inhibition of FGF-receptor substrate 2α (FRS2α) phosphorylation. The combination of LENVIMA and everolimus showed increased anti-angiogenic and anti-tumor activity as demonstrated by decreased human endothelial cell proliferation, tube formation, and VEGF signaling in vitro and tumor volume in mouse xenograft models of human renal cell cancer greater than each drug alone. In syngeneic mouse tumor models, the combination of lenvatinib with an anti-PD-1 monoclonal antibody decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity compared to either treatment alone.
Warnings and Precautions
Hypertension. In DTC (differentiated thyroid cancer), hypertension occurred in 73% of patients on LENVIMA (44% grade 3-4). In RCC (renal cell carcinoma), hypertension occurred in 42% of patients on LENVIMA + everolimus (13% grade 3). Systolic blood pressure ≥160 mmHg occurred in 29% of patients, and 21% had diastolic blood pressure ≥100 mmHg. In HCC (hepatocellular carcinoma), hypertension occurred in 45% of LENVIMA-treated patients (24% grade 3). Grade 4 hypertension was not reported in HCC.
Serious complications of poorly controlled hypertension have been reported. Control blood pressure prior to initiation. Monitor blood pressure after 1 week, then every 2 weeks for the first 2 months, and then at least monthly thereafter during treatment. Withhold and resume at reduced dose when hypertension is controlled or permanently discontinue based on severity.
Cardiac Dysfunction. Serious and fatal cardiac dysfunction can occur with LENVIMA. Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of LENVIMA-treated patients. Monitor for clinical symptoms or signs of cardiac dysfunction. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Arterial Thromboembolic Events. Among patients receiving LENVIMA or LENVIMA + everolimus, arterial thromboembolic events of any severity occurred in 2% of patients in RCC and HCC and 5% in DTC. Grade 3-5 arterial thromboembolic events ranged from 2% to 3% across all clinical trials.
Among patients receiving LENVIMA with pembrolizumab, arterial thrombotic events of any severity occurred in 5% of patients in CLEAR, including myocardial infarction (3.4%) and cerebrovascular accident (2.3%).
Permanently discontinue following an arterial thrombotic event. The safety of resuming after an arterial thromboembolic event has not been established, and LENVIMA has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.
Hepatotoxicity. Across clinical studies enrolling 1327 LENVIMA-treated patients with malignancies other than HCC, serious hepatic adverse reactions occurred in 1.4% of patients. Fatal events, including hepatic failure, acute hepatitis, and hepatorenal syndrome, occurred in 0.5% of patients. In HCC, hepatic encephalopathy occurred in 8% of LENVIMA-treated patients (5% grade 3-5). Grade 3-5 hepatic failure occurred in 3% of LENVIMA-treated patients; 2% of patients discontinued LENVIMA due to hepatic encephalopathy, and 1% discontinued due to hepatic failure.
Monitor liver function prior to initiation, then every 2 weeks for the first 2 months, and at least monthly thereafter during treatment. Monitor patients with HCC closely for signs of hepatic failure, including hepatic encephalopathy. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Renal Failure or Impairment. Serious including fatal renal failure or impairment can occur with LENVIMA. Renal impairment was reported in 14% and 7% of LENVIMA-treated patients in DTC and HCC, respectively. Grade 3-5 renal failure or impairment occurred in 3% of patients with DTC and 2% of patients with HCC, including 1 fatal event in each study. In RCC, renal impairment or renal failure was reported in 18% of LENVIMA + everolimus–treated patients (10% grade 3).
Initiate prompt management of diarrhea or dehydration/hypovolemia. Withhold and resume at reduced dose upon recovery or permanently discontinue for renal failure or impairment based on severity.
Proteinuria. In DTC and HCC, proteinuria was reported in 34% and 26% of LENVIMA-treated patients, respectively. Grade 3 proteinuria occurred in 11% and 6% in DTC and HCC, respectively. In RCC, proteinuria occurred in 31% of patients receiving LENVIMA + everolimus (8% grade 3). Monitor for proteinuria prior to initiation and periodically during treatment. If urine dipstick proteinuria ≥2+ is detected, obtain a 24-hour urine protein. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Diarrhea. Of the 737 LENVIMA-treated patients in DTC and HCC, diarrhea occurred in 49% (6% grade 3). In RCC, diarrhea occurred in 81% of LENVIMA + everolimus–treated patients (19% grade 3). Diarrhea was the most frequent cause of dose interruption/reduction, and diarrhea recurred despite dose reduction. Promptly initiate management of diarrhea. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Fistula Formation and Gastrointestinal Perforation. Of the 799 patients treated with LENVIMA or LENVIMA + everolimus in DTC, RCC, and HCC, fistula or gastrointestinal perforation occurred in 2%. Permanently discontinue in patients who develop gastrointestinal perforation of any severity or grade 3-4 fistula.
QT Interval Prolongation. In DTC, QT/QTc interval prolongation occurred in 9% of LENVIMA-treated patients and QT interval prolongation of >500 ms occurred in 2%. In RCC, QTc interval increases of >60 ms occurred in 11% of patients receiving LENVIMA + everolimus and QTc interval >500 ms occurred in 6%. In HCC, QTc interval increases of >60 ms occurred in 8% of LENVIMA-treated patients and QTc interval >500 ms occurred in 2%.
Monitor and correct electrolyte abnormalities at baseline and periodically during treatment. Monitor electrocardiograms in patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or those who are taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. Withhold and resume at reduced dose upon recovery based on severity.
Hypocalcemia. In DTC, grade 3-4 hypocalcemia occurred in 9% of LENVIMA-treated patients. In 65% of cases, hypocalcemia improved or resolved following calcium supplementation with or without dose interruption or dose reduction. In RCC, grade 3-4 hypocalcemia occurred in 6% of LENVIMA + everolimus–treated patients. In HCC, grade 3 hypocalcemia occurred in 0.8% of LENVIMA-treated patients. Monitor blood calcium levels at least monthly and replace calcium as necessary during treatment. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS). Across clinical studies of 1823 patients who received LENVIMA as a single agent, RPLS occurred in 0.3%. Confirm diagnosis of RPLS with MRI. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity and persistence of neurologic symptoms.
Hemorrhagic Events. Serious including fatal hemorrhagic events can occur with LENVIMA. In DTC, RCC, and HCC clinical trials, hemorrhagic events, of any grade, occurred in 29% of the 799 patients treated with LENVIMA as a single agent or in combination with everolimus. The most frequently reported hemorrhagic events (all grades and occurring in at least 5% of patients) were epistaxis and hematuria. In DTC, grade 3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage. In HCC, grade 3-5 hemorrhage occurred in 5% of LENVIMA-treated patients, including 7 fatal hemorrhagic events. Serious tumor-related bleeds, including fatal hemorrhagic events, occurred in LENVIMA-treated patients in clinical trials and in the postmarketing setting. In postmarketing surveillance, serious and fatal carotid artery hemorrhages were seen more frequently in patients with anaplastic thyroid carcinoma (ATC) than other tumors. Safety and effectiveness of LENVIMA in patients with ATC have not been demonstrated in clinical trials.
Consider the risk of severe or fatal hemorrhage associated with tumor invasion or infiltration of major blood vessels (eg, carotid artery). Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction. LENVIMA impairs exogenous thyroid suppression. In DTC, 88% of patients had baseline thyroid stimulating hormone (TSH) level ≤0.5 mU/L. In patients with normal TSH at baseline, elevation of TSH level >0.5 mU/L was observed post baseline in 57% of LENVIMA-treated patients. In RCC and HCC, grade 1 or 2 hypothyroidism occurred in 24% of LENVIMA + everolimus–treated patients and 21% of LENVIMA-treated patients, respectively. In patients with normal or low TSH at baseline, elevation of TSH was observed post baseline in 70% of LENVIMA-treated patients in HCC and 60% of LENVIMA + everolimus–treated patients in RCC.
Monitor thyroid function prior to initiation and at least monthly during treatment. Treat hypothyroidism according to standard medical practice.
Impaired Wound Healing. Impaired wound healing has been reported in patients who received LENVIMA. Withhold LENVIMA for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of LENVIMA after resolution of wound healing complications has not been established.
Osteonecrosis of the Jaw (ONJ). ONJ has been reported in patients receiving LENVIMA. Concomitant exposure to other risk factors, such as bisphosphonates, denosumab, dental disease, or invasive dental procedures, may increase the risk of ONJ.
Perform an oral examination prior to treatment with LENVIMA and periodically during LENVIMA treatment. Advise patients regarding good oral hygiene practices and to consider having preventive dentistry performed prior to treatment with LENVIMA and throughout treatment with LENVIMA.
Avoid invasive dental procedures, if possible, while on LENVIMA treatment, particularly in patients at higher risk. Withhold LENVIMA for at least 1 week prior to scheduled dental surgery or invasive dental procedures, if possible. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ.
Withhold LENVIMA if ONJ develops and restart based on clinical judgement of adequate resolution.
Embryo-Fetal Toxicity. Based on its mechanism of action and data from animal reproduction studies, LENVIMA can cause fetal harm when administered to pregnant women. In animal reproduction studies, oral administration of lenvatinib during organogenesis at doses below the recommended clinical doses resulted in embryotoxicity, fetotoxicity, and teratogenicity in rats and rabbits. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception during treatment with LENVIMA and for at least 30 days after the last dose.
Adverse Reactions
In DTC, the most common adverse reactions (≥30%) observed in LENVIMA-treated patients were hypertension (73%), fatigue (67%), diarrhea (67%), arthralgia/myalgia (62%), decreased appetite (54%), decreased weight (51%), nausea (47%), stomatitis (41%), headache (38%), vomiting (36%), proteinuria (34%), palmar-plantar erythrodysesthesia syndrome (32%), abdominal pain (31%), and dysphonia (31%). The most common serious adverse reactions (≥2%) were pneumonia (4%), hypertension (3%), and dehydration (3%). Adverse reactions led to dose reductions in 68% of LENVIMA-treated patients; 18% discontinued LENVIMA. The most common adverse reactions (≥10%) resulting in dose reductions were hypertension (13%), proteinuria (11%), decreased appetite (10%), and diarrhea (10%); the most common adverse reactions (≥1%) resulting in discontinuation of LENVIMA were hypertension (1%) and asthenia (1%).
In RCC, the most common adverse reactions (≥20%) observed in LENVIMA + pembrolizumab-treated patients were fatigue (63%), diarrhea (62%), musculoskeletal pain (58%), hypothyroidism (57%), hypertension (56%), stomatitis (43%), decreased appetite (41%), rash (37%), nausea (36%), decreased weight (30%), dysphonia (30%), proteinuria (30%), palmar-plantar erythrodysesthesia syndrome (29%), abdominal pain (27%), hemorrhagic events (27%), vomiting (26%), constipation (25%), hepatotoxicity (25%), headache (23%), and acute kidney injury (21%). The most common serious adverse reactions (≥2%) were hemorrhagic events (5%), diarrhea (4%), hypertension (3%), myocardial infarction (3%), pneumonitis (3%), vomiting (3%), acute kidney injury (2%), adrenal insufficiency (2%), dyspnea (2%), and pneumonia (2%). Fatal adverse reactions occurred in 4.3% of patients receiving LENVIMA in combination with pembrolizumab, including cardio-respiratory arrest (0.9%), sepsis (0.9%), and one case (0.3%) each of arrhythmia, autoimmune hepatitis, dyspnea, hypertensive crisis, increased blood creatinine, multiple organ dysfunction syndrome, myasthenic syndrome, myocarditis, nephritis, pneumonitis, ruptured aneurysm and subarachnoid hemorrhage. Serious adverse reactions occurred in 51% of patients receiving LENVIMA and pembrolizumab. Serious adverse reactions in ≥2% of patients were hemorrhagic events (5%), diarrhea (4%), hypertension (3%), myocardial infarction (3%), pneumonitis (3%), vomiting (3%), acute kidney injury (2%), adrenal insufficiency (2%), dyspnea (2%), and pneumonia (2%). Permanent discontinuation of LENVIMA, pembrolizumab, or both due to an adverse reaction occurred in 37% of patients; 26% LENVIMA only, 29% pembrolizumab only, and 13% both drugs. The most common adverse reactions (≥2%) leading to permanent discontinuation of LENVIMA, pembrolizumab, or both were pneumonitis (3%), myocardial infarction (3%), hepatotoxicity (3%), acute kidney injury (3%), rash (3%), and diarrhea (2%). Dose interruptions of LENVIMA, pembrolizumab, or both due to an adverse reaction occurred in 78% of patients receiving LENVIMA in combination with pembrolizumab. LENVIMA was interrupted in 73% of patients and both drugs were interrupted in 39% of patients. LENVIMA was dose reduced in 69% of patients. The most common adverse reactions (≥5%) resulting in dose reduction or interruption of LENVIMA were diarrhea (26%), fatigue (18%), hypertension (17%), proteinuria (13%), decreased appetite (12%), palmar-plantar erythrodysesthesia (11%), nausea (9%), stomatitis (9%), musculoskeletal pain (8%), rash (8%), increased lipase (7%), abdominal pain (6%), and vomiting (6%), increased ALT (5%), and increased amylase (5%).
In RCC, the most common adverse reactions (≥30%) observed in LENVIMA + everolimus–treated patients were diarrhea (81%), fatigue (73%), arthralgia/myalgia (55%), decreased appetite (53%), vomiting (48%), nausea (45%), stomatitis (44%), hypertension (42%), peripheral edema (42%), cough (37%), abdominal pain (37%), dyspnea (35%), rash (35%), decreased weight (34%), hemorrhagic events (32%), and proteinuria (31%). The most common serious adverse reactions (≥5%) were renal failure (11%), dehydration (10%), anemia (6%), thrombocytopenia (5%), diarrhea (5%), vomiting (5%), and dyspnea (5%). Adverse reactions led to dose reductions or interruption in 89% of patients. The most common adverse reactions (≥5%) resulting in dose reductions were diarrhea (21%), fatigue (8%), thrombocytopenia (6%), vomiting (6%), nausea (5%), and proteinuria (5%). Treatment discontinuation due to an adverse reaction occurred in 29% of patients.
In HCC, the most common adverse reactions (≥20%) observed in LENVIMA-treated patients were hypertension (45%), fatigue (44%), diarrhea (39%), decreased appetite (34%), arthralgia/myalgia (31%), decreased weight (31%), abdominal pain (30%), palmar-plantar erythrodysesthesia syndrome (27%), proteinuria (26%), dysphonia (24%), hemorrhagic events (23%), hypothyroidism (21%), and nausea (20%). The most common serious adverse reactions (≥2%) were hepatic encephalopathy (5%), hepatic failure (3%), ascites (3%), and decreased appetite (2%). Adverse reactions led to dose reductions or interruption in 62% of patients. The most common adverse reactions (≥5%) resulting in dose reductions were fatigue (9%), decreased appetite (8%), diarrhea (8%), proteinuria (7%), hypertension (6%), and palmar-plantar erythrodysesthesia syndrome (5%). Treatment discontinuation due to an adverse reaction occurred in 20% of patients. The most common adverse reactions (≥1%) resulting in discontinuation of LENVIMA were fatigue (1%), hepatic encephalopathy (2%), hyperbilirubinemia (1%), and hepatic failure (1%).
In EC, the most common adverse reactions (≥20%) observed in LENVIMA and pembrolizumab–treated patients were hypothyroidism (67%), hypertension (67%), fatigue (58%), diarrhea (55%), musculoskeletal disorders (53%), nausea (49%), decreased appetite (44%), vomiting (37%), stomatitis (35%), decreased weight (34%), abdominal pain (34%), urinary tract infection (31%), proteinuria (29%), constipation (27%), headache (26%), hemorrhagic events (25%), palmar‐plantar erythrodysesthesia (23%), dysphonia (22%), and rash (20%). Fatal adverse reactions occurred in 4.7% of those treated with LENVIMA and pembrolizumab, including 2 cases of pneumonia, and 1 case of the following: acute kidney injury, acute myocardial infarction, colitis, decreased appetite, intestinal perforation, lower gastrointestinal hemorrhage, malignant gastrointestinal obstruction, multiple organ dysfunction syndrome, myelodysplastic syndrome, pulmonary embolism, and right ventricular dysfunction. Serious adverse reactions occurred in 50% of patients receiving LENVIMA and pembrolizumab. Serious adverse reactions with frequency ≥3% were hypertension (4.4%), and urinary tract infection (3.2%). Discontinuation of LENVIMA due to an adverse reaction occurred in 26% of patients. The most common (≥1%) adverse reactions leading to discontinuation of LENVIMA were hypertension (2%), asthenia (1.8%), diarrhea (1.2%), decreased appetite (1.2%), proteinuria (1.2%), and vomiting (1.2%). Dose reductions of LENVIMA due to adverse reactions occurred in 67% of patients. The most common (≥5%) adverse reactions resulting in dose reduction of LENVIMA were hypertension (18%), diarrhea (11%), palmar-plantar erythrodysesthesia syndrome (9%), proteinuria (7%), fatigue (7%), decreased appetite (6%), asthenia (5%), and weight decreased (5%). Dose interruptions of LENVIMA due to an adverse reaction occurred in 58% of these patients. The most common (≥2%) adverse reactions leading to interruption of LENVIMA were hypertension (11%), diarrhea (11%), proteinuria (6%), decreased appetite (5%), vomiting (5%), increased alanine aminotransferase (3.5%), fatigue (3.5%), nausea (3.5%), abdominal pain (2.9%), decreased weight (2.6%), urinary tract infection (2.6%), increased aspartate aminotransferase (2.3%), asthenia (2.3%), and palmar-plantar erythrodysesthesia (2%).
Use in Specific Populations
Because of the potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for at least 1 week after the last dose. LENVIMA may impair fertility in males and females of reproductive potential.
No dose adjustment is recommended for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe (CLcr 15-29 mL/min) renal impairment. Reduce the dose for patients with DTC, RCC, or EC and severe renal impairment. There is no recommended dose for patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end-stage renal disease.
No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dose adjustment is recommended for patients with DTC, RCC, or EC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe hepatic impairment. Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment.
LENVIMA (lenvatinib) is available as 10 mg and 4 mg capsules.
Please see Prescribing information for LENVIMA (lenvatinib) at http://www.lenvima.com/pdfs/prescribing-information.pdf.
HALAVEN® (eribulin mesylate) is a microtubule dynamics inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. First in the halichondrin class, eribulin is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells.
Warnings and Precautions
Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.
Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.
Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.
QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.
Adverse Reactions
In patients with mBC receiving HALAVEN, the most common adverse reactions (≥25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).
Use in Specific Populations
Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose.
Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.
For more information about HALAVEN, click here for the full Prescribing Information.
In March 2018, Eisai and Merck, known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA.
In addition to ongoing clinical studies evaluating the KEYTRUDA plus LENVIMA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in multiple different tumor types across more than 15 clinical trials.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.
For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on Twitter (U.S. and global) and LinkedIn (for U.S. and EMEA).
LENVIMA® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
HALAVEN® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
# # #
View original content to download multimedia:
SOURCE Eisai Inc. | https://www.kswo.com/prnewswire/2022/09/06/eisai-presents-new-data-its-oncology-portfolio-pipeline-esmo-congress-2022/ | 2022-09-06T13:01:23Z | https://www.kswo.com/prnewswire/2022/09/06/eisai-presents-new-data-its-oncology-portfolio-pipeline-esmo-congress-2022/ | true |
SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executive Officer Piers Ingram, Ph.D., and Chief Financial Officer Josh House will participate in one-on-one investor meetings at Morgan Stanley's 20th Annual Global Healthcare Conference (September 12-14, 2022), held at the Sheraton New York Hotel in New York City.
About Hummingbird Bioscience
Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. We are currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase 1 studies. At Hummingbird Bioscience, our commitment to rigorous science, teamwork and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.
For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, Twitter, and YouTube.
View original content:
SOURCE Hummingbird Bioscience | https://www.kswo.com/prnewswire/2022/09/06/hummingbird-bioscience-participate-morgan-stanley-20th-annual-global-healthcare-conference/ | 2022-09-06T13:02:22Z | https://www.kswo.com/prnewswire/2022/09/06/hummingbird-bioscience-participate-morgan-stanley-20th-annual-global-healthcare-conference/ | false |
SOUTHFIELD, Mich., Sept. 6, 2022 /PRNewswire/ -- The SyBridge Technologies' Board of Directors is pleased to announce that Byron J. Paul has joined SyBridge Technologies ("SyBridge" or the "Company") as Chief Executive Officer and will also serve as a member of the Board of Directors. Mr. Paul will build upon the Company's strategic vision of becoming a global technological leader in value-added design and manufacturing solutions ranging from design and prototyping to production-as-a-service and aftermarket services for customers. Mr. Paul brings extensive experience in industrial technology and a 20+ year track record of driving profitable growth in complex, global enterprises.
Mr. Paul was most recently Group President at Signode Industrial Group where he led a global portfolio of businesses focused on end-of-line packaging technologies and warehouse automation solutions. He previously served as President of Destaco, a leading designer and manufacturer of precision engineered components for industrial automation and robotics applications. Mr. Paul has also held senior leadership roles at John Crane, a leader in rotating equipment solutions, and at the Boston Consulting Group. Mr. Paul holds an MBA from the Kellogg School of Management at Northwestern University and a Master of Public Administration from Harvard University's Kennedy School of Government. He also attended the University of Western Australia where he earned a Bachelor of Commerce with first class honors in accounting and finance.
Mr. Paul stated, "I am thrilled to be joining a world-class team at SyBridge Technologies. They have done an outstanding job expanding SyBridge Technologies' global reach, growing from three sites in 2019 to 16 locations today. I look forward to partnering with the Board and Crestview Partners as we embark on the next phase of growth to build an unrivaled leader in digital manufacturing."
Jason Luo, Chairman of SyBridge Technologies and Crestview Operating Executive noted, "Byron is a committed leader with a proven track record of successfully growing businesses and we are excited to partner with him as we plan to execute on the Company's next chapter of growth."
Mr. Paul succeeds Tony Nardone who has departed the company to pursue other interests. "We appreciate the many contributions Tony has made to SyBridge and wish him well in his future endeavors," said Mr. Luo.
About SyBridge Technologies
SyBridge Technologies was established in 2019 by Crestview Partners to create a global technology leader that provides value-added design and manufacturing solutions across multiple industries. SyBridge is the combination of 12 acquisitions made to combine different products, services and technologies into a singular technology enabled solution. SyBridge is based in Southfield, Michigan and has 16 locations throughout the United States, Canada and Mexico. For more information, please visit www.sybridgetech.com.
About Crestview Partners
Founded in 2004, Crestview is a value-oriented private equity firm focused on the middle market. The firm is based in New York and manages funds with approximately $10 billion of aggregate capital commitments. The firm is led by a group of partners who have complementary experience and backgrounds in private equity, finance, operations and management. Crestview has senior investment professionals focused on sourcing and managing investments in each of the specialty areas of the firm: industrials, media, and financial services. For more information, please visit us at www.crestview.com
For more information, please contact:
Jeffrey Taufield or Daniel Yunger
Kekst CNC
(212) 521-4800
jeffrey.taufield@kekstcnc.com / daniel.yunger@kekstcnc.com
View original content to download multimedia:
SOURCE SyBridge Technologies & Crestview Partners | https://www.kait8.com/prnewswire/2022/09/06/sybridge-technologies-board-directors-announces-byron-j-paul-ceo/ | 2022-09-06T13:02:37Z | https://www.kait8.com/prnewswire/2022/09/06/sybridge-technologies-board-directors-announces-byron-j-paul-ceo/ | true |
YOKNEAM ILLIT, Israel, Sept. 6, 2022 /PRNewswire/ -- PixCell Medical, innovator of rapid hematology testing solutions at the point-of-care, today announced a partnership with Insight Medical, a medical supply and service company based in Port Moresby, Papua New Guinea. Insight Medical will serve as the exclusive distributor of PixCell's HemoScreen™, a hematology analyzer designed for use at the point of care, across Papua New Guinea.
Insight Medical's mission is to enhancing the healthcare quality available in Papua New Guinea, with a commitment to providing quality health care access, including modern medical equipment and specialist care. Currently, most of Papua New Guinea's 9 million citizens live in rural communities, facing many healthcare and infrastructure challenges. HemoScreen was chosen for its suitability in meeting these challenges, delivering lab-grade blood diagnostics at the point-of-care, with no need for user maintenance or external reagents and requiring only minimal training.
"We see HemoScreen as a cutting-edge analyzer that can provide lab-grade diagnostics in remote regions of PNG where laboratories lack basic infrastructure and instrumentation, as well as qualified lab expertise" said Manas Sukumara Panicker, managing director at Insight Medical. "Being a tropical region, PNG has a high prevalence of vector borne diseases such as Malaria. Access to quality CBC results will certainly assist doctors in carrying out timely clinical interventions. We are confident HemoScreen will simplify the blood testing in PNG's rural settings."
"As our mission is to provide lad-quality blood diagnostics to anyone and anywhere, we have been striving to expand to more challenging and rural-centric regions, where HemoScreen can make a huge impact." stated Avishay Bransky, Ph.D., co-founder and CEO of PixCell Medical. "For this reason, we are extremely thrilled to form this partnership with Insight Medical who share our vision and provide services across the challenging Papua New Guinea healthcare network."
About PixCell Medical
PixCell Medical, an innovator of rapid hematology testing solutions at the point-of-care, has developed the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked and TGA-approved for point-of-care use –the HemoScreen™. The portable, easy to use platform offers clinically proven lab-accurate readings of 20 standard blood count parameters within five minutes, with just one finger-prick of blood. This facilitates fast diagnostic results and data-driven disease management decisions. Leveraging a patented, disposable cartridge preloaded with all necessary reagents, the company's unique Viscoelastic Focusing technology and AI-powered machine vision, PixCell enables improved medical outcomes and patient quality of life and reduces costs for healthcare providers.
For more information: www.pixcell-medical.com
Follow PixCell Medical on LinkedIn and Twitter.
Media Contact:
PixCell Medical
Jake Jones
jake.jones@pixcell-medical.com
Logo - https://mma.prnewswire.com/media/1501459/PixCell_Medical_Logo.jpg
View original content to download multimedia:
SOURCE PixCell Medical | https://www.weau.com/prnewswire/2022/09/06/pixcell-medical-partners-with-insight-medical-distribute-hematology-point-of-care-analyzer-hemoscreen-papua-new-guinea/ | 2022-09-06T13:03:48Z | https://www.weau.com/prnewswire/2022/09/06/pixcell-medical-partners-with-insight-medical-distribute-hematology-point-of-care-analyzer-hemoscreen-papua-new-guinea/ | true |
Many of the vegetables we grow in our gardens produce seeds, which, if harvested and stored correctly, have the potential to grace us with free plants. And late summer is the perfect time to start collecting them.
A few notes: Make sure the plants from which you’re collecting seeds are heirloom, or open-pollinated, varieties. These are plants in their original forms whose seeds will produce plants with the same qualities as their parent.
Hybridized varieties, on the other hand, are created by breeding two or more different types to capture the best qualities of each. Attempting to grow seeds collected from hybrids will yield a harvest of disappointment, as the resulting plants will not have the expected attributes but rather carry the traits of only one of the parents — and there’s no way to know what that will be. For this reason, it’s best not to grow seeds from supermarket produce.
Many plants become cross-pollinated in the garden when pollinators, other insects, animals and wind transfer pollen from one plant to another. To ensure the seeds you collect will grow into plants that match their parent, different varieties of the same crop should be kept anywhere from 100 feet to a mile apart, depending on climate, weather and other variables. This is often impractical, if not impossible, in the home garden.
To avoid cross-pollination surprises, plant only one variety of the category of plants from which you plan to harvest seeds. If you want to save tomato seeds, for example, grow only one type of tomato in your garden.
If that feels too limiting, go ahead and experiment, knowing that even if cross-pollinated, both parents are heirloom varieties you selected and planted. They’ll probably be fine even if they’re not what you expect.
Store all seeds in a cool, dry place in a covered glass jar or paper envelope away from ripening fruit, which would affect seed germination. The temporary addition of a silica gel packet to the jar will remove any remaining moisture, but take it out after a couple of days to avoid over-drying.
Here’s how to collect and save seeds from the most common homegrown crops.
LETTUCE
At the end of the growing season, lettuce will bolt, or send up a flower stalk that will develop seed heads reminiscent of dandelion puffs. When the puffs are dry, remove the entire stem, place it into a paper bag, fold over the top and shake. The seeds will disengage from the flower and fall to the bottom of the bag.
PARSLEY
Parsley is a biennial plant with a two-year life cycle that produces only edible foliage in its first year and leaves and flowers in its second. Allow those flowers to remain on second-year plants until they become brown and brittle. Cut them off the plant and store them in a paper bag to dry completely for a couple of weeks. When you remove them from the bag, rub the flowers between your fingers to separate the seeds, then blow away the lightweight dry plant matter and discard.
BASIL
Basil seeds are tiny, so separating them from the small flower petals and chaff can be tedious. When plants bolt at the end of the season, allow flowers to remain until they fade completely. Clip them off and place them in a mesh sieve or colander, then use your fingers to rub them against the bottom of the sieve.
BEETS AND CARROTS
These biennial plants produce seeds only in their second year, after a period of vernalization, or cold storage. In areas with cold winters, simply leave plants in the ground over winter.
In warm climates, you’ll have to create “winter” indoors: At the end of the first season, cut the foliage down to 2 inches, carefully dig up roots, and store them in a refrigerator or cool cellar over winter. Replant them outdoors the following spring.
When the leaves of second-year beet plants turn brown, remove the seed stalk from the top of the plant and place it in a paper bag. Store in a cool, dry place for at least two weeks, then give the bag a good shake to separate the seeds. Pour them onto a plate, then blow on them to separate the chaff.
Allow second-year carrot flowers to dry on the plant, clip them off, and dry them further in a paper bag for a week or two. Shake the bag well and pour seeds out onto a plate, blow on them to separate the chaff.
PEPPERS
Select the nicest-looking pepper from your healthiest plant and allow it to remain on the plant until it is overripe and wrinkled. Slice it in half and remove the seeds, discarding any that are discolored or otherwise undesirable. Spread seeds in a single layer on paper towels and allow them to dry in a warm spot away from direct sunlight. Toss the seeds occasionally to ensure even drying, which should take about a week.
EGGPLANTS
Allow an eggplant to over-ripen on the plant until it becomes hard and wrinkled, and loses its shine and color. Slice it open, remove its seeds and place them in a bowl of water. Agitate the water with your hands to separate seeds from any flesh that is adhered to them. Strain, then pat seeds dry with a towel and spread on a towel or screen to dry, tossing every day for up to a month until completely dry.
GREEN BEANS
Because green beans produce an ongoing harvest throughout the season, enjoy the first flush or two, then leave developing pods on one plant until they are completely dried and brown. You’ll know they’re ready when they play like maracas. Cut the pods off the plant, place them in a cool, dark spot to dry further, then remove the seeds. Discard any that appear discolored or damaged, and spread the rest on a towel for a few days to harden.
TOMATO
There are two ways to save tomato seeds — the right way and the easy way. Full disclosure: I like it easy, and I’ve succeeded with the shortcut. Your results may vary.
Start by cutting a tomato in half, then squeeze out its seeds and pulp over a bowl.
Fermentation improves germination rates and kills some seed-borne pathogens that could sicken plants. To ferment seeds:
1. Place a cover slightly askew over the bowl and allow the seeds to sit in their juices undisturbed for three days.
2. Pour the bowl’s contents, which may be covered with a white film, into a larger container and add water equal to at least 3 times the seeds’ volume.
3. Agitate the water with your hand and pour off the liquid. You’ll notice that most of the seeds will have sunk to the bottom of the container; they are the viable seeds.
Any that float are duds, so pour them out with the juice, pulp and water. Repeat the rinsing process two more times.
To make sure pathogens are killed, soak seeds for 30 minutes in a 90% water, 10% bleach solution, then rinse very well. Spread seeds on a towel and allow to dry for about a week, tossing occasionally.
Or, you can simply allow the whole mess of seeds and pulp to dry on a plate in the open air for about a week, then scrape or pick off the seeds.
ZUCCHINI
Allow your chosen fruit to become overgrown, wrinkled and dry on the plant. Remove it, slice it open and scoop out its seeds. If desired, follow the tomato fermentation process above. You’ll need to add a bit of water to the first step because there won’t be any juice or pulp in the container. | https://wgntv.com/news/nexstar-media-wire/nows-a-good-time-to-prepare-for-next-years-vegetable-garden-heres-how/ | 2022-09-06T13:05:45Z | https://wgntv.com/news/nexstar-media-wire/nows-a-good-time-to-prepare-for-next-years-vegetable-garden-heres-how/ | false |
New 'United Against Flu' campaign to educate people about the flu, encourage vaccination
CHICAGO, Sept. 6, 2022 /PRNewswire/ -- September officially kicks off influenza (flu) season in the U.S., and it is time for all eligible Americans to get their annual flu shot. To help educate adults who are at high risk for flu complications and increase vaccination rates, today the American Lung Association launched a new campaign, "United Against Flu."
Flu is a serious and highly contagious respiratory illness. While anyone can get the flu, certain people are at increased risk for developing serious complications, including those living with chronic medical conditions including chronic lung disease, chronic heart disease and diabetes. Racial and ethnic groups also may be at higher risk for developing serious illness. In fact, from 10 flu seasons beginning in 2009, Black Americans had a 1.8 times greater rate of flu hospitalization, and Latino Americans had a 1.2 times greater rate of flu hospitalization compared to white Americans.
"In past flu seasons, nine out of 10 adults hospitalized with the flu had at least one underlying medical condition. In fact, in the 2021-22 flu season, more than 30% of flu related hospitalizations were among adults with chronic lung disease," said American Lung Association President and CEO Harold Wimmer. "This is why it is important for everyone to get their annual flu shot. Getting a flu vaccine is important to protect yourself, your family and your community from the flu."
Flu vaccination is the best way to help protect against flu and severe illness from the virus. The flu shot is recommended annually in September or October for everyone six months of age and older, although it is not too late to vaccinate throughout the flu season. Over the course of more than 50 years, millions of Americans have safely received flu shots.
Through the "United Against Flu" Campaign, the American Lung Association has partnered with Sanofi to educate Americans about the flu and steps they can take to protect themselves from severe flu illness. Learn more at Lung.org/prevent-flu.
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and is a Gold-Level GuideStar Member, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org.
American Lung Association • 55 W. Wacker Drive, Suite 1150 • Chicago, IL 60601
1331 Pennsylvania Ave. NW, Ste. 1425 North • Washington, D.C. 20004
1-800-LUNGUSA (1-800-586-4872) Lung.org
CONTACT: Jill Dale | American Lung Association
P: 312-940-7001 C:720-438-8289 E: Jill.Dale@Lung.org
View original content to download multimedia:
SOURCE American Lung Association | https://www.wflx.com/prnewswire/2022/09/06/its-time-get-your-flu-shot-what-you-need-know-about-2022-2023-flu-season/ | 2022-09-06T13:05:54Z | https://www.wflx.com/prnewswire/2022/09/06/its-time-get-your-flu-shot-what-you-need-know-about-2022-2023-flu-season/ | false |
VENICE, Italy (AP) — Harry Styles already has an enviable acting resume for a newcomer, from Christopher Nolan’s “Dunkirk” to the upcoming “Don’t Worry Darling” and “My Policeman.” But the pop star said Monday at the Venice International Film Festival that, with acting, he often feels as if he has “no idea what I’m doing.”
Styles’ arrival on the Lido, where “Don’t Worry Darling” is having its world premiere Monday night, has been one of the most anticipated events of a festival full of stars. At a press conference before the premiere, Styles was peppered with questions about his fans, his career and whether or not he would work with director Olivia Wilde again — neither of which he answered.
In “Don’t Worry Darling,” Styles plays Jack, who works for the mysterious Victory Project, run by Chris Pine’s charismatic cult-like leader, in a mid-century-styled experimental community. Florence Pugh plays Jack’s wife Alice, who gets every comfort in the world in exchange for not asking questions. But soon, she starts to see cracks in the veneer.
“I think it’s fun to get to play in worlds that aren’t necessarily your own. This world that is supposedly so perfect, it’s really fun to play pretend in there,” Styles said. “There wasn’t too much acting.”
Styles took several days off from his Madison Square Garden appearances to attend the “ Don’t Worry Darling ” premiere in Venice, with Wilde and co-stars Pine and Gemma Chan. But though he juggles two high-profile careers in the arts, he said he doesn’t see many parallels between music and acting.
“Personally I find them to be kind of opposite in a lot of ways. I think making music is a really personal thing,” Styles said. “There’s aspects of acting where you’re drawing from experiences you’ve had but for the most part you’re pretending to play someone else. I think that’s what I find the most fun about it: playing pretend.”
He added: “I think the fun part is you never know what you’re doing. Music I’ve done for longer, but what I like about acting is I feel like I have no idea what I’m doing.”
Fans were already gathering in front of the theater early Monday to get a prime perch in front of the red carpet for the premiere, hours in advance. Many had personal stories about how Styles’ music impacted their lives.
“I’m incredibly grateful to the people who’ve supported me in my life and the fans in particular have always provided me with a place to be myself and feel comfortable doing so and express myself,” he said about what it’s like to mean so much to so many people. “I would like to hope I can give that space back to them.”
___
Follow AP Film Writer Lindsey Bahr on Twitter: www.twitter.com/ldbahr
___
For more on the Venice Film Festival, visit: www.apnews.com/VeniceFilmFestival | https://pix11.com/entertainment/ap-entertainment/ap-in-venice-harry-styles-talks-acting-music-and-fans/ | 2022-09-06T13:05:54Z | https://pix11.com/entertainment/ap-entertainment/ap-in-venice-harry-styles-talks-acting-music-and-fans/ | true |
MOMBASA, Kenya (AP) — Rich countries said they will spend about $25 billion by 2025 to boost Africa’s efforts to adapt to climate change as the continent continues to struggle with drought, cyclones and extreme heat, according to officials at a summit in Rotterdam in the Netherlands on Monday.
The amount promised by the Africa Adaptation Acceleration Program — a joint initiative between various nations and organizations — is billed as the largest ever adaptation effort globally. Half of the amount is pledged by the African Development Bank with representatives from Denmark, the United Kingdom, France, the Netherlands, the International Monetary Fund and others also offering their support for the initiative.
The continent emits just 3% to 4% of emissions despite being home to nearly 17% of the world’s population but experts say it is particularly vulnerable to climate change as it less able to adapt. African nations hope to use the funds to improve their resilience to extreme weather events, such as droughts or floods, increase tree cover and protect biodiversity, as well as expand their renewable energy capacity.
The summit comes just weeks after the Organization for Economic Cooperation and Development found that rich countries had failed to deliver on their 2009 promise to spend $100 billion a year to aid developing countries to adapt to a warming climate. The organization said $83.3 billion was given to poorer nations in 2020, the highest ever sum, but still short of the original amount.
If the funds promised at the Rotterdam summit are delivered, the decades-old goal will finally be achieved but African nations warn this will not be enough.
“Africa does not have the resources to tackle climate change,” Akinwumi Adesina, president of the African Development Bank, told the summit. “The continent only receives 3% of the total climate financing.”
Africa will need between $1.3 and $1.6 trillion this decade to implement its commitments to the Paris climate agreement, an annual cost between $140 and $300 billion, Adesina said. He added that the costs of adapting to climate change are expected to increase by 2050, as the effects of global warming get more severe.
Ghana’s President Nana Akufo Addo said his country will push for the funds allocated to adapting to a warmer climate to be doubled at the forthcoming United Nations summit in Egypt in November.
After decades of developed countries falling short on their funding promises, many African nations remain skeptical that the funds will ever reach the continent.
The U.N. Climate Change High-Level Champion for Egypt, Mahmoud Mohieldin, said the existing global climate financing structure is “insufficient and ineffective,” especially for Africa.
___
Follow AP’s climate and environment coverage at https://apnews.com/hub/climate-and-environment
___
Associated Press climate and environmental coverage receives support from several private foundations. See more about AP’s climate initiative here. The AP is solely responsible for all content. | https://pix11.com/news/ap-general/ap-as-africas-climate-warms-rich-countries-pledge-more-funds/ | 2022-09-06T13:06:15Z | https://pix11.com/news/ap-general/ap-as-africas-climate-warms-rich-countries-pledge-more-funds/ | true |
Extending the age range for children up to 12 years
ORLANDO, Fla., Sept. 6, 2022 /PRNewswire/ -- The Sunshine Flyer released new, lower ticket prices, and now allows children up to 12 years of age to receive the lower child price. By extending the child age range by three years, more families can enjoy Sunshine Flyer's unique and cost-effective transportation experience from Orlando International Airport (MCO) to Walt Disney World® Resorts.
The Sunshine Flyer offers an engaging transportation experience that allows guests to start the magic of their Walt Disney World® vacation from the moment they step off the plane.
The Sunshine Flyer's buses are late model, premium motorcoaches with themes that center around old-fashioned passenger cars and train engines. From the bus designs to staff dressed as 1920's rail conductors and engineers, the motorcoaches effectively serve as time-machines, offering a glimpse into 1920s rail travel.
"We listen to our guests, and we that know that extending the age range for children is very important to them. While we welcome passengers of all ages, we have a special focus on children. From coloring books and conductor hats to on-board video entertainment, the ride from the airport sets the tone for an exciting family vacation," says Tony Glibkowski, Vice President of the Sunshine Flyer.
The Sunshine Flyer is well-equipped for kids, including:
- Three-point harness seat belts at each seat
- Conductor hats for kids
- Stickers for kids
- Coloring/activity books for kids
- On-board video entertainment
When guests book a future trip, they can experience the following ticket prices at checkout:
- $10 per child
- $16 per adult
All Make-A-Wish® children and families receive complimentary service from the Sunshine Flyer for Disney wishes indefinitely.
For more information about the Sunshine Flyer, visit www.sunshineflyer.com.
About The Sunshine Flyer
The Sunshine Flyer is a unique motorcoach bus experience from Transportation Management Services (TMS) that provides seamless transportation for guests from the Orlando International Airport (MCO) to Walt Disney World® Resorts. Offering a convenient and cost-effective mode of transportation, The Sunshine Flyer is the perfect option for families, groups, and individuals looking to start their Disney vacation from the moment they step off the plane. For more information and to book tickets, visit www.sunshineflyer.com.
Media Contact
Ashley La Fleur
(618) 660-6963
343887@email4pr.com
View original content to download multimedia:
SOURCE The Sunshine Flyer | https://www.wbrc.com/prnewswire/2022/09/06/sunshine-flyer-announces-new-ticket-prices-kids/ | 2022-09-06T13:06:59Z | https://www.wbrc.com/prnewswire/2022/09/06/sunshine-flyer-announces-new-ticket-prices-kids/ | true |
State-of-the-art digital platform simplifies COVID-19 test result management
MADISON, Wis., Sept. 6, 2022 /PRNewswire/ -- MicroGEM, a Virginia-based life sciences and molecular diagnostics company,and Workflow Services by ImageMover, a healthcare software company that provides solutions to capture point-of-care medical data through provider-focused digital workflows, have announced their partnership to streamline COVID-19 test result workflow. In this agreement designating MicroGEM as a premier partner for PCR point of care testing, Workflow Services by ImageMover now offers optional access to its fully-integrated reporting platform with the MicroGEM Sal6830 SARS-CoV-2 Saliva Test to automate and simplify data reporting requirements.
MicroGEM develops innovative point-of-need diagnostic devices based on its ground-breaking approach to sample preparation and nucleic acid extraction. The MicroGEM Sal6830 Point of Care PCR System is designed to capture intact virus, a key indicator of infectiousness. The Sal6830 is simple to operate with non-invasive saliva collection, no extra consumables or sample preparation steps, easy touchscreen instructions, and PCR results at the point of care in under 30 minutes.
"Our goal is to streamline test administration for providers and ensure secure test results for patients so that point-of-care COVID-19 testing can be implemented with ease and efficiency," said LeRoy Blake, Chief Commercial Officer at MicroGEM. "The Workflow Services solution enables our customers to quickly document point of care test results, communicate those automatically to the patient, and automatically report results to state and federal health authorities."
Since its founding in 2013, ImageMover has automated the management of millions of diagnostic images and grown to accommodate numerous clinical workflows and different care settings from pharmacies, to urgent cares, to universities and sports teams. Workflow Services by ImageMover employs an exclusive approach to securely capture and integrate point-of-care medical data, simplifying communication and enhancing patient care. The streamlined workflow reduces errors by capturing data elements through barcode scanning and optical character recognition, and securely stores captured results.
"The MicroGEM innovative saliva PCR test, paired with point-of-care operational support from Workflow Services, brings a compelling, fully integrated solution to the market. This type of combined offering makes high quality diagnostic testing more accessible and meets the demands of point of care service delivery now and into the future," said Kevin Houlihan, ImageMover President and CEO.
The MicroGEM Sal6830 SARS-CoV-2 Saliva Test has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories, including under a CLIA waiver. Find Sal6830 FDA EUA information here: https://microgembiocovid19.com/img/uploads/FDA%20language%20for%20website.pdf
MicroGEM democratizes molecular biology by moving complex molecular biology tools out of highly skilled laboratories to non-laboratory settings where they can be used quickly at the point of need. The company's innovative enzymatic approach to nucleic acid extraction provides the foundation for fast sample preparation suitable for PCR analysis. Coupled with its expertise in microfluidics and synthetic biology, MicroGEM is creating the next generation of person-portable diagnostic devices for the management of infectious diseases and other personalized medicine applications.
www.microgembio.com/covid-19
Contact: Lianne Landers, Sr. Director of Corporate Communications
l.landers@microgembio.com
Workflow Services by ImageMover is a healthcare software company that innovates seamless point-of-care medical workflow software solutions for healthcare professionals and patients. The company's solutions employ exclusive, patented approaches to securely capture and integrate medical data to simplify communication and enhance patient care.
www.workflowservices.com
Contact: Shannon Brenkendorff
Email: shannon@imagemovermd.com
View original content:
SOURCE ImageMoverMD | https://www.wflx.com/prnewswire/2022/09/06/microgem-workflow-services-by-imagemover-join-forces-provide-comprehensive-solution-fast-saliva-pcr-sars-cov-2-testing-point-care/ | 2022-09-06T13:07:00Z | https://www.wflx.com/prnewswire/2022/09/06/microgem-workflow-services-by-imagemover-join-forces-provide-comprehensive-solution-fast-saliva-pcr-sars-cov-2-testing-point-care/ | false |
Isle of Man hosepipe ban to be lifted after heavy rain
- Published
A hosepipe ban on the Isle of Man is set to be lifted after heavy rain helped to replenish water stocks, Manx Utilities has said.
The restrictions were introduced on 29 July after a prolonged dry spell led to low water levels at reservoirs.
Manx Utilities said while stocks remained 9% below average, they had now risen enough to allow the ban to be lifted.
The restrictions will be scrapped at 07:00 BST on Wednesday.
The ban was introduced after the island saw 50% below average rainfall in June and July, causing water levels to fall to 70% of capacity.
A spokeswoman for Manx Utilities said recent rainfall had led overall stocks to recover to 73%, which had "restored our confidence in water stock availability as we move into the autumn and winter periods".
'Use water wisely'
Chairman Rob Callister MHK said although hosepipe bans were "not popular", the law was in place to "protect our precious raw water stocks when it is deemed necessary".
"We would encourage the public to continue to use water wisely both to protect the natural environment and be aware that reduced consumption also reduces the amount of energy we consume as an island community," he added.
Water usage has fallen by eight million litres a day since the restrictions were brought in.
The amount of compensation water released into rivers from Sulby reservoir has already been returned to normal flow levels.
Why not follow BBC Isle of Man on Facebook and Twitter? You can also send story ideas to IsleofMan@bbc.co.uk | https://www.bbc.co.uk/news/world-europe-isle-of-man-62809273 | 2022-09-06T13:07:39Z | https://www.bbc.co.uk/news/world-europe-isle-of-man-62809273 | true |
NEW YORK (AP) — The Latest on the U.S. Open tennis tournament (all times local):
2:30 a.m.
It’s going to be a U.S. Open quarterfinals matchup of two rising stars when third-seeded Carlos Alcaraz plays No. 11-seed Jannik Sinner.
The 19-year-old Alcaraz was the last to advance in one of the longest nights ever at the Open — that included a fourth set that lasted about an hour — with a 6-4, 3-6, 6-4, 4-6, 6-3 win over 2014 U.S. Open champion Marin Cilic at Arthur Ashe Stadium.
Alcaraz, who can end the Open ranked No. 1 in the world, dropped to his knees when he won the grueling match that lasted 3 hours, 54 minutes and ended at 2:23 a.m. — missing the record by 3 minutes for the latest finish in Open history. He would be the youngest No. 1 on the ATP tour since 2001.
Cilic’s exit means there’s not a single former U.S. Open champion left in both the men’s and women’s draw.
Sinner beat Alcaraz in four sets when they played this year at Wimbledon. Sinner, who turned 21 in August, is the youngest player to reach the quarterfinals of all four Grand Slam events in a season since Novak Djokovic was 20 in 2007. The two players could play a pivotal role in a potential changing of the guard in men’s tennis. Rafael Nadal lost Monday and Djokovic, who has 21 Grand Slam titles, did not enter this U.S. Open because he is not vaccinated against COVID-19 and was not allowed to enter the United States. Roger Federer, 41, has undergone a series of operations on his right knee and last played at Wimbledon last year.
Alcaraz was already the youngest man to reach the fourth round in consecutive U.S. Open since Pete Sampras in 1989 and ’90.
The crowd at Ashe went wild on nearly every point in the fifth set. Alcaraz, of Spain, was fist-pumping and exhorting the fans to get louder. And it worked. Fueled by the fandom — and a spate of Cilic’s unforced errors — Alcaraz pulled away in the fifth. Alcaraz high-fived a few fans that stuck around to celebrate his second straight quarterfinal berth at Flushing Meadows.
_____
12:10 a.m.
Eleventh-seeded Jannik Sinner held off feisty Ilya Ivashka and won his U.S. Open match 6-1, 5-7, 6-2, 4-6, 6-3 to clinch a spot in all four Grand Slam quarterfinals this year.
Sinner, who turned 21 in August, became the youngest player to reach the quarterfinals of all four Grand Slam events in a season since Novak Djokovic was 20 in 2007. Sinner was down 3-1 in the fifth set but rallied to win five straight games to close out the unseeded Ivashka.
Sinner won 12 break points in the match and dug deep in the fifth, showcasing why the rising Italian is considered as a potential star. Sinner joins Matteo Berrettini as Italian men in the U.S. Open quarterfinals.
Sinner will play the winner of Monday night’s final match between 2014 U.S. Open champion Marin Cilic and No. 3 Carlos Alcaraz.
___
10:20 p.m.
Sixth-seeded Aryna Sabalenka bounced back from a slow start and visits from the trainer to beat No. 19 seed Danielle Collins 3-6, 6-3, 6-2 and reach the U.S. Open quarterfinals.
Sabalenka advanced to face No. 22 Karolina Pliskova.
Sabalenka continued her mastery at Flushing Meadows over Collins, beating her for the third time at the U.S Open (2018 and 2021). She led 4-3 in the second set when she needed a medical timeout. Sabalenka had a trainer massage her left thigh and it continued throughout breaks in the match. Sabalenka, an Open semifinalist in 2021, said at her on-court interview she was fine.
Sabalenka at one point complained to the chair umpire about fan noise — and again, there were plenty of them inside Arthur Ashe Stadium. The U.S. Open has attracted a record 549,657 fans since the main draw started last Monday. It’s the highest-ever attendance for the tournament through its first eight days. The previous record was 540,333, set in 2019.
She even changed her racket — which she said was “super loose” — in the midst of the second set. It didn’t bother her too much. She had 38 winners.
Sabalenka, who is from Belarus, was not allowed to play at Wimbledon this year after all players from her country and Russia were banned because of the invasion of Ukraine.
___
8 p.m.
No. 24 seed Karolina Pliskova has moved into the U.S. Open quarterfinals with a 7-5, 6-7 (5), 6-2 win over 26th-seeded Victoria Azarenka.
Pliskova, a former world No. 1, was the runner-up at the U.S. Open in 2016 and at Wimbledon in 2021. Pliskova will play the winner of Monday night’s match at Arthur Ashe Stadium between No. 6 seed Aryna Sabalenka and 19th-seeded Danielle Collins.
The women’s field is guaranteed to have a first-time champion.
Pliskova has returned to form in Flushing Meadows after a broken right wrist forced her to miss the Australian Open and she struggled in her first few tournaments when she returned to action.
Azarenka lost for the fifth time in nine career meetings against Pliskova.
___
6:15 p.m.
Frances Tiafoe pulled off the biggest win of his career when the 22nd-ranked American beat second-seeded Rafael Nadal 6-4, 4-6, 6-4, 6-3 to reach the U.S. Open quarterfinals.
Tiafoe buried his head in his hands and cried on the court after he shook hands with Nadal. He sat on the bench and buried his head in a towel as Nadal walked off and waved to the crowd.
The 24-year-old Tiafoe is the youngest American to reach the quarterfinals since Andy Roddick did so at 24 in 2006. Nadal, a four-time U.S. Open champion, was the highest-seeded player left after No. 1 Daniil Medvedev lost Sunday.
Tiafoe already was the first American man to reach the fourth round in three straight years since Mardy Fish in 2010-12.
Nadal entered 22-0 at Grand Slam events in 2022. He was 21-1 against Americans since October 2017, which included straight-set wins over Tiafoe in the 2019 Australian Open quarterfinals and 2019 Madrid third round.
The early edge was a boon for Tiafoe. Nadal has never come back from down 2-1 at the U.S. Open and fell to 0-7 overall at Flushing Meadows with that deficit.
___
4:35 p.m.
No. 1 seed Iga Swiatek survived a slow start to knock off unseeded Jule Niemeier 2-6, 6-4, 6-0 to reach the quarterfinals at the U.S. Open for the first time.
Swiatek, a two-time French Open champion, will play Jessica Pegula next. Pegula eliminated two-time Wimbledon champion Petra Kvitova 6-3, 6-2 to get to her third major quarterfinal of 2022.
Swiatek came into the U.S. Open just 4-4 in her last eight matches after winning 37 straight, but she hadn’t lost a set at Flushing Meadows until Monday. Niemeier got the early jump — as she exhorted the crowd to get louder — and gamely tried for another Grand Slam upset. She knocked out No. 2 seed Anett Kontaveit in Wimbledon.
Swiatek steadied herself in the second set and hit 10 winners, and she turned the third set into a rout. Swiatek became the first Polish woman to reach the quarterfinals at the U.S. Open and is trying to become the first top-seeded woman to win it since Serena Williams in 2014.
___
2:15 p.m.
Jessica Pegula eliminated two-time Wimbledon champion Petra Kvitova 6-3, 6-2 to get to her third major quarterfinal of 2022 and reach that round for the first time at Flushing Meadows.
Play was held up for about 45 minutes at 1-1 in the first set while rain fell. There is a retractable roof at Arthur Ashe Stadium, but it wasn’t closed until after a downpour soaked the court.
The U.S. Tennis Association said in a statement that its “weather team” told U.S. Open organizers there was no rain expected. The statement added: “Unfortunately, a pop-up sunshower occurred.”
The No. 8-seeded Pegula is the highest-ranked American woman and the only player in the top 10 in both singles and doubles.
She reeled off the last three games of Monday’s opening set, which ended with a double-fault by No. 21 Kvitova, and then the last six games of the fourth-round match after trailing 2-0 in the second set.
Pegula is a 28-year-old who was born in New York. Her parents own the NFL’s Buffalo Bills and NHL’s Buffalo Sabres.
She is 0-3 in Grand Slam quarterfinals so far, including losses at that stage at the Australian Open in January and the French Open in June. The loss in Paris came against No. 1-ranked Iga Swiatek, who could be Pegula’s next opponent at Flushing Meadows.
___
1:40 p.m.
Andrey Rublev reached his sixth Grand Slam quarterfinal by beating Cam Norrie 6-4, 6-4, 6-4 in a match delayed by about 25 minutes while the retractable roof at Louis Armstrong Stadium remained open during a downpour.
The No. 9-seeded Rublev is into his third quarterfinal at Flushing Meadows. But he is 0-2 at that stage in New York — and 0-5 at all majors.
Rublev next faces 22-time Grand Slam champion Rafael Nadal or 24-year-old American Frances Tiafoe, who were scheduled to meet later Monday.
No. 7 Norrie was trying to reach the second Grand Slam quarterfinal of his career — and of this year. He lost in the Wimbledon semifinals to eventual champion Novak Djokovic in July.
___
1:15 p.m.
Play has resumed between two-time Wimbledon champion Petra Kvitova and No. 8 seed Jessica Pegula in Arthur Ashe Stadium after a rain delay of 45 minutes while they waited for the retractable roof to close and the court to be dried.
The fourth-round match was halted in the middle of the third game with the score at 1-all.
Action also returned at Louis Armstrong Stadium between No. 7 Cam Norrie and No. 9 Andrey Rublev after a delay of just under 25 minutes.
Shortly after they picked back up, Rublev closed out the second set for a 6-4, 6-4 lead in their fourth-round contest.
No other courts at Flushing Meadows have a roof, so play is suspended in doubles and junior matches.
___
12:45 p.m.
Rain is delaying play in all matches at Flushing Meadows — even in the two arenas with retractable roofs, Arthur Ashe Stadium and Louis Armstrong Stadium.
The courts were not covered when a little drizzle became a heavy downpour.
The match in Ashe between two-time Wimbledon champion Petra Kvitova and No. 8 seed Jessica Pegula was in the middle of the third game with the score at 1-all.
The match in Armstrong between No. 7 Cam Norrie and No. 9 Andrey Rublev was in the third set with Rublev up a set and a break at 6-4, 4-3.
___
11:15 a.m.
Play has started on Day 8 at Flushing Meadows, with No. 7 seed Cam Norrie facing No. 9 Andrey Rublev in Louis Armstrong Stadium for a quarterfinal berth.
The winner of that matchup will face 22-time Grand Slam champion Rafael Nadal or 24-year-old American Frances Tiafoe, who are scheduled to play in Arthur Ashe Stadium later Monday.
After a string of upsets, and Serena Williams’ loss in what is expected to be her final match, left no past U.S. Open women’s champions in the field, all eyes are now on No. 1 Iga Swiatek. The two-time French Open champion will try to make the U.S. Open quarterfinals for the first time when she plays unseeded Jule Niemeier.
The Ashe program begins at noon with two-time Wimbledon champion Petra Kvitova taking on the highest-ranked American woman, Jessica Pegula.
___
More AP coverage of U.S. Open tennis: https://apnews.com/hub/us-open-tennis-championships and https://twitter.com/AP_Sports | https://pix11.com/sports/ap-sports/ap-nadal-swiatek-try-to-reach-quarterfinals-us-open-updates/ | 2022-09-06T13:08:46Z | https://pix11.com/sports/ap-sports/ap-nadal-swiatek-try-to-reach-quarterfinals-us-open-updates/ | false |
NEW YORK (AP) — Frances Tiafoe’s vision was blurry from the tears. He was thrilled — overwhelmed, even — when the last point was over and it hit him that, yes, he had ended Rafael Nadal’s 22-match Grand Slam winning streak Monday and reached the U.S. Open quarterfinals for the first time.
“I felt like the world stopped,” Tiafoe said. “I couldn’t hear anything for a minute.”
Then Tiafoe found himself “losing it in the locker room” when he saw that NBA superstar LeBron James gave him a Twitter shoutout.
“Bro,” Tiafoe said, “I was going crazy.”
What meant the most to Tiafoe about his 6-4, 4-6, 6-4, 6-3 victory over 22-time major champion Nadal in the fourth round at Flushing Meadows, though, was looking up in his Arthur Ashe Stadium guest box and knowing his parents, Constant and Alphina, were there.
“To see them experience me beat Rafa Nadal — they’ve seen me have big wins, but to beat those ‘Mount Rushmore’ guys? For them, I can’t imagine what was going through their heads,” said Tiafoe, a 24-year-old American seeded 22nd at the U.S. Open. “I mean, they’re going to remember today for the rest of their lives.”
His parents both emigrated to the United States from Sierra Leone in West Africa amid its civil war in the 1990s. They ended up in Maryland, where Constant helped construct a tennis training center for juniors, then became a maintenance man there; Alphina, Frances said, was “a nurse, working two jobs, working overtime through the nights.” Frances and his twin brother, Franklin, were born in 1998, and soon would be spending hour upon hour where Dad’s job was, rackets in hand.
Maybe one day, went the dream, a college scholarship would come of it.
“It wasn’t anything supposed to be like this,” Tiafoe said Monday evening, hours after by far his biggest victory.
He is the youngest American man to get this far at the U.S. Open since Andy Roddick in 2006, but this was not a case of a one-sided crowd backing one of its own. Nadal is about as popular as it gets in tennis and heard plenty of support as the volume raised after the retractable roof was shut in the fourth set.
“It’s something to tell the kids, the grandkids: ‘Yeah, I beat Rafa,’” Tiafoe said with a big smile.
He served better than No. 2 seed Nadal. More surprisingly, he returned better, too. And he kept his cool, remained in the moment and never let the stakes or the opponent get to him. Nadal, a 36-year-old from Spain, had won both of their previous matches, and every set they played, too.
“Well, the difference is easy: I played a bad match and he played a good match,” Nadal said. “At the end that’s it.”
This surprise came a day after Tiafoe followed along on TV as his pal Nick Kyrgios “put on a show” and eliminated No. 1 seed and defending champion Daniil Medvedev. That makes this the first U.S. Open without either of the top two seeded men reaching the quarterfinals since 2000, when No. 1 Andre Agassi exited in the second round and No. 2 Gustavo Kuerten in the first.
That was before Nadal, Novak Djokovic, who has 21 Grand Slam titles, and Roger Federer, who has 20, began dominating men’s tennis. Djokovic, 35, did not enter this U.S. Open because he is not vaccinated against COVID-19 and was not allowed to enter the United States; Federer, 41, has undergone a series of operations on his right knee and last played at Wimbledon last year.
Now come the inevitable questions about whether their era of excellence is wrapping up.
“It signifies that the years go by,” Nadal said. “It’s the circle of life.”
Tiafoe now meets No. 9 Andrey Rublev, who beat No. 7 Cam Norrie 6-4, 6-4, 6-4 earlier Monday.
Late Monday turned into early Tuesday when third-seeded Carlos Alcaraz beat No. 15 seed Marin Cilic 6-4, 3-6, 6-4, 4-6, 6-3 in a match that lasted 3 hours, 54 minutes and ended at 2:23 a.m.
No. 11 Jannik Sinner rallied from two games down in the fifth set to beat Ilya Ivashka 6-1, 5-7, 6-2, 4-6, 6-3.
The No. 1 woman, Iga Swiatek, moved into her first quarterfinal at Flushing Meadows by coming back to beat Jule Neiemeier 2-6, 6-4, 6-0.
“I’m just proud,” Swiatek said, “that I didn’t lose hope.”
The 21-year-old from Poland will face another first-time U.S. Open quarterfinalist: No. 8 Jessica Pegula, the highest-ranked American woman, who advanced with a 6-3, 6-2 victory over two-time Wimbledon winner Petra Kvitova.
Another women’s quarterfinal will be two-time major finalist Karolina Pliskova against No. 6 Aryna Sabalenka.
Nadal won the Australian Open in January and the French Open in June. Then he made it to the semifinals at Wimbledon in July before withdrawing from that tournament because of a torn abdominal muscle.
Nadal competed only once in the 1 1/2 months between leaving the All England Club and arriving in New York, where he has won four trophies.
He tweaked his service motion, tossing the ball lower than he normally does so as not to put as much strain on his midsection. There were plenty of signs Monday that his serve was not in tip-top shape: nine double-faults, a first-serve percentage hovering around 50%, five breaks by Tiafoe.
Earlier in the tournament, he lost the first set of his first-round match. Did the same in the second round, when he also accidentally cut the bridge of his nose and made himself dizzy when the edge of his racket frame bounced off the court and caught him in the face.
Still, on Monday, Nadal appeared on the verge of turning things around when he broke early in the fourth set and went ahead 3-1.
Tiafoe told himself: “Stay in it. Stay with him.”
That’s tied to two key areas Tiafoe credits with helping make him a stronger player of late: an improved in-match mindset and a commitment to fitness.
“Rafa is there every point. I’ve been known to have some dips in my game at times, where it’s like you’re watching (and thinking), ‘What’s that?!’” Tiafoe said. “That was my thing, match intensity.”
No concern now: He grabbed the last five games. The next-to-last break came for a 4-3 edge in the fourth set, when Nadal put a backhand into the net, and Tiafoe skipped backward toward the sideline for the ensuing changeover, his fist raised.
Fifteen minutes later, Tiafoe broke again, and it was over. This represents the latest significant step forward for Tiafoe, whose only previous trip to a Grand Slam quarterfinal came at the 2019 Australian Open — and ended with a loss to Nadal.
When one last backhand by Nadal found the net, Tiafoe chucked his racket and put his hands on his head. He glanced into the stands — Mom, Dad, brother, girlfriend, Washington Wizards All-Star Bradley Beal, others — then sat in his sideline chair and buried his face in a towel.
“It was just wild. My heart is going a thousand miles an hour. I was so excited. I was like: Let me sit down,” Tiafoe said. “Yeah, I’ve never felt something like that in my life, honestly.”
___
More AP coverage of U.S. Open tennis: https://apnews.com/hub/us-open-tennis-championships and https://twitter.com/AP_Sports | https://pix11.com/sports/ap-sports/ap-no-1-swiatek-comes-back-at-us-open-faces-no-8-pegula-next/ | 2022-09-06T13:08:53Z | https://pix11.com/sports/ap-sports/ap-no-1-swiatek-comes-back-at-us-open-faces-no-8-pegula-next/ | false |
Stark County program aims to keep children out of foster care, provide help to families
CANTON − Family Court Judge Rosemarie Hall has spent countless hours in her office talking to Stark County children involved in custody cases.
The majority have told her the same thing when she asked what they hope the outcome of the case will be.
"They want to stay with their parents," Hall said. "And we want them to stay there if at all possible. If they can be safe."
Removing children from their homes can be a traumatic experience. The National Library of Medicine reports that youth in foster care have a nearly 90% trauma exposure rate and are significantly more likely than the general population to have direct experience with violence, abuse or neglect. Last year, the Division of Children Services had a total of 649 children in agency custody, and currently there are 391 children.
Foster care in Stark County:Commentary: Stark County teens need adopted, including me
Several Stark County agencies have come together to create the Boosting Understanding, Interventions and Legal Defense program, otherwise known as B.U.I.L.D. The multi-agency initiative provides support and legal counsel to Stark County families in an effort to keep more children out of the foster care system. It is part of a larger pilot program through the Ohio Supreme Court.
What is Stark County's B.U.I.L.D. program?
The program is a collaboration between Job & Family Services, Family Court, the public defender's office, Community Legal Aid Services and Stark County Family Council.
Jerry Coleman, assistant deputy director of legal services for Stark County Job & Family Services, said the agency has strived in recent years to help families at risk of involvement in the child welfare or juvenile court systems through alternative responses. This practice aims "to help families access services, support and other help that will resolve concerns when a report is made without requiring a formal investigation of child abuse or neglect," according to Childrenservices.org.
One notable issue, Coleman said, is that many families do not have the ability to have legal representation prior to filing a case with Children Services.
'It's been a long journey.'Canton mom's road to redemption results in governor's pardon
"There were barriers at times that could have been removed through legal involvement or legal advice," he said.
Another problem is that even when agencies use alternative response methods, many families remain skeptical of the process.
"There's always an inherent distrust of the system," Coleman said. "There's always defensiveness when you come to court. It's just a natural anxiety of being drawn to court. You don't want to cooperate. You don't get the buy-in from families."
Hall is part of the Ohio Supreme Court's Child Welfare Quality Legal Representation Project. The initiative's main focus is to find a solution to limit the number of cases that end up in the system while prioritizing children's safety and limiting their exposure to trauma.
"When we remove kids, and they go through the process, these families struggle to do everything they're supposed to do in their case plan. So why would we think that some of these families would be doing wonderful if we tell them, 'Go do this. Go do this.' and they don't even have an attorney?"
The B.U.I.L.D. program provides custodial parents with an attorney at no cost in the early stages of a child welfare case. Hall said the attorney gives the parents legal advice and helps them understand their rights while the child still remains in the home.
Families also receive support from engagement specialist Monica Holt-Parish, who helps them meet the goals of their case plan.
"She's like a case manager wraparound person. ... She'll do anything that's needed to help this family, whether it's transporting them to a doctor's appointment, making an extra phone call for them, leading them through the system and giving them some confidence, giving them some peer support," Hall said.
The program is voluntary. Children Services refers eligible families.
Hall said 25 cases have been in the program so far, and the current caseload is 17. She said Holt-Parish expected to close five cases on Friday. She has already closed seven successful cases, Hall said. There has been only one case where children were removed from the home.
"We're hoping that with all this the success rate is going to be much higher," she said.
How is the program being funded?
The Ohio Supreme Court is funding the project in Stark, along with similar pilot programs in Summit, Wayne, Clark, Erie and Cuyahoga counties. Hall said each of the programs are slightly different. Summit County's initiative, for example, addresses issues once a complaint has already been filed by a family service agency.
The Ohio Supreme Court partnered with the state Department of Job and Family Services and the Ohio Children's Trust Fund for the project. It received $850,000 in federal grants from the Court Improvement Program for the project, according to the Ohio Supreme Court.
Stark County recently finished the first year of the project. It is a three-year grant cycle, Hall said, and they already have received approval for funding the program next year.
Coleman said the agencies are evaluating the program's success using both short-term and long-term criteria and comparing the results to cases that didn't utilize the program.
"There's the immediate measure that we're doing (which) is while this case is open, did we successfully get through the program and not have to file? Then we're also looking longitudinal in the long term. Did the family come back again? Did those changes ... keep families from coming back in?" he said.
They said they hope if the program is a success that they will be able to expand it.
"We're just trying to evaluate it all the way through and see what we can do to help these families to keep children in the home, families together and keep them safe," Hall said.
Reach Paige at 330-580-8577 or pmbennett@gannett.com, or on Twitter at @paigembenn. | https://www.cantonrep.com/story/news/local/stark-county/2022/09/06/stark-county-initiative-aims-to-keep-children-out-of-foster-care/65409656007/ | 2022-09-06T13:11:23Z | https://www.cantonrep.com/story/news/local/stark-county/2022/09/06/stark-county-initiative-aims-to-keep-children-out-of-foster-care/65409656007/ | true |
GMMI reaffirms its commitment to delivering high-quality care to members while managing client costs.
PEMBROKE PINES, Fla., Sept. 6, 2022 /PRNewswire/ -- GMMI – the U.S. cost containment entity of Generali Global Assistance – today announced that it has earned URAC accreditation for its Health Utilization Program. This year marks GMMI's 30th anniversary as the pioneer and leader of the U.S. and international cost containment landscape.
"This is yet another milestone to achieve our vision to be the most reliable care company in the world. GMMI's URAC accreditation is a testament of the quality of care all our client's members can experience as we bring them from distress to relief. Anytime, anywhere," said Chris Carnicelli, CEO.
URAC is the nation's leading health care accrediting organization and the undisputed leader in telehealth accreditation. Earning a URAC accreditation means that GMMI's Care Management Program follows the industry's most rigorous standards while reinforcing its commitment to quality improvement.
Zaydee Capo, RN., BSN., CCM., Vice President of Healthcare Services added: "GMMI's Health Utilization Management Program focuses on cost containment while ensuring our client's and members have accessibility, quality, and timeliness of care. GMMI maintains a critical role in improving patient care and health outcomes. Receiving the URAC 'Gold Star Standard' recognizes our commitment to quality and accountability."
Watch GMMI's Medical Team on URAC's accreditation of GMMI: https://youtu.be/NHAgcuq4504
About GMMI, Inc.
GMMI delivers industry-leading medical cost containment and medical risk management solutions that elevate standards of care. Through best-in-class provider networks, multilingual customer service, URAC accredited case management, and prompt and efficient claims administration worldwide, we provide members with exceptional care at the right time and the right place for the right cost.
To learn more, please visit: https://www.gmmi.com
About Generali Global Assistance
Generali Global Assistance (GGA) is a leading brand comprised of Travel Insurance & Assistance, Cost Containment, Identity & Cyber Protection, as well as other care services. GGA is part of the Generali Group, which for over 190 years has provided peace of mind to its clients and their customers and is now supported by more than 72,000 employees worldwide. Our success has been built on establishing trust by putting the customer at the core of everything we do, offering assistance and protection during our customer's most difficult and stressful situations.
To learn more, please visit: https://us.generaliglobalassistance.com/
CONTACT: Patrick Jordan, pjordan@mgroupsc.com, 9176762190
View original content to download multimedia:
SOURCE Generali Global Assistance | https://www.kbtx.com/prnewswire/2022/09/06/gmmi-earns-urac-accreditation-its-health-utilization-management-program/ | 2022-09-06T13:12:58Z | https://www.kbtx.com/prnewswire/2022/09/06/gmmi-earns-urac-accreditation-its-health-utilization-management-program/ | true |
This is a carousel. Use Next and Previous buttons to navigate
States around the country are making it easier for new moms to keep Medicaid in the year after childbirth, a time when depression and other health problems can develop.
But tight government budgets and the program’s low reimbursement may ultimately limit this push or make it hard for women with extended coverage to find doctors.
“A lot of things have changed since the pandemic,” said Venessa Aiken, a new mom in Orlando, Florida. “A lot of places no longer take Medicaid or if they do, you have to wait like two months before you can be seen.”
Many women enroll in government-funded Medicaid health insurance when they become pregnant, because qualifying income levels are higher than for women who aren’t pregnant. The federal government requires states to maintain that coverage for 60 days postpartum, or after the baby arrives. After that, moms in many states lose the coverage unless their income levels are extremely low.
Since the spring, 23 states and Washington, D.C., have said they will extend that coverage for a full year postpartum. Several more states are planning to do so.
These extensions will start helping people after the federal government’s COVID-19 public health emergency ends because states are required to keep patients enrolled during the emergency. It currently will extend at least into early next year.
The push to extend coverage has grown to include both conservative and liberal-leaning states. It also is endorsed by President Joe Biden’s administration as a way to improve equality: Postpartum mortality rates can be much higher among Black and American-Indian or Alaskan Native populations.
“There’s no reason why we should stop before we have every particular mother and baby (covered),” Health and Human Services Secretary Xavier Becerra told The Associated Press. “Why wouldn’t you want to provide to a new mother and new baby a full year’s peace of mind?”
The state and federally funded Medicaid program covers prenatal doctor visits for moms and about 42% of births in the U.S.
Having that coverage eliminated some stress for Maureen Forman, who said she was already concerned about her pregnancy when she gave birth to her son last year.
“It was really nice not to worry,” the 41-year-old Bloomington, Indiana, resident said. “I just knew it was all going to be covered. I wish other pregnant women had that same experience.”
Care providers and researchers say that coverage should extend well beyond 60 days after the baby arrives.
They note that many new moms need more time to squeeze in doctor visits while they recover from childbirth and care for a newborn. Some also are juggling a return to work while doing this.
A coverage extension “matches the reality of the postpartum period,” said Usha Ranji of the non-profit Kaiser Family Foundation, which researches health care issues.
Issues like postpartum depression can develop months later, and some mothers might have lingering health problems that need care. Some also may need continued substance abuse treatment.
Those who lose coverage may not be able to afford another option like private insurance.
The non-partisan Congressional Budget Office estimated last year that about 45% of women on Medicaid will become uninsured after the 60-day postpartum coverage period ends.
While nearly half the states have expanded the coverage, health economist Joe Antos said he thinks others will hesitate to add the expense to their budgets.
Mississippi lawmakers scuttled a bill earlier this year that would have extended postpartum coverage partly over concerns about expanding the program.
The coverage extensions, which last five years, are backed partly by funding from the 2021 American Rescue Plan Act. States will have to pay some of the bill.
If the economy slides into a recession, “state enthusiasm for further expansions will also drop off as their own budgets tighten up,” said Antos, who's with the American Enterprise Institute.
Extending the coverage does not automatically guarantee better care, because finding doctors can be difficult.
Jennie Joseph says the idea of trying to get a referral to a mental health specialist for a Medicaid patient is “laughable.” The Florida midwife said patients first have to find a doctor to provide that referral and then land a therapist who accepts Medicaid, which is even harder.
Joseph is the founder of Commonsense Childbirth, a nonprofit that operates a birth center and clinic in central Florida. She said low Medicaid reimbursement rates and payment hassles are challenging for care providers. She said the government program pays her clinic less than half of what a commercial insurer would pay for a prenatal visit. Medicaid reimbursement for postpartum visits is even less, as little as $34.
“It’s all about trying to get your claim paid, and they are more readily denied than they are paid,” she said. “Because of that, providers don’t make postpartum appointments for these mothers.”
Aiken, the Orlando newborn mom, gave birth at Joseph’s center in July. She has had a hard time getting a call back from her primary care doctor's office, and she's worried about getting a referral to a specialist.
“It’s pretty confusing," she said. "Who do you turn to when you don’t have a (primary care physician)?”
Becerra said he knows that doctor access must be improved. But he sees the coverage extensions as a step toward making things better.
“Let’s get people through the door and let’s continue to work to increase the number of quality caregivers who will be there to meet those folks,” he said. “But today we have hundreds of thousands of women and babies who can’t even walk through the door. “
___
Follow Tom Murphy on Twitter: @thpmurphy
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. | https://www.stamfordadvocate.com/business/article/Medicaid-extensions-for-new-moms-grow-may-run-17420131.php | 2022-09-06T13:15:17Z | https://www.stamfordadvocate.com/business/article/Medicaid-extensions-for-new-moms-grow-may-run-17420131.php | false |
VANCOUVER, BC, Sept. 6, 2022 /PRNewswire/ - PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) ("PlantX" or the "Company"), the digital face of the plant-based community, operating a one-stop shop for plant-based products, today announced unaudited monthly financial metrics for August 2022.
PlantX generated monthly gross revenue of $1.381 million in August 2022, an increase of 32% compared to $1.048 million in August 2021. The increase was driven primarily by expansion of our distribution channels and retail footprint. Gross profit for August 2022 was $525,000, or 38% gross margin, compared to gross profit of $367,000, or 35% gross margin in August 2021. Notably, the Little West cold-pressed juice brand continues to generate strong sell-through across its retail distribution partners. Additionally, the Chicago Uptown location had its best month since it was acquired by PlantX in December 2021. This growth was driven by expanded selection and special events.
"PlantX continues to generate significant year-over-year growth, driven by positive market reception to the Little West cold-pressed juice brand and the success of live events at our retail locations to drive store traffic as we build loyal customers," said PlantX CEO, Lorne Rapkin. "Consumers increasingly see PlantX as the first stop for all things involved with the plant-based lifestyle, and this growing presence is resulting in revenue acceleration."
The financial metrics disclosed in this press release are management prepared and have not been audited or reviewed by the Company's auditors. Unless otherwise indicated, all amounts are expressed in Canadian dollars.
As the digital face of the plant-based community, PlantX's platform is a one-stop shop for plant-based products. With its fast-growing category verticals, the Company offers customers across North America more than 5,000 plant-based products. In addition to offering delivery service for meals and indoor plants, the Company currently has plans underway to expand its product lines to include a juice and coffee company. The Company uses its digital platform to build a community of likeminded consumers and, most importantly, to provide education. Its successful enterprise is being built and fortified on partnerships with the top nutritionists, chefs, and brands. The Company's digital presence works to eliminate the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier, and happier life.
Connect with PlantX: Email | Website | Facebook | LinkedIn | Twitter | Instagram | YouTube | TikTok
This press release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may," "will," "expect," "likely", "should," "would," "plan," "anticipate," "intend," "potential," "proposed," "estimate," "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, statements regarding the business and strategic plans of the Company.
By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: receiving sufficient demand for the Offering; the Company's ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; the conflict in eastern Europe; having a limited operating history; the ability of the Company to access capital to meet future financing needs; the Company's reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.
Additional risk factors can also be found in the Company's continuous disclosure documents, which have been filed on SEDAR and can be accessed at www.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
View original content to download multimedia:
SOURCE PlantX Life Inc. | https://www.kbtx.com/prnewswire/2022/09/06/plantx-announces-monthly-gross-revenue-14-million-august-2022-up-32-year-over-year/ | 2022-09-06T13:16:35Z | https://www.kbtx.com/prnewswire/2022/09/06/plantx-announces-monthly-gross-revenue-14-million-august-2022-up-32-year-over-year/ | true |
PROVIDENCE, R.I. (AP) — The heavy rain that caused street flooding and forced the closure of major roads in Rhode Island on Labor Day was expected to continue on Tuesday, according to the National Weather Service.
Nearly 11 inches of rain had fallen in the city of Cranston by early Tuesday, according to a weather service report, while some other areas of the state got around eight inches of rain.
A flood warning remains in effect in northern parts of the state.
The rain blocked Interstate 95 and other roads in and around Providence and stranded several drivers on Monday, but the roadway was reopened later in the evening, the state Transportation Department said in a tweet.
Agency Peter Alviti said at a Monday news conference that the rain was overwhelming the drainage systems.
“It was simply that the rain came down at an intensity that exceeded its capacity to accept it,” he said.
Even though commuters were expected to take to the roads after the long holiday weekend, Gov. Dan McKee advised people to “avoid unneccesary travel" and not to drive through floodwaters.
In Providence, an unccupied building collapsed, and at Brown University about 30 students were temporarily displaced from their dorm when rainwaters flooded a lower floor. | https://www.sfgate.com/news/article/Heavy-rains-that-flooded-Rhode-Island-streets-17421743.php | 2022-09-06T13:18:19Z | https://www.sfgate.com/news/article/Heavy-rains-that-flooded-Rhode-Island-streets-17421743.php | false |
The Sensex and Nifty closed modestly lower on Tuesday after investors offloaded FMCG, IT and banking stocks in the last hour of trade amid mixed global cues.
ADVERTISEMENT
The selling pressure emerged towards the fag-end of the session.
After rising over 320 points in intra-day trade, the 30-share BSE Sensex pared all gains to settle 48.99 points or 0.08% lower at 59,196.99. During the day, it hit a high of 59,566.67 and a low of 58,974.26.
The NSE Nifty also slipped 10.20 points or 0.06% to 17,655.60.
ADVERTISEMENT
From the Sensex pack, Bajaj Finserv, Kotak Mahindra Bank, Hindustan Unilever, Mahindra & Mahindra, Bajaj Finance and Nestle were among the major laggards.
On the other hand, Bharti Airtel, NTPC, Tata Steel, Reliance Industries and Power Grid were among the major gainers.
Elsewhere in Asia, markets in Seoul, Tokyo and Shanghai ended in the green, while Hong Kong settled lower.
Equities in Europe were trading higher during the mid-session deals. The U.S. markets were closed on Monday.
"Domestic indices wiped out its early gains to close flat, tracking mixed global cues," said Vinod Nair, Head of Research at Geojit Financial Services.
Meanwhile, the international oil benchmark Brent crude declined 2.37% to $93.47 per barrel.
Foreign institutional investors (FIIs) offloaded shares worth ₹811.75 crore on Monday, as per the exchange data.
"Nifty failed to capitalise on the early gain as profit-taking happened," said Rupak De, Senior Technical Analyst at LKP Securities. | https://www.thehindu.com/business/markets/markets-settle-modestly-lower-in-volatile-trade/article65857174.ece/amp/ | 2022-09-06T13:18:38Z | https://www.thehindu.com/business/markets/markets-settle-modestly-lower-in-volatile-trade/article65857174.ece/amp/ | false |
HENGCHUN, Taiwan (AP) — Taiwanese President Tsai Ing-wen said Tuesday that China is conducting “cognitive warfare” by spreading misinformation in addition to its regular incursions into nearby waters and airspace intended at intimidating the self-governing island.
Experts have warned that China has made substantial inroads within Taiwanese mass media and could plant false narratives in social media and elsewhere to erode military morale and public confidence in the event it makes good on its threat to use force to take control of the island it claims as its own territory.
“The situation around the Taiwan Strait continues to be tense, and the threat has never ceased," Tsai said in a speech during a visit to an air defense and missile battalion in the eastern country of Hualien.
“In addition to frequent intrusions by China’s aircraft and ships, China also conducted cognitive warfare, using false information to create disturbance in minds of people," the president said.
Tsai also referenced China's use of drones “to increase pressure on Taiwan’s military,” following incidents in which Taiwanese troops based on islands just off the Chinese coast warned off and in once case, shot down unmanned aerial vehicles that had been hovering over their positions.
Anti-drone defenses are included in a 12.9% increase in Taiwan's budget for next year. The rise will increase total spending to $13.8 billion, or roughly 2.4% of GDP.
Taiwan on Tuesday was also launching military exercises on the Hengchun Peninsula in the far south of the island simulating ground warfare against an invading enemy, aided by Apache attack helicopters.
Alongside promoting Taiwan's high-tech economy, Tsai has made strengthening the island's defenses a key feature of her second and last four-year term in office. That includes bulking up the domestic defense industry as well as procuring more weaponry from the U.S., including fighter jets and missiles, to resist a Chinese attack or attempted blockade.
On Friday, the Biden administration announced a $1.09 billion sale, including $355 million for Harpoon air-to-sea missiles and $85 million for Sidewinder air-to-air missiles, the State Department said.
The largest portion of the sale, however, is a $655 million logistics support package for Taiwan’s surveillance radar program, which provides air defense warnings. Early warning air defense systems have become more important as China has stepped up military drills near Taiwan.
Tensions that have been running high ever since Tsai's initial 2016 election and spiked last month when U.S. House Speaker Nancy Pelosi visited Taipei. China fired missiles into the Taiwan Strait and over the island into the Pacific and sent ships and planes across the midline of the strait that had long been a buffer against outright conflict.
Since Pelosi’s trip to Taipei, there have been at least two other congressional visits and several by governors of U.S. states, all of which China has condemned. The U.S. also sent a pair of guided missile cruisers through the strait in defiance of China's claims that the waterway, one of the busiest in the world, belongs to it entirely.
Responding Tuesday to the U.S. arms sale, China's Defense Ministry accused Washington of “making trouble," adding, “We demand that the U.S. side immediately withdraw the above-mentioned arms sales plan to Taiwan and immediately cease military ties between the U.S. and Taiwan."
“The Chinese People’s Liberation Army continues to train and prepare for war, and will resolutely thwart any interference by an external force and separatist ‘Taiwan independence' plots," the ministry said in a statement posted on its website.
___
Associated Press video journalist Johnson Lai contributed to this report. | https://www.sfgate.com/news/article/Taiwan-leader-cites-threat-of-Chinese-cognitive-17421667.php | 2022-09-06T13:19:14Z | https://www.sfgate.com/news/article/Taiwan-leader-cites-threat-of-Chinese-cognitive-17421667.php | false |
‘Ahimsa Santhai,’ a five-day fair to promote local eco-friendly initiatives and support the rural economy, is to be held between September 22 and 26 in Gandhi Memorial Museum near here.
The fair is jointly organised by the museum, Centre for Experiencing Socio Cultural Interaction (CESCI) and International Gandhian Institute of Nonviolence and Peace (IGINP).
Addressing press persons, P.V. Rajagopal, advisor, CESCI, said the fair would be inaugurated by former Bhutan Prime Minister Jigmi Y. Thinley and Madurai MP Su. Venkatesan.
“The fair aims to popularise the concept of nonviolent economy among the masses, especially youth, who must realise their role in fighting against the climate crisis. A change is not possible through holding conferences but through our behaviour and choices we make,” he said.
“Through the fair, we want to bridge the gap between producers of healthier and eco-friendlier products and consumers to adopt green methods of living,” said Mr. Rajagopal.
IGINP director Jill Carr Harris said the fair would house more than 140 stalls showcasing a range of products such as handicrafts, organic food, handloom textile, herbal items by small-scale local producers, organic farmers, rural artisans and women’s groups from Tamil Nadu, Kerala, Karnataka, Andhra Pradesh and Telangana.
The organisers said that hands-on-work workshops such as natural dyeing, terrace gardening, spinning, pottery, carpentry, documentary screening, photo exhibition, panel discussions and sessions by over 40 speakers, social workers and experts and cultural events are also scheduled.
Gandhi Memorial Museum Director (Administration) K.R. Nanda Rao said the fair’s first day marked the centenary year of the historic event of Mahatma Gandhi changing into a loincloth in Madurai. “The fair is a befitting tribute to the Mahatma which will enable us to inch towards a nonviolent way of living.”
The entry-free fair would be open between 10 a.m. and 9 p.m. | https://www.thehindu.com/news/cities/Madurai/five-day-fair-to-be-held-to-promote-rural-eco-friendly-initiatives/article65856913.ece | 2022-09-06T13:21:17Z | https://www.thehindu.com/news/cities/Madurai/five-day-fair-to-be-held-to-promote-rural-eco-friendly-initiatives/article65856913.ece | true |
Wet weather moves into Northeast as thunderstorms sweep Gulf Coast, Southeast
Dangerous heat remains a threat for the West
Heavy rain has moved into the Northeast, where flooding has already caused issues for Rhode Island.
CALIFORNIA WILDFIRE LEAVES 2 DEAD, EXPLODES TO 700 ACRES AS EVACUATIONS ARE ORDERED
The wet weather will continue through Wednesday.
Dangerous record-breaking heat remains a big story for the West, including California.
The high temperatures combined with dry conditions have elevated the fire risk for the Northwest and northern High Plains.
Showers and storms are going to set up again for flood-prone regions along the Gulf Coast and Southeast later this week.
CLICK HERE TO GET THE FOX NEWS APP
The Tropics are active, with several systems swirling around in the Atlantic, but with no major impacts on the U.S. coast. | https://www.foxnews.com/us/wet-weather-moves-into-northeast-thunderstorms-sweep-gulf-coast-southeast | 2022-09-06T13:21:50Z | https://www.foxnews.com/us/wet-weather-moves-into-northeast-thunderstorms-sweep-gulf-coast-southeast | false |
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)
Mariya Yukhymenko, California State University, Fresno
(THE CONVERSATION) The Research Brief is a short take about interesting academic work.
The big idea
When it comes to academic success for college students, having a sense of purpose and gratitude makes a significant difference. That’s what I found in a peer-reviewed study published in June 2022 in the Journal of College Student Retention: Research, Theory & Practice.
For the study, I analyzed answers provided by 295 undergraduates to questions about whether they did better academically if they had a sense of purpose and gratitude during the COVID-19 pandemic.
I wondered if students were more likely to be academically engaged – and less likely to suffer academic burnout – if they had a strong sense of purpose. I specifically asked about three types of purpose: self-growth, others-growth and career-focused purpose orientations. I also wanted to know if being grateful for positive experiences made a difference.
I defined academic engagement as a motivational mindset that is characterized by students’ enthusiasm for school-related activities. I also looked at three types of academic burnout: devaluation of schoolwork, reduced sense of accomplishment and mental exhaustion.
I found that only one type of purpose was directly relevant to engagement and burnout - career-focused purpose. When undergraduate students connect their life purpose with career aspirations, they tend to be engaged in their academic studies. They are also less likely to devalue their schoolwork or feel unaccomplished in their studies.
I also found that gratitude was just as important. These findings suggest that the more grateful undergraduate students feel, the more they are engaged in their academic work and the more they feel accomplished and value schoolwork.
Why it matters
This study adds to a growing body of research that suggests having a deep sense of life purpose is important for people’s well-being, success and ability to cope with challenging life situations.
My study suggests that university advisers and faculty should recognize the role that sense of purpose plays for student success. They should also engage in practices that foster students’ sense of life purpose. For example, faculty members can use assignments to encourage students to reflect on their life purpose and connect it with their future career aspirations.
Fostering gratitude is also important. This is because gratitude is also associated with greater academic engagement and less burnout among undergraduate students. My study also suggests that it benefits students if they are given opportunities to reflect on things in life for which they are grateful. Such opportunities can be incorporated into first-year experience courses or incoming student orientations.
What still isn’t known
Since this study was conducted when participants had few, if any, opportunities to help others due to COVID19 restrictions, I wonder if others-growth and self-growth types of purpose will be more relevant to academic success once these restrictions are eased.
I also wonder whether classroom activities aimed at connecting life purpose with students’ future careers will lead to higher graduation rates.
What’s next?
As part of Graduation Initiative 2025 – an initiative is meant to increase graduation rates and close gaps in the rates of graduation between different groups – my colleague Gitima Sharma and I created an undergraduate course, titled “Fostering Sense of Purpose.” Our preliminary data showed that students who took this course in spring of 2022 reported a strengthened sense of life purpose. We plan to continue to examine how effective the course is at fostering sense of purpose in life. We also plan to look at whether the course leads to lasting positive effects for students’ academic and career success, such as higher graduation rates.
This article is republished from The Conversation under a Creative Commons license. Read the original article here: https://theconversation.com/purpose-and-gratitude-boost-academic-engagement-186623. | https://www.mrt.com/news/article/Purpose-and-gratitude-boost-academic-engagement-17421732.php | 2022-09-06T13:22:19Z | https://www.mrt.com/news/article/Purpose-and-gratitude-boost-academic-engagement-17421732.php | true |
PASADENA, Calif., Sept. 6, 2022 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) today announced that its Board of Directors declared a quarterly cash dividend of $1.18 per common share for the third quarter of 2022. The dividend is payable on October 14, 2022, to shareholders of record on September 30, 2022. The common stock dividend for the 12 months ending September 30, 2022, of $4.66 per common share represents an increase of 24 cents, or 5 percent, over the 12 months ended September 30, 2021.
The dividend allows the company to share its continued high-quality, strong and increasing net cash provided by operating activities with its common shareholders while retaining a significant portion for reinvestment into its highly leased pipeline of new Class A development and redevelopment projects. For the 10-year period ending December 31, 2022, the company expects an aggregate $2.0 billion of cash flows from operating activities after dividends will have been generated for reinvestment. Additionally, its funds from operations (FFO) payout ratio (quarterly common stock dividends divided by quarterly funds from operations) remains favorably low at 56 percent for the three months ended June 30, 2022. Growth in the company's net cash flows provided by operating activities continues to generate opportunities to increase the company's quarterly cash dividend per common share while maintaining a low FFO payout ratio.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® urban office real estate investment trust, is the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations. Founded in 1994, Alexandria pioneered this niche and has since established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland and Research Triangle. For more information, please visit www.are.com.
This press release contains "forward-looking statements" within the meaning of the federal securities laws. Actual results might differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in the company's Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission.
CONTACT: Sara Kabakoff, Vice President – Communications, (626) 788-5578, skabakoff@are.com
View original content:
SOURCE Alexandria Real Estate Equities, Inc. | https://www.wlbt.com/prnewswire/2022/09/06/alexandria-real-estate-equities-inc-declares-cash-dividend-118-per-common-share-3q22-an-aggregate-466-per-common-share-12-months-ending-september-30-2022-up-24-cents-or-5-percent-over-12-months-ended-september-30-2021/ | 2022-09-06T13:23:30Z | https://www.wlbt.com/prnewswire/2022/09/06/alexandria-real-estate-equities-inc-declares-cash-dividend-118-per-common-share-3q22-an-aggregate-466-per-common-share-12-months-ending-september-30-2022-up-24-cents-or-5-percent-over-12-months-ended-september-30-2021/ | true |
PARIS, Sept. 6, 2022 /PRNewswire/ -- Global turnover from Fine Art auction sales increased by 8.8% in H1 2022, despite another wave of Covid-19 in China. Artprice counted a record number of auction transactions around the world and observes a growing enthusiasm for works by artists from the second half of the 20th and the beginning of the 21st century, whose prices are highly volatile.
Four indicators of the health of global Fine Art auction activity in H1 2022
Infographic - https://mma.prnewswire.com/media/1891851/Artmarket_Fine_Art_Infographic.jpg
thierry Ehrmann, President, and Founder of Artmarket.com: "A comprehensive study of the results of public auctions reveals growing competition between New York, London, and Hong Kong. This competition is rapidly inflating the prices of works by young artists to levels usually reserved for great masters. On the occasion of the Frieze London and Paris+ fairs (the latter run by Art Basel), Artprice will be publishing an exclusive report dedicated to 'Ultra Contemporary' Art: a term that designates a dynamic that is developing around artists under 40 years old, like Matthew Wong, Avery Singer, and Refik Anadol.
The analysis of the Art Market presented in this H1 2022 Report is based on the Fine Art public auction results recorded by Artprice and only concerns paintings, sculptures, drawings, photographs, prints, videos, installations, tapestries as well as NFTs, and excludes antiquities, anonymous cultural property, and furniture. All prices indicated in this Report refer to public auction results, including buyers' fees, and the $ sign refers to the US dollar.
H1 2022 KEY FIGURES
- Global Fine Art auction proceeds reached $7.49 billion.
- The art market's 5th most prosperous H1 period ever recorded.
- An increase of 8.8% versus H1 2021.
- A record 326,000 lots sold in H1 2022 versus 313,400 in H1 2021
- Christie's hammered the 2nd best art auction result of all time at $195 million.
- The unsold rate rose to 31% versus 27% in H1 2021.
- With a turnover of $3.27 billion, New York was clearly the world's leading marketplace.
- In second and third place, London hammered $1.43 billion and Hong Kong took $610 million.
- Not far behind, the Parisian art market generated $518 million and has attracted a growing number of international institutions.
- Christie's and Sotheby's account for 38% of global fine art turnover.
- The Macklowe Collection became the most expensive collection ever sold in the world, generating $922 million.
- 180 NFTs sold at auction generating $8.5 million.
ORGANIZATION AND STRUCTURE OF THE ART MARKET
As the health crisis wanes worldwide, Fine Art auctions settled down to an unsold rate of 31%, almost one in three works offered for sale. This level corresponds to a stable average over the last twenty years, fluctuating between 36% in 2009 and 27% in 2021. Indeed, this key market indicator has reacted quite differently compared with how it reacted in the last major crisis that affected the global art market, the 2009 financial crisis. Back then, collectors decided to take less financial risk, whereas the health crisis of 2021 prompted buyers to switch to a new entirely dematerialized sales channel.
In the first half of 2022, the market found a new balance thanks to the coexistence of two different and complementary sales channels (one physical, the other digital), which allowed auction transactions to continue at a healthy pace reaching a historic number of 326,000 Fine Art lots in six months. In H1 2022 this volume further increased to an unprecedented intensity, despite the postponement of many auctions in China (whose turnover volume is down 53%) due to an additional wave of Covid-19.
The United States (up 42% vs. H1 2021) and the UK (up 26%) have driven growth. The two powerful Anglo-Saxon markets alone accounted for exactly two-thirds of global Fine Art auction turnover. China, for its part, only accounted for 12% of global fine art auction turnover, a result that it owes in large part to Hong Kong which accounted for 70% of the value of the entire Chinese art market (including Hong Kong, Macao, and Taiwan).
France continued to grow (+14%) consolidating its 4th place ahead of Germany (-5%) after a sensational performance in 2021. In addition to the presence of Christie's and Sotheby's, several Parisian auction operators posted exceptionally strong performances: Artcurial (+42%) and Aguttes (+154%), among others. Meanwhile, The French capital is attracting a growing number of major international players like David Zwirner, while the Gagosian and Continua galleries have opened new spaces in France. Paris is delighted to see the upcoming arrival of Hauser & Wirth as well as the opening of a Phillips auction room. Bonhams has acquired the French house Cornette de Saint-Cyr (operating in Paris and Brussels). Lastly, the Art Basel company will henceforth be the official organizer of the international autumn art fair organized at the Grand Palais in Paris, entitled Paris+, which will replace the FIAC.
Japan and Switzerland also had an excellent start to 2022 with increases of 74% and 145% in their respective auction turnover totals. Without directly competing with Hong Kong (which still weighs seven times more), Tokyo is positioning itself on the Asian continent as a hub for major contemporary artists, including Andy Warhol, Yoshitomo Nara, Yayoi Kusama, but also young talents like Mr Doodle and Ayako Rokkaku (born in 1982), whose auction sales have already exceeded $18.6 million this year. For its part, Switzerland is continuing to carve out a place for itself in the Post-Impressionist and Modern Art market, with sales of important works by Ferdinand Hodler, Alberto Giacometti, and Marc Chagall.
Ferdinand Hodler, Der Brienzersee von Breitlauenen aus (1906); sold for CHF 2,875,000 (~$3 million) on 17 June 2022 by Galerie Kornfeld in Bern
Photo - https://mma.prnewswire.com/media/1891852/Artmarket_Ferdinand_Hodler.jpg
TRENDS: NFTs AND ULTRA CONTEMPORARY ART
Propelled to center stage in March 2021 with a first public auction result at $69.4 million, NFTs (non-fungible tokens) have created something of a revolution in the art market, with a new type of work, new collectors, and a new currency.
Of the 277 NFTs auctioned in H1 2022, 65% sold for an average price of $47,000. This situation is very different from H2 2021 in which 225 NFTs were offered for sale, of which 86% sold at an average price of $520,000. Beeple's Human One (2021) fetched nearly $29 million last November at Christie's, whereas the best NFT result in H1 2022 was just $1.38 million for Living Architecture: Casa Batlló (2022) by Refik Anadol.
The 104 CryptoPunks that Sotheby's announced in February 2022 were finally withdrawn on the eve of their scheduled sale. The withdrawal of such a lot, estimated between $20 and $30 million, underscores the extent to which NFT market players remain somewhat skeptical about the service provided by traditional intermediaries. Not only are they expensive (transaction costs amount to an average of 20% compared with around 2% to 3% via NFT platforms) but they also are governed by a much less flexible schedule. The major auction houses are nevertheless continuing their efforts to participate in this emerging market, although they only very rarely sell major NFT collections (BAYC, WoW, etc.). For the time being, such projects no longer seem to need the marketing efforts or the legitimacy of regulated auction houses.
At the same time, the volatility of cryptocurrencies, has exacerbated the mistrust of traditional collectors vis-à-vis this disruptive market. Fortunately, this lull will provide a good number of artists, dealers, collectors, and institutions – starting with museums – an opportunity to take an interest in digital works and to consider acquiring NFTs without the pressure of record sales and over-mediatization.
The NFT phenomenon stems from the same enthusiasm that Artprice is observing for the work of young artists, some of whom are eliciting record multi-million dollar results even before their work has been exhibited in a major museum or before they have even enjoyed a solo show in a gallery. The recent auction records for works by artists under 40 (whose very recent works are already trading on the secondary market) will be analyzed by the next Artprice Ultra Contemporary Art Report to be published in October 2022. This will notably be an opportunity to highlight the growing success and influence of young female painters.
Top 10 personal records for living artists under 40 at auction in H1 2022
©artprice.com
1. Avery Singer (1987): $5,253,000
2. Christina Quarles (1985): $4,527,000
3. Jennifer Packer (1984): $2,349,000
4. María Berrio (1982): $1,562,500
5. Robbie Barrat (1999): $841,317
6. Robert Nava (1985): $639,401
7. Issy Wood (1993): $588,042
8. Lauren Quin (1992): $588,042
9. Louis Fratino (1993): $365,400
10. Jordy Kerwick (1982): $277,200
FIVE EXCEPTIONAL RESULTS IN H1 2022
Andy Warhol's Shot Sage Blue Marilyn elicited the second highest ever art auction bid. For the first time since Leonardo Da Vinci's Salvator Mundi in November 2017 (four and a half years ago), the ultra-high-end market is back with a result that once again questions the notion of an absolute masterpiece and its value. The charity sale that produced this result was guaranteed by Christie's and ended with a result of $195 million (including fees). The 'painting' was acquired by Larry Gagosian himself, the powerful gallery owner who had already sold the canvas to Thomas Ammann in the early 1980s.
The French auction house Artcurial had the honor of presenting an exceptional still-life by Jean-Baptiste Chardin, Le panier de fraises des bois, painted in 1761 and exhibited the same year at the Grand Salon in Paris. While this was the first appearance of this painting at auction, art expert Eric Turquin insists on the immense historical importance of the work, importance to which the labels on the back of the painting attest, having been included in many prestigious exhibitions around the world. A gentle and magic painting, the Jean-Baptiste Chardin masterpiece was estimated between $13 and $16 million and finally sold for $26.8 million.
The biggest sensation of the year was undoubtedly created by the canvas The Sugar Shack (1976) by Ernie Barnes (1938 - 2009). Last year, the African-American painter set a new auction record at $550,000. But on 12 May this year, Christie's proposed his painting The Sugar Shack (1976) in New York with an estimate of $150,000 - $200,000. The work finally sold for $15,275,000, more than 100 times the low estimate. In the days and weeks that followed, six more important Ernie Barnes paintings were offered at Christie's and Bonhams, and they all sold well beyond their estimates.
Last year, the Japanese artist Yayoi Kusama became the first female artist to enter the world's Top 10 performing artists as calculated by Artprice (all periods of creation combined). She was also the third best performing living artist of the year behind Gerhard Richter and Banksy. This year, Yayoi Kusama has repeated that performance with 208 lots sold worldwide for more than $115 million. She also set a new auction record when her Untitled (Nets) (1959) reached $10.5 million at Phillips on 18 May 2022.
Matthew Wong would have been 38 if he hadn't taken his own life in 2019. Since his death, his paintings have enjoyed stunning success in auction rooms. On 19 May 2022, his Night Watcher (2018) was acquired for $5.9 million at Christie's New York. In H1 2022, Matthew Wong ranked 52nd in the global ranking of artists by auction turnover (all periods of creation combined), a success that has a certain Basquiat flavor to it, even if Wong's place in art history has not yet been recognized.
Read Artprice.com's H1 2022 Global Art Market Report online at:
The information and econometric studies produced by Artmarket.com are presented uniquely for the purpose of analyzing and understanding the statistical realities of the art market and should in no way be considered as advice or a suggestion or a solicitation to invest in the art market.
[https://imgpublic.artprice.com/img/wp/sites/11/2022/08/image2-Ferdinand-Hodler.jpeg]
Copyright 1987-2022 thierry Ehrmann www.artprice.com - www.artmarket.com
Don't hesitate to contact our Econometrics Department for your requirements regarding statistics and personalized studies: econometrics@artprice.com
Try our services (free demo): https://www.artprice.com/demo
Subscribe to our services: https://www.artprice.com/subscription
Artmarket.com is listed on Eurolist by Euronext Paris, SRD long only and Euroclear: 7478 - Bloomberg: PRC - Reuters: ARTF.
Discover Artmarket and its Artprice department on video: www.artprice.com/video
Artmarket and its Artprice department was founded in 1997 by its CEO, thierry Ehrmann. Artmarket and its Artprice department is controlled by Groupe Serveur, created in 1987.
See certified biography in Who's who ©:
Biographie_thierry_Ehrmann_2022_WhosWhoInFrance.pdf
Artmarket is a global player in the Art Market with, among other structures, its Artprice department, world leader in the accumulation, management and exploitation of historical and current art market information in databanks containing over 30 million indices and auction results, covering more than 787,000 artists.
Artprice by Artmarket, the world leader in information on the art market, has set itself the ambition through its Global Standardized Marketplace to be the world's leading Fine Art NFT platform.
Artprice Images® allows unlimited access to the largest Art Market image bank in the world: no less than 180 million digital images of photographs or engraved reproductions of artworks from 1700 to the present day, commented by our art historians.
Artmarket with its Artprice department accumulates data on a permanent basis from 6300 Auction Houses and produces key Art Market information for the main press and media agencies (7,200 publications). Its 5.4 million ('members log in'+social media) users have access to ads posted by other members, a network that today represents the leading Global Standardized Marketplace® to buy and sell artworks at a fixed or bid price (auctions regulated by paragraphs 2 and 3 of Article L 321.3 of France's Commercial Code).
Artmarket with its Artprice department, has been awarded the State label "Innovative Company" by the Public Investment Bank (BPI) (for the second time in November 2018 for a new period of 3 years) which is supporting the company in its project to consolidate its position as a global player in the market art.
Artprice by Artmarket's 2020 Global Art Market Report published in March 2022:
https://www.artprice.com/artprice-reports/the-art-market-in-2021
Artprice's 2020/21 Contemporary Art Market Report by Artmarket.com:
https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2021
Index of press releases posted by Artmarket with its Artprice department:
serveur.serveur.com/Press_Release/pressreleaseEN.htm
Follow all the Art Market news in real time with Artmarket and its Artprice department on Facebook and Twitter:
www.facebook.com/artpricedotcom/ (over 5.9 million followers)
Discover the alchemy and universe of Artmarket and its artprice department https://www.artprice.com/video headquartered at the famous Organe Contemporary Art Museum "The Abode of Chaos" (dixit The New York Times): https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013
- L'Obs - The Museum of the Future: https://youtu.be/29LXBPJrs-o
- www.facebook.com/la.demeure.du.chaos.theabodeofchaos999 (4.3 million followers)
- https://vimeo.com/124643720
Contact Artmarket.com and its Artprice department - Contact: Thierry Ehrmann, ir@artmarket.com
Logo - https://mma.prnewswire.com/media/1009603/Art_Market_logo.jpg
View original content to download multimedia:
SOURCE Artmarket.com | https://www.wlbt.com/prnewswire/2022/09/06/artmarketcom-presents-artprice-2022-half-year-report-art-market-returns-strong-growth-west/ | 2022-09-06T13:23:59Z | https://www.wlbt.com/prnewswire/2022/09/06/artmarketcom-presents-artprice-2022-half-year-report-art-market-returns-strong-growth-west/ | false |
WATSONVILLE, Calif., Sept. 6, 2022 /PRNewswire/ -- The MILPA Collective releases "Truth Telling and Palabra: A Project at Rikers Island," a report that memorializes a transformative project that brought safety, stability, and healing to incarcerated young people [ages 18-21] and correctional staff at the RNDC jail at Rikers Island in Queens, New York.
From June 2021 through January 2022, at the request of Commissioner Vincent Schiraldi, MILPA and a team of expert consultants led a project at Rikers Island to stabilize conditions for incarcerated young adults and frontline staff. Like most jurisdictions across the country, rates of violence are nine times higher among young adults than any other group, making a focus on young adults key to stabilizing conditions agency-wide.
The MILPA approach of working in community and carceral settings across the U.S via the leadership of formerly incarcerated Chicano Indigenous and Black relatives uniquely positioned them to guide this project. "Our work wasn't about flooding Rikers with more programs. Our work was about making systemic change. Organizing with those who live and work inside, to challenge the systemic racism and toxic culture that sustains the status quo at Rikers," says Juan Gomez, Executive Director of MILPA. "And while we always try to balance urgency with the process, at Rikers, we had to treat every day like a war zone with a disaster relief mission."
In just seven months MILPA led a team of expert consultants and accomplished the following:
- Completed a participatory planning process in partnership with frontline staff and incarcerated young adults
- Designed a new model of jail operations for young adults
- Opened four transformed pilot living units using the new operations model
- Trained upwards of 50 correctional staff to work in the units
- Facilitated healing-engaged workshops
- Crafted a new antiracist policy to codify the new model with an eye toward scale.
Planning and preparation began in June 2021, and on November 1st the first pilot units opened, with the second two opening in mid-December 2021. From then through January 2022, only one fight occurred, while the other RNDC units experienced a total of 47 stabbings and slashings during the same period. Using a unique combination of facility-based organizing tactics, a participatory planning process, and a disaster relief approach, the team built an "inside" coalition of Black and Chicano Indigenous frontline staff and incarcerated people aligned in purpose, process, and hope for the future.
In January 2022, the project ended when Commissioner Schiraldi and his administration were ousted by the incoming Mayor. "While this story has an equivocal ending, the report has been written to memorialize the heart and hard work that staff and incarcerated people put into making this vision a reality while reflecting on its implications for the field."
You can access the full report, "Truth Telling and Palabra: A Project at Rikers Island," here and the Executive Summary here.
About MILPA: MILPA is a non-profit organization that is founded and led by formerly incarcerated Chicano Indigenous people. MILPA is a movement space dedicated to Cultivating Change Makers for The Next Seven Generations. For more, visit milpacollective.org
MEDIA CONTACT:
Dayanna Macias- Carlos
Email: pressoffice@milpacollective.org
Phone: (559)289-9885
View original content to download multimedia:
SOURCE MILPA Collective | https://www.wlbt.com/prnewswire/2022/09/06/truth-telling-palabra-project-rikers-island-report-released-by-milpa-collective/ | 2022-09-06T13:31:33Z | https://www.wlbt.com/prnewswire/2022/09/06/truth-telling-palabra-project-rikers-island-report-released-by-milpa-collective/ | false |
Liz Truss now officially the new prime minister of the UK after ‘kissing of hands’ with Queen in Balmoral
Liz Truss beat Rishi Sunak to number 10 yesterday
Liz Truss has officially replaced Boris Johnson as prime minister after she was invited by her majesty, Queen Elizabeth II, to form a new government.
Liz Truss is now officially the new prime minister after she met with the Queen in Balmoral on Tuesday afternoon.
In a result that had a narrower margin than many anticipated, Ms. Truss defeated fellow Conservative leader candidate Rishi Sunak after receiving more than 57% of the vote.
This was the smallest margin of victory in a Conservative leadership election since members were given a vote.
Most Popular
What was the margin of victory?
Liz Truss was victorious over Rishi Sunak with 57% of votes from Conservative Party members.
This equates to 81,326 votes to Sunak’s 60,399.
What did Liz Truss say about Boris Johnson?
Following confirmation of the election result,Liz Truss gave a victory speech in which she started by thanking outgoing PM Boris Johnson.
She also paid tribute to the other candidates who had joined her in the leadership race, including Rishi Sunak.
Liz Truss said: “I’d like to pay tribute to my fellow candidates, particularly Rishi Sunak. It’s been a hard-fought campaign.
“I think we have shown the depth and breadth of talent in our Conservative party. I also want to thank our outgoing leader, my friend, Boris Johnson. Boris, you got Brexit done.
“You crushed Jeremy Corbyn. You rolled out the vaccine and you stood up to Vladimir Putin. You are admired from Kyiv to Carlisle.”
Deliver, deliver, deliver
Looking ahead to the coming months, Liz Truss went on in her speech to outline everything she wanted to deliver on, including the energy crisis which continues to affect millions in the UK.
She said: “During this leadership campaign, I campaigned as a conservative and I will govern as a conservative. And my friends, we need to show that we will deliver over the next two years.
“I will deliver a bold plan to cut taxes and grow our economy. I will deliver on the energy crisis, dealing with people’s energy bills, but also dealing with the long term issues we have on energy supply. And I will deliver on the National Health Service.
“But we all will deliver for all for our country, and I will make sure that we use all the fantastic talents of the Conservative Party: our brilliant Members of Parliament and peers, our fantastic councillors. Our MS, our MSPs, all of our councillors and activists and members right across our country.
“Because my friends, I know that we will deliver, we will deliver, we will deliver and we... and we... and we will deliver a great victory for the Conservative Party in 2024. Thank you.” | https://www.wakefieldexpress.co.uk/read-this/liz-truss-now-officially-the-new-prime-minister-of-the-uk-after-kissing-of-hands-with-queen-in-balmoral-3833000 | 2022-09-06T13:32:13Z | https://www.wakefieldexpress.co.uk/read-this/liz-truss-now-officially-the-new-prime-minister-of-the-uk-after-kissing-of-hands-with-queen-in-balmoral-3833000 | true |
ADVERTISEMENT
Dilip Kumar, a Neera technician trained by the Coconut Mission of the Kerala Agricultural University (KAU) and working at the Centre of Advanced Agriculture Science and Technology (CAAST), a project of KAU, has been awarded the best Neera Technician in the national level.
The award was instituted as part of World Coconut Day celebrations by the Coconut Development Board. | https://www.thehindu.com/news/national/kerala/award-for-neera-technician/article65857399.ece/amp/ | 2022-09-06T13:36:52Z | https://www.thehindu.com/news/national/kerala/award-for-neera-technician/article65857399.ece/amp/ | true |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.